Pathology In Depth

Library › Bladder, urothelial tract and prostate pathology: benign lesions, urothelial neoplasia, bladder cancer staging, prostate carcinoma and Gleason grading

Bladder, urothelial tract and prostate pathology: benign lesions, urothelial neoplasia, bladder cancer staging, prostate carcinoma and Gleason grading

Last reviewed 2026-11-17 by a board-certified pathologist. 250 references.

Non-neoplastic Lesions of the Bladder and Urothelial Tract

Definition. Non-neoplastic lesions of the urothelial tract are reactive, metaplastic, infectious, iatrogenic, developmental and pseudoneoplastic proliferations of the renal pelvis, ureter, bladder and urethra. Their main diagnostic importance is distinction from urothelial carcinoma, adenocarcinoma, prostatic adenocarcinoma and sarcoma. Overdiagnosis of a high-grade mimic can lead to radical surgery, chemotherapy or radiotherapy. Overdiagnosis of a low-grade mimic can lead to lifelong cystoscopic surveillance (Samaratunga et al. 2021).

Related page: Urothelial Neoplasia: Papillomas, Flat Lesions, Noninvasive Papillary Carcinoma, Carcinoma In Situ and Invasive Urothelial Carcinoma (flat lesions, CIS, the CK20, p53 and CD44 panel and nested urothelial carcinoma) Related page: Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder (AJCC 8th edition staging, villous adenoma, adenocarcinoma, urachal carcinoma and embryonal rhabdomyosarcoma) Related page: Normal and Benign Findings in Urine Cytology (BCG, radiation and chemotherapy effect in urine, decoy cells, Schistosoma haematobium eggs, lithiasis) Related page: Non-Urothelial and Secondary Malignancies in Urine Cytology (nephrogenic adenoma in urine) Related page: Tubulointerstitial, Obstructive, Cystic and Developmental Kidney Disease (malakoplakia and xanthogranulomatous pyelonephritis in the kidney, reflux nephropathy, obstructive uropathy) Related page: Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology (BK polyomavirus nephropathy) Related page: Gram-Negative Bacteria: Enterobacterales, Nonfermenters, Neisseria, Haemophilus and Fastidious Gram-Negative Rods (Escherichia coli and other uropathogens) Related page: Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria (BCG and Mycobacterium bovis) Related page: Laboratory Evaluation of Inborn Errors of Immunity and Secondary Immunodeficiency (chronic granulomatous disease, a differential of malakoplakia-like histiocytic lesions)

Normal urothelium and the layers of the bladder wall

  • Urothelium. Urothelium is a multilayered epithelium that lines the renal pelvis, ureters and bladder. Its cells mature toward large surface umbrella cells. It measures 2 to 4 cell layers when the bladder is distended and 5 to 7 layers when it is contracted (Montironi et al. 2011).
  • Normal variation that mimics atypia. Urothelium of the renal pelvis, urethra and bladder neck has slightly larger cells with less cytoplasmic clearing and can be misread as dysplasia. Umbrella cells can show nuclear pleomorphism. Thick sections and tangential cuts can make normal urothelium appear hyperchromatic and hyperplastic (Montironi et al. 2011).
  • Normal immunoprofile. CK20 stains only the umbrella cell layer, CD44 stains basal and parabasal cells, and nuclear p53 is absent (Montironi et al. 2011; McKenney et al. 2001b). Uroplakin II and uroplakin III are highly specific markers of urothelial differentiation (Li et al. 2014).
  • Urothelial hyperplasia. The WHO/ISUP definition is a markedly thickened urothelium without atypia. Counting cell layers is not recommended, and the relation of hyperplasia to neoplasia is unknown (Montironi et al. 2011).
  • Muscularis mucosae. In 100 cystectomies, muscle in the lamina propria formed a distinct layer in 3, an interrupted layer in 20 and dispersed thin bundles in 71, and was absent in 6. Large vessels run along the lamina propria, and muscularis mucosae fibers accompany them (Ro et al. 1987). In 35 mapped bladders, muscularis mucosae was hyperplastic in 53%, most often at the dome. It was rare in the trigone, where the muscularis propria lies close to the surface (Paner et al. 2007).
  • Lamina propria depth by site. Lamina propria measured 0.46 to 1.58 mm at the trigone and 0.98 to 3.07 mm at the dome (Paner et al. 2007).
  • Separating muscularis mucosae from muscularis propria. Isolated bundles immediately beneath the urothelium with loose, haphazard fibers and irregular outlines favor muscularis mucosae (Paner et al. 2007). Desmin can separate muscle from desmoplasia and outline muscle contours. Smoothelin and vimentin are not recommended for routine muscle subclassification (Amin et al. 2014). When the muscle type cannot be determined, "muscle invasion, indeterminate for type" is an accepted descriptive diagnosis (Montironi et al. 2011; CAP Bladder Biopsy 2025).
  • Fat in the bladder wall. Adipose tissue occurs in the lamina propria and the muscularis propria. Carcinoma in fat on a biopsy or transurethral resection (TUR) does not establish extravesical spread, and that determination is reserved for cystectomy specimens (Montironi et al. 2011; CAP Bladder Biopsy 2025).
  • Muscularis propria as an adequacy marker. The muscularis propria is the landmark for pT2 and a surrogate for adequacy of the TUR (Paner et al. 2017). The CAP reporting options for muscularis propria are listed in Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder.
Layer Histologic features Meaning when invaded (AJCC 8th edition) Source
Urothelium 2 to 7 cell layers with surface umbrella cells pTis (flat carcinoma in situ) or pTa (noninvasive papillary carcinoma) Montironi et al. 2011; CAP Bladder Resection 2023
Lamina propria with muscularis mucosae Connective tissue with thin, wavy, discontinuous muscle bundles beside large vessels; may contain fat pT1 Ro et al. 1987; Paner et al. 2007; CAP Bladder Resection 2023
Muscularis propria (detrusor) Thick, compact smooth muscle bundles pT2a inner half; pT2b outer half (subcategorized only on cystectomy) CAP Bladder Resection 2023; CAP Bladder Biopsy 2025
Perivesical soft tissue Fat outside the muscularis propria pT3a microscopic; pT3b macroscopic (extravesical mass) CAP Bladder Resection 2023
Adjacent organs and walls Prostatic stroma, seminal vesicles, uterus, vagina; pelvic or abdominal wall pT4a prostatic stroma, uterus or vagina; pT4b pelvic or abdominal wall CAP Bladder Resection 2023
Wall of a diverticulum Mucosa and lamina propria without muscularis propria pT2 not applicable CAP Bladder Resection 2023; Walker et al. 2014

Von Brunn nests, cystitis cystica and cystitis glandularis

  • Morphology. Von Brunn nests are clusters of normal urothelium that invaginate into the lamina propria. Cystitis cystica is cystic dilatation of these nests. In conventional (typical) cystitis glandularis, glands are lined by cuboidal to low columnar cells and are often surrounded by residual urothelium. In the intestinal type, the glands are lined by tall columnar mucin-secreting cells with goblet cells and occasional Paneth cells (Khan et al. 2025).
  • Clinical profile. In 67 patients, the median age was 61 years and 85.1% were men. Lesions involved the bladder neck or trigone in 62.7%. Intestinal-type metaplasia was present in 23.9% (Khan et al. 2025). In 89 patients with intestinal metaplasia, 67 lesions were on or near the trigone, and hematuria and mucosuria were the main complaints (Xin et al. 2016).
  • Concurrent carcinoma. Among 117 patients with florid cystitis cystica et glandularis, urothelial carcinoma was present at diagnosis in 29%, squamous cell carcinoma in 3% and mucinous adenocarcinoma in under 1%. Among 19 with pure intestinal metaplasia, adenocarcinoma was present in 10% and urothelial carcinoma in 21% (Smith et al. 2008).
  • Future risk. Only 1 new urothelial carcinoma followed florid cystitis cystica et glandularis, and intestinal metaplasia did not increase the future risk of malignancy (Smith et al. 2008). None of 53 patients with intestinal metaplasia, including patients with exstrophy, developed adenocarcinoma during a median follow-up of 13 to 14 years (Corica et al. 1997). No de novo carcinoma arose from cystitis glandularis during a median follow-up of 9.2 years (Khan et al. 2025). In 89 patients, 1 adenocarcinoma followed at 6 months, and that lesion had shown intestinal metaplasia with severe dysplasia (Xin et al. 2016).
  • Precursor terminology (ISUP 2024). Grading of glandular and squamous dysplasia and the ISUP 2024 precursor terms are described in Urothelial Neoplasia: Papillomas, Flat Lesions, Noninvasive Papillary Carcinoma, Carcinoma In Situ and Invasive Urothelial Carcinoma.
  • Pseudocarcinomatous patterns. Florid von Brunn nests can mimic invasive urothelial carcinoma (Hameed and Humphrey 2010; Samaratunga et al. 2021). Carcinoma in situ involving von Brunn nests is a recognized pitfall in diagnosing lamina propria invasion (Montironi et al. 2011). Nested and large nested urothelial carcinomas are the malignant mimics and are described in Urothelial Neoplasia: Papillomas, Flat Lesions, Noninvasive Papillary Carcinoma, Carcinoma In Situ and Invasive Urothelial Carcinoma.
Glandular lesion of the bladder Defining features Behavior Source
Cystitis glandularis, conventional type Cuboidal to low columnar glands rimmed by urothelium in the lamina propria Benign; no de novo carcinoma in 9.2 years of median follow-up Khan et al. 2025
Cystitis glandularis, intestinal type (intestinal metaplasia) Tall columnar mucinous cells with goblet cells and occasional Paneth cells Concurrent carcinoma in some patients; no clear increase in future risk Khan et al. 2025; Smith et al. 2008; Corica et al. 1997
Nephrogenic adenoma Tubules, cysts and papillae lined by cuboidal and hobnail cells; PAX8 and PAX2 positive Benign Kunju 2010; Tong et al. 2006; Tong et al. 2008
Prostatic-type polyp Acini and papillae of prostatic epithelium, PSA and PSAP positive Benign; recurrence extremely rare Anjum et al. 1997
Villous adenoma Colonic-type villous epithelium with stratified hyperchromatic nuclei Benign when isolated; coexistent adenocarcinoma in 8 of 23 Cheng et al. 1999
Primary adenocarcinoma Enteric, mucinous, signet-ring cell or mixed patterns with invasion Malignant Santa et al. 2025

Nephrogenic adenoma

  • Morphology. Nephrogenic adenoma is a circumscribed proliferation of tubules, cysts and papillae lined by low cuboidal to columnar cells. Features favoring nephrogenic adenoma are the mixture of patterns, stromal edema and inflammation, a hyaline sheath around tubules, eosinophilic colloid-like secretion and absent mitotic activity (Kunju 2010).
  • Features of nephrogenic adenoma that mimic malignancy. Enlarged nuclei with prominent nucleoli, degenerative atypia, tiny tubules with blue mucin that resemble signet-ring cells and focal extension into superficial muscle can mimic malignancy (Kunju 2010).
  • Histogenesis. In 46 nephrogenic adenomas from 29 kidney-transplant recipients, every lesion showed the sex chromosomes of the donor kidney and expressed aquaporin 1 and PAX2. Nephrogenic adenomas in transplant recipients therefore derive from shed renal tubular cells (Mazal et al. 2002). PAX2 was positive in all 39 nephrogenic adenomas from patients without transplants, which supports a renal tubular origin outside transplantation as well (Tong et al. 2006).
  • PAX2 and PAX8. PAX2 stained 100% of nephrogenic adenomas and no prostatic or invasive urothelial carcinomas (Tong et al. 2006). PAX8 stained all 35 nephrogenic adenomas and all 7 clear cell adenocarcinomas of the lower urinary tract. It was negative in 100 prostatic adenocarcinomas, 48 urothelial carcinomas, 9 bladder adenocarcinomas and 5 squamous cell carcinomas (Tong et al. 2008).
  • AMACR, basal markers and GATA3. AMACR was strongly positive in 58% of nephrogenic adenomas, and 34βE12 was negative in 62% (Gupta et al. 2004). In 63 lesions, AMACR was positive in 56%, CK903 in 97% and p63 in only 2 cases. GATA3 was positive in 40% and does not separate nephrogenic adenoma from urothelial carcinoma (McDaniel et al. 2014).
  • Prostatic urethra. Nephrogenic adenoma of the prostatic urethra mimics prostatic adenocarcinoma. NKX3.1 is negative, PSA and PSAP may be focally and weakly positive, and PAX8 is positive (Beeter et al. 2023). A PIN-4 pattern compatible with prostate cancer occurred in only 2 of 63 lesions, because AMACR and CK903 are usually coexpressed (McDaniel et al. 2014).
  • Clear cell adenocarcinoma. Clear cell adenocarcinoma also expresses PAX8. Greater cytologic atypia and mitotic activity separate it from nephrogenic adenoma (Oliva and Young 1996; Tong et al. 2008).
Marker Nephrogenic adenoma Result in the main mimic Source
PAX8 Positive in 35 of 35 Prostatic adenocarcinoma 0 of 100; urothelial carcinoma 0 of 48; clear cell adenocarcinoma 7 of 7 Tong et al. 2008
PAX2 Positive in 39 of 39 Prostatic adenocarcinoma and invasive urothelial carcinoma negative; clear cell adenocarcinoma 2 of 7 Tong et al. 2006; Tong et al. 2008
NKX3.1 Negative Prostatic adenocarcinoma positive Beeter et al. 2023; Gurel et al. 2010
PSA and PSAP Negative, or focal and weak Prostatic adenocarcinoma positive Beeter et al. 2023
AMACR Positive in 56% to 58% Clear cell adenocarcinoma also positive Gupta et al. 2004; McDaniel et al. 2014; Sun et al. 2008
High-molecular-weight cytokeratin 34βE12 negative in 62%; CK903 positive in 97% Coexpression with AMACR argues against prostatic adenocarcinoma Gupta et al. 2004; McDaniel et al. 2014
p63 Positive in 2 of 63 Urothelial carcinoma positive in 87% McDaniel et al. 2014; Higgins et al. 2007
GATA3 Positive in 40% Urothelial carcinoma positive in 67% to over 90% McDaniel et al. 2014; Higgins et al. 2007; Miettinen et al. 2014

Cystitis by cause and pattern

Type Cause or setting Key histologic or clinical findings Differential or management point Source
Interstitial cystitis with Hunner lesion Chronic bladder pain syndrome of unknown cause; Hunner lesion in 5% to 57% of patients Pancystitis with B-cell abnormalities, epithelial denudation, granulation tissue, fibrin and detrusor mastocytosis; cystoscopy shows a red area with radiating vessels that splits on distension Cystoscopy with hydrodistention is standard; cystoscopy excludes other bladder disease Akiyama et al. 2019; Whitmore et al. 2019
Interstitial cystitis without Hunner lesion Same symptom complex Minimal histologic change; mast cell counts of uncertain value Distinct from Hunner lesion disease, which is a true inflammatory disorder Akiyama et al. 2019
Polypoid and papillary cystitis Indwelling catheter, stones, fistula, stents, prior radiation Reaction to mucosal injury; papillary cystitis is the more chronic phase; analogous polypoid urethritis, ureteritis and pyelitis; 41 of 155 consult cases were first misdiagnosed as papillary neoplasms Papillary urothelial neoplasms Lane and Epstein 2008b; Norlén et al. 1988
Eosinophilic cystitis Often no cause found Urgency, frequency, pain and hematuria; may form a tumor-like mass and resolve spontaneously Bladder tumor Verhagen et al. 2001
Follicular cystitis Chronic inflammation, including after intravesical gemcitabine Lymphoid follicles in the lamina propria; follicular elevations at cystoscopy Cystoscopic follicular elevations mimic tumor recurrence Wu et al. 2026
Hemorrhagic cystitis, drug induced Cyclophosphamide and ifosfamide Acrolein, a caustic metabolite, causes the injury; mesna neutralizes it Carcinoma in situ (reactive atypia) Matz and Hsieh 2017; Lopez-Beltran et al. 2018
Hemorrhagic cystitis, BK polyomavirus Allogeneic hematopoietic stem cell transplant (7% to 54% of adults; 8% to 25% of children) Cystitis, gross hematuria and urine BK viral load above 7 log10 copies/mL Diagnosis requires exclusion of other causes Cesaro et al. 2018
Hemorrhagic cystitis, adenovirus Kidney transplant recipients Gross hematuria, frequency, dysuria and fever; serotype 11 in 3 of 4 patients; self-limited Resolves without reduction of immunosuppression Koga et al. 1993
Emphysematous cystitis Diabetes mellitus (67%); women (64%); median age 66 years Gas within the bladder wall; E. coli most common; mortality 7% Most common and least severe gas-forming urinary infection Thomas et al. 2007
Encrusted cystitis Urea-splitting bacteria, most often Corynebacterium urealyticum, after instrumentation Intramucosal calcification Antibiotics, urine acidification and endoscopic removal of encrustations Johnson et al. 2012
Ketamine cystitis Recreational ketamine use Ulceration with urothelial atypia; p53 high in 9 of 10 and Ki-67 moderate to high in 7 of 10, CK20 negative in all Carcinoma in situ Oxley et al. 2009
Radiation cystitis Pelvic radiotherapy Ulceration, fibrin, hemorrhage, vascular ectasia, atypical fibroblasts and pseudocarcinomatous epithelial nests Invasive urothelial carcinoma Baker and Young 2000
  • Scope. Mitomycin C after TUR, intravesical BCG for high-risk non-muscle-invasive disease and carcinoma in situ, platinum-based neoadjuvant chemotherapy, cyclophosphamide and ketamine all produce urothelial atypia that can mimic carcinoma in situ, dysplasia or invasive carcinoma. The CK20, p53 and CD44 panel may help after therapy (Lopez-Beltran et al. 2018).
  • BCG. After intravesical BCG, biopsies showed marked edema and variable inflammation. Granulomas were present in 11 of 35 biopsies, with acid-fast bacilli in 2. The infiltrate was mainly helper T cells, often as a band beneath residual or denuded epithelium (Leong et al. 1990). Granulomatous prostatitis was found in 9 of 12 cystoprostatectomies after BCG, with acid-fast bacilli in 7 of the 9 (LaFontaine et al. 1997). BCG granulomatous prostatitis is described in Prostate Anatomy, Benign Prostatic Hyperplasia, Prostatitis and Benign Mimics of Prostatic Carcinoma.
  • Radiation atypia and immunohistochemistry. Radiation atypia keeps CK20 in umbrella cells and often shows diffuse CD44. Strong diffuse p53 occurred only in carcinoma in situ (Oliva et al. 2013). The CK20, p53 and CD44 figures are tabulated in Urothelial Neoplasia: Papillomas, Flat Lesions, Noninvasive Papillary Carcinoma, Carcinoma In Situ and Invasive Urothelial Carcinoma.
  • Pseudocarcinomatous hyperplasia after radiation. Irregular aggregates of urothelial cells in the upper and middle lamina propria, with mild to severe pleomorphism and focal squamous differentiation, mimic invasion. Ulceration, vascular ectasia and atypical fibroblasts indicate radiation injury (Baker and Young 2000).
  • Pseudocarcinomatous hyperplasia without radiation. The same pattern occurs with ischemia or chronic irritation, such as atrial fibrillation, vascular disease, arteriovenous malformation or an indwelling catheter. All 8 patients had gross hematuria, and none developed carcinoma. Hemorrhage, fibrin in vessels or stroma, edema and vascular congestion were common (Lane and Epstein 2008a).

Malakoplakia

  • Definition and morphology. Malakoplakia is a granulomatous inflammatory disease that occurs most often in the urinary tract. Sheets of histiocytes (von Hansemann cells) contain granular, PAS-positive, diastase-resistant inclusions. Calcified Michaelis–Gutmann bodies are pathognomonic but are not required for the diagnosis (Yousef et al. 2007).
  • Pathogenesis. Malakoplakia reflects defective macrophage phagolysosomal activity. The macrophages cannot fully digest phagocytosed bacteria, and Michaelis–Gutmann bodies are calcified lysosomes. Most cases are associated with gram-negative infection, mainly E. coli (Bishara et al. 2026). In one patient, monocytes had low cyclic GMP, failed to release β-glucuronidase after phagocytosis and killed E. coli poorly. A cholinergic agonist (bethanechol) corrected these defects (Abdou et al. 1977).
  • Clinical setting. Bladder malakoplakia presents with dysuria, frequency or a tumor-like mass. Most cases are associated with gram-negative infection, mainly E. coli, and the index bladder case of Bapir et al. grew Morganella morganii (Bishara et al. 2026; Bapir et al. 2026). The disease occurs in immunocompromised hosts, including transplant recipients and patients receiving immunosuppressive therapy (Bishara et al. 2026).
  • Stains. PAS, Prussian blue, Alcian blue and von Kossa highlight Michaelis–Gutmann bodies. The histiocytes are CD68 positive and AE1/AE3 and S100 negative (Bapir et al. 2026).
  • Mimicry. Ulcerated nodules with lymph node involvement can mimic malignancy. Malakoplakia can coexist with tuberculosis or carcinoma in the same specimen (Yousef et al. 2007).

Urachal remnants and bladder diverticula

  • Urachus. The urachus is a fibrous tube from the umbilicus to the anterosuperior bladder dome. It usually obliterates by week 12 of gestation and becomes the median umbilical ligament (Das et al. 2020). Incomplete obliteration produces four anomaly types: urachal cyst, urachal sinus, patent urachus and vesicourachal diverticulum (Blomqvist et al. 2026).
  • Remnants in children. In 103 children, remnants were urachal cysts (38), patent urachus (21), nonspecific atretic remnants (20), diverticula (13) and sinuses (11). Of 19 observed remnants that were reimaged, 15 (78.9%) had resolved spontaneously (Naiditch et al. 2013).
  • Remnants in adults. Among 245 adults with radiologically reported urachal anomalies, bladder malignancy or PUNLMP was found in 14 (5.7%). None of 92 incidentally detected anomalies harbored neoplasia. Macroscopic hematuria was the main predictor, and most tumors were of nonurachal histology (Blomqvist et al. 2026). Urachal carcinoma is described in Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder.
  • Diverticulum tumors. Tumors within a bladder diverticulum account for about 1% of bladder tumors. Urinary stasis is the proposed reason for the higher risk (Walker et al. 2014).
  • Diverticulum staging. Invasion beyond the lamina propria of a diverticulum is described as T3 (Walker et al. 2014).
  • Diverticulum outcome. In 39 patients, 5-year disease-specific survival was 83% for noninvasive tumors, 67% for tumors invading only the lamina propria and 45% for tumors with extradiverticular spread. Clinical stage was the only independent predictor (Golijanin et al. 2003).

Urethral caruncle, prostatic-type polyp and other urethral polyps

  • Urethral caruncle. Urethral caruncle is the most frequent benign tumor of the female urethra and occurs mainly after menopause (Chiba et al. 2015). Urethral diverticulum, Skene gland cyst, urethral prolapse and caruncle are the common benign urethral lesions in women (Maetzold et al. 2022). Histology shows edematous, inflamed connective tissue with papillary hyperplasia under the surface epithelium. Estrogen deficiency contributes in adults (Chiba et al. 2015).
  • Prostatic-type polyp (ectopic prostatic tissue). These polyps usually arise in the prostatic urethra and cause hematuria in young men (Craig and Hart 1975). They contain acini and papillae of prostatic-type epithelium positive for PSA and PSAP. Recurrence after resection is extremely rare (Anjum et al. 1997). A verumontanum polyp with typical prostatic acinar epithelium supports origin from ectopic prostatic tissue (Fan 1984).
  • Polypoid urethritis. All 20 men with indwelling catheters had urethral lesions, and 11 were histologically almost identical to polypoid cystitis. Mechanical irritation by the catheter is the proposed cause (Norlén et al. 1988).
  • Fibroepithelial polyp. In 12 adults, most fibroepithelial polyps were near the verumontanum or bladder neck and were lined by normal urothelium. They had broad stalks of dense fibrous tissue and lacked the edema and inflammation of polypoid cystitis. None recurred (Tsuzuki and Epstein 2005).

Pseudosarcomatous myofibroblastic proliferation and inflammatory myofibroblastic tumor

  • Terminology. Inflammatory pseudotumor, pseudosarcomatous fibromyxoid tumor and postoperative spindle cell nodule share overlapping or identical histology (Harik et al. 2006). One series grouped them as inflammatory myofibroblastic tumor (IMT) of the urinary tract (Montgomery et al. 2006). Harik et al. proposed the unifying term pseudosarcomatous myofibroblastic proliferation (Harik et al. 2006).
  • Clinical profile. In 42 bladder lesions, patients were 7 to 77 years old (mean 47 years), men predominated 3.2 to 1 and 31 presented with hematuria. Prior instrumentation or surgery was present in 9, and lesions with or without instrumentation were indistinguishable (Harik et al. 2006).
  • Morphology. Spindle and stellate cells lie in a myxoid stroma with many inflammatory cells. Hypocellular myxoid areas lie near the surface and more cellular fascicles lie deeper. Mitoses range from 0 to 20 per 10 high-power fields without atypical forms. Necrosis was present in 22 of 42 lesions and muscularis propria involvement in 28 of 32 (Harik et al. 2006).
  • Immunohistochemistry and genetics. Cytokeratin was positive in 31 of 33 lesions, SMA in 23 of 34, desmin in 21 of 35 and ALK in 12 of 26 (Harik et al. 2006). In 46 urinary tract IMTs, ALK was positive in 57% and ALK alterations were detected by FISH in 72% of tested cases. AE1/AE3 was positive in 25 of 34, while S100 and CD34 were negative (Montgomery et al. 2006). Cytoplasmic ALK staining occurred in 8 of 9 bladder IMTs and in none of 5 sarcomatoid carcinomas, 2 leiomyosarcomas or 2 rhabdomyosarcomas (Freeman et al. 2004).
  • Behavior. Three of 28 patients had recurrences, and none had metastases (Harik et al. 2006). In 32 patients with follow-up, 10 had recurrences, and recurrence was unrelated to muscle invasion or ALK status. Two IMTs preceded sarcomatoid urothelial carcinoma, and 1 ALK-rearranged postirradiation tumor was overtly sarcomatous and fatal (Montgomery et al. 2006).
  • Recommended panel. For a spindle cell proliferation of the bladder, ISUP recommends a 6-marker panel: ALK1, SMA, desmin, cytokeratin AE1/AE3, p63, and either high-molecular-weight cytokeratin or CK5/6 (Amin et al. 2014).
Feature Inflammatory myofibroblastic tumor or pseudosarcomatous myofibroblastic proliferation Sarcomatoid urothelial carcinoma Leiomyosarcoma Source
Age and setting Mean 47 years; prior instrumentation in a minority Mean 71 years; smoking is a risk factor Mean 64 years Harik et al. 2006; Fatima et al. 2015; Martin et al. 2002
Size Mean 4 to 4.2 cm Mean 5 cm Mean 7.1 cm Harik et al. 2006; Montgomery et al. 2006; Fatima et al. 2015; Martin et al. 2002
Morphology Spindle and stellate cells in inflamed myxoid stroma; necrosis and muscle invasion possible Biphasic epithelial and mesenchymal tumor; heterologous elements in 10% Fascicles of spindle cells with atypia; coagulative necrosis in 78%; actin positive in 83% and desmin in 39% Harik et al. 2006; Fatima et al. 2015; Martin et al. 2002
Mitoses 0 to 20 per 10 HPF; none atypical Graded high grade, as are all urothelial subtypes 1 to 42 per 10 HPF (mean 12) Harik et al. 2006; Paner et al. 2024; Martin et al. 2002
Keratin Positive in 31 of 33 pseudosarcomatous proliferations; AE1/AE3 in 25 of 34 IMTs Epithelial differentiation by morphology or IHC Negative in all 18 Harik et al. 2006; Montgomery et al. 2006; Fatima et al. 2015; Martin et al. 2002
ALK Positive in 46% to 89% Negative (0 of 5) Negative (0 of 2) Harik et al. 2006; Montgomery et al. 2006; Freeman et al. 2004
Outcome Local recurrence; no metastasis in typical lesions 56% died within 1 year 50% of high-grade tumors fatal Harik et al. 2006; Fatima et al. 2015; Martin et al. 2002

Posterior urethral valves, prune belly syndrome and bladder exstrophy

  • Posterior urethral valves. Posterior urethral valves are persistent mucosal folds in the urethra that obstruct urine flow. They are the most common cause of lower urinary tract obstruction in fetuses and children, and one third of affected children reach end-stage kidney disease before adulthood. Management includes prenatal vesicoamniotic shunting and postnatal endoscopic valve ablation (El-Ghoneimi et al. 2025).
  • Prune belly syndrome. Prune belly (Eagle-Barrett or triad) syndrome combines an abdominal wall deficient in muscle, a dilated urinary tract and bilateral cryptorchidism. About 3 of 4 patients have cardiopulmonary, gastrointestinal or orthopedic malformations (Jennings 2000).
  • Prune belly pathology. In 11 male fetuses and infants with prune belly syndrome, 8 had mechanical lower tract obstruction, most often a flap-valve angulation between the prostatic and penile urethra, and 1 had a posterior urethral valve. The 3 without obstruction had megacystis with a thick wall, interstitial fibrosis and disarrayed smooth muscle. The prostate had no glands or only sparse flattened glands in 10, which suggests pressure-induced dysplasia (Volmar et al. 2001).
  • Bladder exstrophy. Adenocarcinoma accounts for 95% of cancers in exstrophic bladders and squamous cell carcinoma for 3% to 5%. Repair method, chronic irritation and infection contribute to the risk (Town et al. 2025). In 103 adults with classical exstrophy, the overall risk of neoplasia was 17.5% and was 38% after mixing of urine and feces in a colorectal reservoir. Even in low-risk patients, the risk of malignancy was 27 times that of the age-matched population (Smeulders and Woodhouse 2001).

Urothelial Neoplasia: Papillomas, Flat Lesions, Noninvasive Papillary Carcinoma, Carcinoma In Situ and Invasive Urothelial Carcinoma

Definition. Urothelial neoplasms are tumors of urothelial lineage that range from benign papillomas through noninvasive papillary and flat carcinoma to invasive urothelial carcinoma and its subtypes. They are classified by the WHO Classification of Tumours, Urinary and Male Genital Tumours, 5th edition (2022). That edition organizes urinary tract tumors by lineage (urothelial, squamous, glandular). It has no separate organ-based chapters for urothelial tumors of the prostate, urethra and upper tract, and it keeps dedicated sections for urachal, diverticular and urethral accessory gland tumors (Raspollini et al. 2022; Netto et al. 2022). Flat, papillary and invasive lesions are graded separately (CAP Bladder Resection 2023).

Terminology. The WHO 5th edition uses "subtype" throughout in place of "variant", the 2016 (4th edition) term (Raspollini et al. 2022).

Related page: Non-neoplastic Lesions of the Bladder and Urothelial Tract (normal urothelium, bladder wall layers, von Brunn nests, reactive and treatment-related atypia) Related page: Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder (AJCC 8th edition pT and pN tables, CAP elements, predictive biomarkers, upper tract and urethral carcinoma, pure squamous, glandular and neuroendocrine carcinomas) Related page: The Paris System for Reporting Urinary Cytology (Paris System 2nd edition categories for urine cytology) Related page: Low-Grade Urothelial Neoplasia and High-Grade Urothelial Carcinoma Variants in Urine Cytology (WHO 2022 urothelial tumors and high-grade subtypes in urine) Related page: Ancillary Tests, Indications and Management in Urine Cytology (UroVysion FISH and urine biomarkers)

Epidemiology and risk factors of bladder carcinoma

  • Frequency. Bladder cancer is about four times more common in men than in women, and about 80% of cases are diagnosed in adults aged 65 years or older (Saginala et al. 2020). US bladder cancer incidence fell by about 1% per year over the past decade in both sexes (Siegel et al. 2026).
  • Tobacco. Smoking is the strongest risk factor and accounts for 50% to 65% of cases. Tobacco smoke contains beta-naphthylamine and polycyclic aromatic hydrocarbons, and the latency from the start of smoking to diagnosis is about 30 years (Saginala et al. 2020).
  • Occupational and environmental exposure. Occupational and environmental chemicals account for about 20% of cases, and cancer can develop decades after a brief exposure. Arsenic exposure also increases the risk (Saginala et al. 2020).
  • Susceptibility genes. Slow-acetylator NAT2 genotypes, which detoxify aromatic amines poorly, and GSTM1 variants increase susceptibility. Known risk factors explain 81% of cases and heritable mutations 7% (Saginala et al. 2020).
  • Other settings. Schistosoma haematobium, upper tract risk factors and Lynch syndrome are described in Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder.

WHO 5th edition classification of urothelial tumors and the 2016 rules it replaced

WHO 5th edition (2022) category Entities Previous rule or term (WHO 4th edition, 2016) Source
Noninvasive urothelial lesions Urothelial papilloma; inverted urothelial papilloma; papillary urothelial neoplasm of low malignant potential (PUNLMP); noninvasive papillary urothelial carcinoma, low grade; noninvasive papillary urothelial carcinoma, high grade; urothelial carcinoma in situ Same entities CAP Bladder Resection 2023; Raspollini et al. 2022
Inverted lesions Inverted urothelial papilloma has its own section; inverted PUNLMP and inverted low-grade and high-grade noninvasive carcinomas are described with their exophytic counterparts, with criteria for tumors with inverted histology Inverted growth in carcinoma was not formally addressed Raspollini et al. 2022; Amin et al. 2021
Urothelial dysplasia Retained as a term; described briefly within the urothelial carcinoma in situ chapter Own chapter; "better defined" lesion Raspollini et al. 2022; Humphrey et al. 2016
Lesions formerly called urothelial proliferation of uncertain malignant potential Not a stand-alone entity; regarded as early noninvasive low-grade papillary carcinoma or the edge of such a tumor Urothelial proliferation of uncertain malignant potential, often in patients with prior urothelial carcinoma Raspollini et al. 2022; Humphrey et al. 2016
Grading of noninvasive papillary carcinoma Low and high grade; high grade when the high-grade component is 5% or more; "low grade with less than 5% high-grade component" otherwise Two-tier grade (ISUP 1998); WHO 2004 consensus graded on the worst area Raspollini et al. 2022; Montironi et al. 2011
Invasive urothelial carcinoma Conventional; with squamous, glandular or trophoblastic differentiation; nested (including large nested); tubular and microcystic; micropapillary; lymphoepithelioma-like; plasmacytoid; giant cell; lipid-rich; clear cell (glycogen-rich); poorly differentiated "Variants"; large nested and tubular not separately named; plasmacytoid listed with signet ring cell and diffuse; clear cell without "glycogen-rich" CAP Bladder Resection 2023; Raspollini et al. 2022
Divergent differentiation Squamous, glandular, trophoblastic, Müllerian and neuroendocrine lineages; presence and percentage reported Percentage of divergent histologies mentioned in the report Raspollini et al. 2022; Humphrey et al. 2016
Grading of invasive carcinoma Every invasive urothelial carcinoma is graded Invasive tumors graded low or high grade by the scheme for noninvasive lesions (WHO 2004) Raspollini et al. 2022; Montironi et al. 2011
Neuroendocrine neoplasms Dedicated section using the 2017 IARC neuroendocrine framework Classified before the 2017 IARC framework existed Raspollini et al. 2022
  • Pure nonurothelial carcinoma. The WHO 5th edition requires pure histology for a diagnosis of squamous cell carcinoma, adenocarcinoma or Müllerian carcinoma. Any recognizable papillary, invasive or flat in situ urothelial component makes the tumor urothelial carcinoma with divergent differentiation (CAP Bladder Resection 2023).
  • Molecular classification. Six expression-based subgroups of muscle-invasive carcinoma are recognized, but the WHO 5th edition does not adopt a molecular classification (Raspollini et al. 2022). The subgroups are described in Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder.

Urothelial papilloma and inverted urothelial papilloma

  • Urothelial papilloma. Papillomas have simple, nonhierarchical papillae with slender fibrovascular cores, lined by normal-appearing urothelium without hyperplasia and often with a prominent umbrella cell layer. In 26 patients, de novo papillomas occurred at a mean age of 46 years. Of 14 with follow-up, 12 had no recurrence, 1 had a recurrent papilloma and 1, who was immunosuppressed after renal transplant, developed high-grade carcinoma (McKenney et al. 2003).
  • Inverted urothelial papilloma. Inverted papilloma typically arises in the trigone of younger patients. It consists of anastomosing trabeculae of urothelium beneath a normal or attenuated surface, with no significant pleomorphism, few mitoses and occasional squamous or glandular differentiation. Recurrence is under 5% (Montironi et al. 2011).
  • Molecular findings. FGFR3 point mutations occurred in 9 of 20 inverted papillomas (45%), most often R248C, and none had TP53 mutations. None recurred or progressed during a mean follow-up of 78 months (Lott et al. 2009).
  • Inverted growth in carcinoma. Some papillary carcinomas grow endophytically as anastomosing cords that resemble inverted papilloma or as broad, pushing bulbous invaginations (broad-front pattern). Invasion requires irregular nests or single cells in the lamina propria, with or without a desmoplastic or inflammatory response (Montironi et al. 2011).
  • Reporting inverted lesions. Reporting an inverted growth pattern aids correlation with cystoscopy (Raspollini et al. 2022). No primary PUNLMP with exclusively inverted growth recurred or progressed in 12 patients (Maxwell et al. 2015).

Flat urothelial lesions and their immunohistochemistry

Lesion Histologic definition Significance Source
Flat hyperplasia Markedly thickened urothelium without atypia Relation to neoplasia unknown Montironi et al. 2011
Papillary hyperplasia Slight tenting or undulation without true fibrovascular cores; small vessels at the base Usually seen with papillary neoplasia; de novo significance unknown Montironi et al. 2011
Reactive atypia Uniformly enlarged vesicular nuclei with central nucleoli, mitoses in lower layers, inflammation Nonneoplastic; history of instrumentation, infection or intravesical therapy Montironi et al. 2011
Atypia of unknown significance Flat atypia listed between reactive atypia and dysplasia Category of the 2004 WHO/1998 ISUP scheme CAP Bladder Resection 2023
Urothelial dysplasia Architectural distortion with enlarged, hyperchromatic, pleomorphic nuclei that fall short of carcinoma in situ Precursor; 15% risk of cancer at a mean follow-up of 4.9 years; poor reproducibility Montironi et al. 2011; Raspollini et al. 2022
Urothelial carcinoma in situ Unequivocal severe cytologic atypia; need not be full thickness; single pagetoid cells suffice Direct precursor of invasive carcinoma; invasion in 20% to 30% on follow-up Montironi et al. 2011
  • ISUP 2024 precursor consensus. Pathologists preferred existing terms such as dysplasia, verrucous squamous lesion and papillary hyperplasia, favored grading glandular and squamous dysplasia, and supported judicious use of immunohistochemistry (Downes et al. 2025).
  • CK20, p53 and CD44. In 21 carcinomas in situ, intense CK20 and p53 staining occurred in the majority of malignant cells in 81% and 57%, and at least one of the two was abnormal in every case. Neoplastic cells were CD44 negative, although residual basal cells stained in 44%. Reactive urothelium kept CK20 in umbrella cells and overexpressed CD44 through the full thickness in 60% (McKenney et al. 2001b).
  • Limits of the panel. ISUP 2013 recommended morphology as the gold standard for reactive atypia versus carcinoma in situ. The CK20, p53 and CD44 panel has potential utility with limitations, particularly after treatment. Immunohistochemistry has no role in separating dysplasia from carcinoma in situ or in grading papillary carcinoma (Amin et al. 2014). Ketamine cystitis, a p53-high and CK20-negative mimic, is described in Non-neoplastic Lesions of the Bladder and Urothelial Tract.
Marker Normal urothelium Reactive atypia, including radiation Urothelial carcinoma in situ Source
CK20 Umbrella cells only Umbrella cells only (15 of 15 reactive; 22 of 28 irradiated) Strong in most neoplastic cells (81%); diffuse in 11 of 17 McKenney et al. 2001b; Oliva et al. 2013
p53 Absent or weak and patchy Mostly negative or weak (24 of 28 irradiated) Strong in most neoplastic cells (57%); strong and diffuse in about 50% McKenney et al. 2001b; Oliva et al. 2013
CD44 (standard isoform) Basal and parabasal cells Full thickness (60% of reactive; 7 of 17 irradiated) or intermediate cells Neoplastic cells negative; residual basal cells may stain McKenney et al. 2001b; Oliva et al. 2013

Urothelial carcinoma in situ

  • Patterns. In 77 cases, five patterns of carcinoma in situ often coexisted: large cell with pleomorphism (57%), large cell without pleomorphism (48%), small cell (14%), clinging (40%) and cancerization with pagetoid spread or undermining of normal urothelium (16%). High-grade cytologic atypia is the defining feature, and the report uses the single term urothelial carcinoma in situ (McKenney et al. 2001a).
  • Denuding cystitis. Lack of cohesion produces extensive denudation, and sometimes only a few atypical cells cling to the basement membrane (Montironi et al. 2011).
  • Nuclear-to-cytoplasmic ratio. A high ratio is not required. It is absent in the large cell type (Montironi et al. 2011).
  • Microinvasion. Carcinoma in situ with invasion of the lamina propria to less than 2 mm most often showed single cells or small groups with retraction artifact that mimicked vascular invasion (77%). Some had desmoplasia or no stromal response (McKenney et al. 2001a).
  • Clinical types. Primary carcinoma in situ occurs without prior or simultaneous urothelial tumor, secondary carcinoma in situ is diagnosed after treatment of a papillary tumor, and concurrent carcinoma in situ accompanies a papillary tumor. Five-year survival was 41% for primary, 100% for secondary and 49% for concurrent carcinoma in situ (Fukui et al. 1987). In an EORTC trial of 168 patients, 52% had concurrent, 23% primary and 24% secondary carcinoma in situ (de Reijke et al. 2005).
  • Severe dysplasia. Lesions formerly graded as severe dysplasia are classified as carcinoma in situ, which is the most reproducible flat category (Montironi et al. 2011; CAP Bladder Resection 2023).

PUNLMP and noninvasive papillary urothelial carcinoma

  • Grading principle. Grade reflects architectural and cytologic disorder. Low-grade carcinoma shows mild loss of polarity and mild variation in nuclear size. High-grade carcinoma shows marked architectural and cytologic disorder, loss of polarity, irregular pleomorphic nuclei, many mitoses and anaplasia (Raspollini et al. 2022).
  • Two-tier system. The low-grade and high-grade system was proposed by the 1998 WHO/ISUP consensus and maintained in the 3rd, 4th and 5th WHO editions. It is more reproducible than older systems, aligns with management and corresponds to the Paris System for urine cytology (Raspollini et al. 2022).
  • WHO 1973 grades. The 1973 system classified papillary lesions as papilloma and transitional cell carcinoma grades 1, 2 and 3 (CAP Bladder Resection 2023). WHO 1973 papilloma equals 2004 papilloma, and grade 3 is by definition high grade. Grades 1 and 2 have no direct translation (Montironi et al. 2011). Both systems may be used concurrently (CAP Bladder Resection 2023).
  • PUNLMP. PUNLMP has delicate papillae with little fusion, minimal architectural irregularity, nuclei of roughly normal size, fine chromatin, inconspicuous nucleoli and infrequent basal mitoses. Pooled data showed recurrence in 36% and stage progression in 3.7% (Montironi et al. 2011). Among 189 primary PUNLMPs followed for a median of 61 months, 20.1% recurred, mostly as PUNLMP or low-grade carcinoma, and 1.6% progressed to high-grade carcinoma (Maxwell et al. 2015). The WHO 5th edition retains PUNLMP because its recurrence and progression rates are lower than those of pTa low-grade carcinoma (Raspollini et al. 2022).
  • Low-grade papillary carcinoma. Papillae are largely delicate with some fusion, and the cells look ordered at low power. Nuclei are uniformly enlarged with fine chromatin and inconspicuous nucleoli, and mitoses are few and basal. Mean recurrence was 50% and mean stage progression 10% (Montironi et al. 2011).
  • High-grade papillary carcinoma. Papillae are often fused, with disordered growth, discohesive cells, hyperchromatic pleomorphic nuclei, clumped chromatin, prominent nucleoli and mitoses at any level. Progression to invasive carcinoma ranges from 15% to 40% (Montironi et al. 2011).
Feature Urothelial papilloma PUNLMP Noninvasive papillary carcinoma, low grade Noninvasive papillary carcinoma, high grade Source
Architecture Simple, nonhierarchical papillae Delicate papillae, little fusion Mostly delicate papillae, some fusion Frequent fusion, disordered growth McKenney et al. 2003; Montironi et al. 2011
Urothelium Normal thickness with prominent umbrella cells Thickened, minimal irregularity Ordered at low power Variable thickness; discohesive McKenney et al. 2003; Montironi et al. 2011
Nuclei and mitoses Normal-appearing urothelial nuclei Roughly normal size; fine chromatin; infrequent basal mitoses Uniformly enlarged; fine chromatin; small nucleoli; few basal mitoses Pleomorphic, hyperchromatic; prominent nucleoli; frequent mitoses at any level McKenney et al. 2003; Montironi et al. 2011
WHO 1973 equivalent Papilloma No direct translation No direct translation Includes all WHO 1973 grade 3 Montironi et al. 2011
Recurrence 1 of 14 (de novo) 20% to 36% About 50% About 50% McKenney et al. 2003; Maxwell et al. 2015; Montironi et al. 2011
Progression 1 of 14 (immunosuppressed patient) 1.6% to 3.7% About 10% 15% to 40% McKenney et al. 2003; Maxwell et al. 2015; Montironi et al. 2011
  • Grade heterogeneity. Mixed grade occurs in about one third of noninvasive papillary carcinomas (Raspollini et al. 2022).
  • WHO 5th edition rule. A papillary carcinoma is reported as high grade when the high-grade component is 5% or more. A tumor with less than 5% high-grade component is reported as low grade with less than 5% high-grade component (Raspollini et al. 2022; CAP Bladder Resection 2023).
  • Previous rule. The WHO 2004 consensus graded heterogeneous tumors on their worst area (Montironi et al. 2011).
  • ISUP 2022 position. Predominantly low-grade tumors with a focal high-grade component had outcomes intermediate between low-grade and high-grade tumors, but no consensus defined a focal high-grade component (Paner et al. 2024).
  • Other grading proposals. ISUP 2022 Working Group 1 found a strong preference to refine grading into a three-tier scheme by dividing WHO 2004 high grade into clinically relevant categories, with variable opinions on PUNLMP (Downes et al. 2024). A hybrid grading approach has been proposed (Collins et al. 2026). The WHO 5th edition keeps the two-tier system (Raspollini et al. 2022).
  • Molecular pathways. Papillomas and low-grade carcinomas show a high incidence of FGFR3 mutations, unlike high-grade and high-stage cancers (Lott et al. 2009). TERT promoter mutations occur in about 60% to 80% of bladder cancers and across benign, precursor and malignant urothelial lesions (Cheng et al. 2023).

Invasive urothelial carcinoma: recognizing lamina propria and muscularis propria invasion

  • Features of lamina propria invasion. Invasion appears as single cells, nests or finger-like extensions. Invasive cells often show more nuclear pleomorphism and more abundant eosinophilic cytoplasm than the overlying tumor. The stroma may be desmoplastic or heavily inflamed. When there is no stromal response, the diagnosis rests on the irregular contours of nests, architectural complexity and single-cell invasion (Montironi et al. 2011).
  • Paradoxical maturation and pseudoinvasion. Retraction artifact, paradoxical maturation (differentiation), desmoplasia and complex irregular growth are the morphologic criteria of invasion. Irregular carcinoma nests in dense hyalinized stroma without the other criteria (pseudoinvasion) occurred in 26 of 233 noninvasive papillary carcinomas (11.2%). Pseudoinvasion was associated with larger tumors, male sex and infarcted papillae, and none of these tumors progressed to invasive carcinoma (Abulaban et al. 2024).
  • Location of invasion. In papillary tumors, invasion occurs most often at the base and very infrequently in the stalk (CAP Bladder Biopsy 2025).
  • Retraction artifact. Nests in the lamina propria often show retraction spaces that are overdiagnosed as vascular invasion. Vascular invasion with lamina propria invasion is uncommon and is diagnosed only when unequivocal or confirmed by immunohistochemistry (Montironi et al. 2011). Endothelial markers such as CD31 and CD34 highlight vessels but do not resolve lymphatic invasion versus artifactual retraction (CAP Bladder Biopsy 2025).
  • Sources of error in assessing invasion. Recognized sources of error are tangential sectioning, thermal artifact, obscuring inflammation, carcinoma in situ in von Brunn nests, deceptively bland nested and microcystic carcinomas, invasion into muscle of indeterminate type and invasion into lamina propria fat (Montironi et al. 2011).
  • Immunohistochemistry in staging. Broad-spectrum keratin can reveal early or obscured invasion, and desmin can separate muscle from desmoplasia (Amin et al. 2014).
  • Type of muscle. "Muscle invasive" alone is inappropriate, and the report states whether muscularis mucosae (pT1) or muscularis propria (pT2) is invaded. Muscularis mucosae anatomy and the descriptive diagnosis used when the muscle type cannot be determined are given in Non-neoplastic Lesions of the Bladder and Urothelial Tract. Reporting of muscularis propria status and pT2 subcategories is covered in Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder.

Grading of invasive urothelial carcinoma

  • WHO 5th edition. Every invasive urothelial carcinoma must be graded. Most show high-grade cytology, but invasive carcinomas lacking marked atypia and architectural disorder occur. Low-grade pT1 tumors have a more favorable outcome than high-grade pT1 tumors (Raspollini et al. 2022).
  • Distribution of grades. By the 2004 WHO system, most pT1 carcinomas are high grade, and the rare invasive low-grade tumors show only limited superficial invasion. By the 1973 system, most pT1 tumors are G2 or G3 with significant outcome differences. ISUP 2022 reached no consensus on which system to use for T1 tumors (Paner et al. 2024).
  • Subtypes and pure nonurothelial carcinomas. All subtypes and divergent differentiations are graded high grade, even bland ones such as nested and microcystic carcinoma (Raspollini et al. 2022; Paner et al. 2024). Grading of pure squamous cell carcinoma and adenocarcinoma is described in Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder.

Extent of lamina propria invasion (pT1 subcategorization)

  • WHO 5th edition. The WHO 5th edition strongly suggests quantifying lamina propria invasion with any of the proposed systems. Histoanatomic systems use invasion within or beyond the muscularis mucosae or the large vessels of the lamina propria. Micrometric systems measure the invasive component, with variable cut-offs (Raspollini et al. 2022).
  • ISUP 2022 Working Group 3. Consensus (83% of attendees) favored routine reporting of T1 subcategory on transurethral resections. Semiquantitative methods were favored by 37% and histoanatomic methods by 4%, and 59% had no preference. The report states the method, criteria including cut-off, and limitations. Terminology preferences were T1 microinvasive versus T1 extensive (34%) and T1 focal versus T1 nonfocal (20%) (Lopez-Beltran et al. 2024).
  • CAP. CAP encourages an estimate of lamina propria invasion as the maximum dimension of the invasive focus, the depth in millimeters or the level relative to the muscularis mucosae (CAP Bladder Biopsy 2025).
  • Feasibility of histoanatomic substaging. The micrometric cut-off for microinvasion now proposed is 0.5 mm (Paner et al. 2017). Histoanatomic substaging is less feasible in TUR specimens because the depth of lamina propria, muscularis mucosae and vascular plexus varies (Paner et al. 2017). Before this consensus, the WHO 2004 group recommended an estimate of lamina propria invasion without formal adoption into TNM (Montironi et al. 2011).

Subtypes and divergent differentiation of invasive urothelial carcinoma

  • Reporting rule (ISUP 2022). Participants unanimously recommended reporting every subtype and divergent differentiation because of concern for undertreatment. Their extent is documented in biopsy, TUR and cystectomy specimens. Each is diagnosed without a threshold, and each is listed in tumors with combined morphologies. All are high grade, and their behavior differs by subtype (Paner et al. 2024).
  • WHO 5th edition and CAP. The WHO 5th edition emphasizes reporting the presence and percentage of each subtype and divergent differentiation (Raspollini et al. 2022). CAP offers an optional list of percentages that total 100%, including admixed neuroendocrine carcinoma (CAP Bladder Resection 2023). CAP names sarcomatoid, micropapillary and plasmacytoid carcinoma as more aggressive subtypes (CAP Bladder Resection 2023).
  • Deceptively bland subtypes. Microcystic, tubular, nested and large nested carcinomas can look benign when pure (Raspollini et al. 2022).
Subtype or divergent differentiation Diagnostic features Immunohistochemistry, genetics or other findings Behavior Source
Squamous differentiation Squamous component with a recognizable urothelial component Pure squamous histology is required for squamous cell carcinoma High grade CAP Bladder Resection 2023; Paner et al. 2024
Glandular differentiation Gland formation within urothelial carcinoma SATB2 in the glandular component of 22% High grade Giannico et al. 2017; Paner et al. 2024
Trophoblastic differentiation Syncytiotrophoblasts or choriocarcinoma within urothelial carcinoma; other subtypes in 31% hCG in 93%, often also in the urothelial component; HSD3B1 in 100% and limited to trophoblasts Muscle invasion in 71% of bladder tumors; metastases in 44% Przybycin et al. 2020
Müllerian differentiation Müllerian-type component within urothelial carcinoma Pure clear cell or endometrioid carcinoma is classified as a Müllerian tumor High grade CAP Bladder Resection 2023; Raspollini et al. 2022
Nested Small, variably sized, crowded nests with banal cytology and a jagged, infiltrative deep interface; focal random atypia in 90% CK7 93%, CK20 68%, p63 92%, CK903 92% 65% in perivesical fat and 17% in adjacent organs at resection Wasco et al. 2010
Large nested Large regular or irregular nests with bland nuclei; low-grade papillary surface component in 18 of 23 Conventional invasive patterns in 7 of 23 Muscularis propria invasion in 20 of 23; metastases in 3 of 17 Cox and Epstein 2011
Tubular and microcystic Tubules or round to oval cysts lined by urothelial, low columnar or flattened cells CK7, CK20, p63 and GATA3 variably positive Survival similar to conventional carcinoma; mimics cystitis glandularis and adenocarcinoma Lopez Beltran et al. 2014; Raspollini et al. 2022
Micropapillary Slender filiform processes on the surface; tight clusters within lacunae in the invasive component, resembling ovarian serous carcinoma High-grade cytology; vascular invasion in micropapillary areas High stage; metastases in 8 of 18; micropapillary pattern predominant in metastases Amin et al. 1994
Lymphoepithelioma-like Syncytial sheets resembling nasopharyngeal lymphoepithelioma; carcinoma in situ in 50% 34βE12 75%, CK7 57%, p63 53%, CK20 negative; EBV and HPV negative Pure or predominant tumors did well after TUR and chemotherapy Williamson et al. 2011
Plasmacytoid Discohesive cells with eccentric nuclei and abundant cytoplasm, in cords, nests, sheets or single cells; signet-ring-like vacuoles in some CK7 94%, CD138 94%; truncating CDH1 alterations in 84% 11 of 16 died of disease; mimics chronic cystitis, plasmacytoma and gastric or breast metastasis Nigwekar et al. 2009; Al-Ahmadie et al. 2016
Giant cell Bizarre, anaplastic tumor giant cells forming 10% to 30% of the tumor, always with conventional high-grade carcinoma Uroplakin II, GATA3, CK7, CK20 and S100P; Ki-67 mean 71% Advanced disease in 35%; lower survival Portugal-Gaspar et al. 2024
Poorly differentiated, including osteoclast-rich undifferentiated carcinoma Mononuclear tumor cells with evenly spaced osteoclast-like giant cells; adjacent carcinoma in situ or high-grade papillary carcinoma Giant cells CD68 positive and keratin negative; mononuclear cells keratin positive in 4 of 6 4 of 5 patients died within 15 months Baydar et al. 2006; Portugal-Gaspar et al. 2024
Lipid-rich Lipoblast-like tumor cells MDM2 positive in 6 of 8, a pitfall for liposarcoma 5-year survival 46%; worse with more than 10% lipid-rich component Li et al. 2026
Clear cell (glycogen-rich) Sheets of cells with clear cytoplasm "Glycogen-rich" separates it from Müllerian clear cell adenocarcinoma High grade Raspollini et al. 2022
Sarcomatoid Biphasic tumor with epithelial and mesenchymal differentiation; heterologous elements in 10% Epithelial differentiation by morphology or immunohistochemistry 56% died within 1 year Fatima et al. 2015
  • Behavior of nested carcinoma. Despite bland cytology, nested carcinoma was more often muscle invasive at TUR, extravesical at cystectomy and metastatic than pure high-grade conventional carcinoma (Wasco et al. 2010). Large nested carcinoma is separated from inverted growth and von Brunn nests by muscularis propria invasion, irregular infiltrating nests or a stromal reaction (Cox and Epstein 2011).
  • Micropapillary carcinoma on biopsy. A surface micropapillary component is a poor prognostic feature, and deeper biopsies are recommended when the biopsy lacks muscularis propria (Amin et al. 1994).
  • Urothelial markers in subtypes. Uroplakin II and GATA3 expression by subtype, small cell carcinoma and pure neuroendocrine tumors are described in Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder.

Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder

Definition. Carcinomas of the bladder, renal pelvis and ureter, and urethra are staged pathologically by the AJCC 8th edition and reported with CAP elements, immunohistochemistry for urothelial origin and predictive biomarkers. Nonurothelial tumors of the bladder include squamous cell carcinoma, adenocarcinoma, urachal carcinoma, neuroendocrine carcinomas, villous adenoma and mesenchymal tumors, including embryonal rhabdomyosarcoma. More than 95% of carcinomas of the bladder and of the renal pelvis and ureter are urothelial (CAP Bladder Resection 2023; CAP Ureter Renal Pelvis 2025).

Current standards. Tumor types follow the WHO Classification of Tumours, Urinary and Male Genital Tumours, 5th edition (2022) (Netto et al. 2022; CAP Bladder Resection 2023). AJCC 8th edition staging applies to the bladder, renal pelvis and ureter, and urethra (CAP Bladder Resection 2023; CAP Ureter Renal Pelvis 2025; CAP Urethra 2024). The current CAP protocols are Urinary Bladder Resection 4.2.0.0 (September 2023), Urinary Bladder Biopsy and TURBT 4.3.0.0 (June 2025), Urethra Resection 4.3.0.0 (December 2024) and Ureter, Renal Pelvis Resection 2.4.0.0 (March 2025) (CAP Protocol Templates 2026).

Related page: Non-neoplastic Lesions of the Bladder and Urothelial Tract (bladder wall layers and their staging meaning, diverticula, urachal remnants, intestinal metaplasia) Related page: Urothelial Neoplasia: Papillomas, Flat Lesions, Noninvasive Papillary Carcinoma, Carcinoma In Situ and Invasive Urothelial Carcinoma (WHO 5th edition classification, grading, invasion criteria, subtypes and T1 extent) Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (renal pelvic urothelial carcinoma versus collecting duct and FH-deficient renal cell carcinoma) Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (Lynch syndrome and mismatch repair and microsatellite instability testing) Related page: Colorectal Adenocarcinoma: Histologic Subtypes, Grade, Tumor Budding and the Malignant Polyp (colorectal adenocarcinoma involving the bladder) Related page: Non-Urothelial and Secondary Malignancies in Urine Cytology (squamous cell carcinoma, adenocarcinoma and small cell carcinoma in urine) Related page: Ancillary Tests, Indications and Management in Urine Cytology (urine biomarkers and surveillance)

Immunohistochemistry for urothelial origin

ISUP 2013 found no single ideal marker of urothelial differentiation. In the appropriate context, positivity for GATA3, CK20, p63 and either high-molecular-weight cytokeratin or CK5/6 supports urothelial origin (Amin et al. 2014a).

Marker Urothelial carcinoma Other tumors that express it, or the contrasting tumor Source
GATA3 67% of 308 (one antibody); more than 90% (clone L50-823) Breast carcinoma over 90%; paraganglioma usually positive; chromophobe RCC 51%; prostatic adenocarcinoma under 10% Higgins et al. 2007; Miettinen et al. 2014
Uroplakin II 44% of bladder and 67% of upper tract carcinomas; 91% of micropapillary, 63% of plasmacytoid, 29% of sarcomatoid Rare in small cell carcinoma Li et al. 2014
Uroplakin III 17% of bladder and 46% of upper tract carcinomas Less sensitive than uroplakin II in every subtype tested Li et al. 2014
S100P 78% to 86% Prostatic adenocarcinoma 2% to 3%; RCC 0% to 1% Higgins et al. 2007
p63 87% (95% when combined with S100P) CK5/6, the alternative basal marker, stained only 54% Higgins et al. 2007
CK7 and CK20 Nested carcinoma CK7 93%, CK20 68%; plasmacytoid CK7 94%, CK20 31% CK20 negative in lymphoepithelioma-like carcinoma Wasco et al. 2010; Nigwekar et al. 2009; Williamson et al. 2011
PAX8 Negative in 48 of 48 Nephrogenic adenoma and clear cell adenocarcinoma positive Tong et al. 2008
GATA3 in subtypes Plasmacytoid 44% (7 of 16), 82% (37 of 45) and 96% in three series; micropapillary 57%; nested carcinoma expressed GATA3 with other luminal markers in all 60 cases Sarcomatoid 16%, small cell 5% and squamous cell carcinoma 7% Liang et al. 2014; Borhan et al. 2017; Perrino et al. 2019; Weyerer et al. 2019
SATB2 and CDX2 Glandular component of urothelial carcinoma SATB2 positive in 22% Primary bladder adenocarcinoma 49% and colorectal adenocarcinoma 77%; SATB2 does not separate them Giannico et al. 2017

Predictive and molecular biomarkers in urothelial carcinoma

Biomarker Test Therapy and regulatory status Pathology points Source
FGFR3 genetic alterations FDA-approved companion diagnostic test Erdafitinib: FDA traditional approval on January 19, 2024, for locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations that progressed after at least 1 prior systemic therapy; not recommended for patients eligible for and not yet treated with PD-1 or PD-L1 inhibitors In the THOR trial, median overall survival was 12.1 months with erdafitinib and 7.8 months with chemotherapy Maguire et al. 2026; Loriot et al. 2023
Nectin-4 Immunohistochemistry (H-score above 15 as positive in one study) Target of the antibody-drug conjugate enfortumab vedotin; enfortumab vedotin plus pembrolizumab received FDA traditional approval on December 15, 2023, for locally advanced or metastatic urothelial carcinoma Positive in 87% of nonmuscle-invasive tumors; low in sarcomatoid (1 of 10), micropapillary (3 of 11) and small cell carcinoma (0 of 15) Brave et al. 2024; Hoffman-Censits et al. 2021
HER2 (ERBB2) Immunohistochemistry Trastuzumab deruxtecan: FDA accelerated approval on April 5, 2024, for unresectable or metastatic HER2-positive (IHC 3+) solid tumors after prior systemic treatment without satisfactory alternatives Sarcomatoid and small cell carcinomas with low nectin-4 often express ERBB2 or TROP2 RNA FDA 2024; Hoffman-Censits et al. 2021
PD-L1 Immunohistochemistry with 22C3, SP263 or SP142, scored by combined positive score or immune cell algorithms Checkpoint inhibitors; EAU recommends offering pembrolizumab or atezolizumab to patients with PD-1 or PD-L1-positive metastatic upper tract carcinoma 22C3 and SP263 agreed in 89.6% by combined positive score; SP142 gave lower positivity rates Munari et al. 2022; Rouprêt et al. 2023
TERT promoter mutation Sequencing of tissue, urine or plasma cell-free DNA Diagnostic and surveillance marker Present in about 60% to 80% of bladder cancers, including subtypes and some benign and precursor lesions Cheng et al. 2023
Tumor mutational burden (TMB) FDA-approved test; TMB-high is 10 or more mutations per megabase Pembrolizumab: FDA approval on June 16, 2020, for unresectable or metastatic TMB-high solid tumors that progressed after prior treatment without satisfactory alternatives First FDA cancer approval based on TMB; overall response rate 29% in 102 TMB-high tumors of nine types (KEYNOTE-158) Marcus et al. 2021
DNA damage repair genes Sequencing Associated with better response to cisplatin-based chemotherapy Alterations in ERCC2 and other DNA damage repair genes Raspollini et al. 2022
  • Molecular subgroups of muscle-invasive carcinoma. Six expression-based subgroups have different prognoses: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal-squamous (35%) and neuroendocrine-like (3%). FGFR3 mutations are more frequent in the luminal papillary subgroup, and TP53 mutations in the neuroendocrine-like, basal-squamous and luminal unstable subgroups. The WHO 5th edition does not use them for classification (Raspollini et al. 2022). ISUP 2022 Working Group 4 recognized three major molecular subtypes (luminal, basal-squamous and neuroendocrine) and found the data insufficient for routine use of subtyping to guide management (Warrick et al. 2024).
  • Small cell carcinoma phenotype. A fraction of small cell carcinomas express CK5/6, a basal subtype marker, which may underlie their response to chemotherapy (Wang et al. 2018).

Bladder cancer staging and CAP reporting

CAP reporting of bladder biopsy and transurethral resection specimens

  • Status of the specimen. A TURBT is not the definitive resection specimen even if it removes the whole tumor. The biopsy and TURBT protocol is recommended for clinical care and is not required for accreditation (CAP Bladder Biopsy 2025; CAP Bladder Resection 2023).
  • Reported elements. The protocol records procedure, tumor site, histologic type with optional percentages of subtypes and divergent differentiation, histologic grade, tumor extent, lymphatic and vascular invasion, tumor configuration and muscularis propria status. Extent options are noninvasive papillary carcinoma, flat carcinoma in situ, lamina propria invasion with its extent where possible, and muscularis propria invasion. Associated epithelial lesions, therapy-related change, cautery artifact, cystitis cystica et glandularis, keratinizing squamous metaplasia and intestinal metaplasia are optional additional findings (CAP Bladder Biopsy 2025).
  • Muscularis propria (version 4.3.0.0, June 2025). Muscularis propria is recorded as not identified, present and negative for tumor, present and involved by tumor, or cannot be determined (CAP Bladder Biopsy 2025). In the previous version the question did not offer "present, negative for tumor" and "present, involved by tumor" (CAP Protocol Templates 2026).
  • Prostatic tissue in TURBT chips. Three extent options record carcinoma in prostatic urethra, ducts or acini without stromal invasion; in prostatic subepithelial connective tissue; and in prostatic stroma. Prostatic involvement on TUR is not automatically T4 (CAP Bladder Biopsy 2025).
  • Lymphatic and vascular invasion. Lymphatic and vascular invasion independently predicts recurrence and decreased overall survival, and on TURBT it is associated with nodal metastasis. Retraction artifact in lamina propria invasion and in micropapillary carcinoma is the main pitfall (CAP Bladder Biopsy 2025).

Cystectomy grossing and sampling

  • Tumor and mucosa. Several sections of tumor include the deepest gross penetration. Mucosa remote from the tumor is sampled from the lateral walls, dome and trigone, especially if abnormal. After neoadjuvant chemotherapy with no gross lesion, all bladder sites are sampled with correlation to prior TUR sites (CAP Bladder Resection 2023).
  • Margins. One section each of the ureteral margins and the urethral margin is submitted unless sent as frozen sections. Long ureteral segments need mid-portion sections because urothelial cancer is often multifocal. Soft tissue margins state peritoneal involvement, and partial cystectomies are assessed at the bladder wall margin (CAP Bladder Resection 2023).
  • Prostate and seminal vesicles. Sections include the prostatic urethra with surrounding parenchyma at the margin, the peripheral and central zones and the seminal vesicles. Targeted sections show the relationship of bladder tumor to an invaded prostate, uterus or vagina (CAP Bladder Resection 2023).
  • Lymph nodes. One section is submitted from each grossly positive node, and all other nodes are submitted entirely. Nodes may be found in the perivesical fat (CAP Bladder Resection 2023).
  • Treatment response. CAP grades response after neoadjuvant chemotherapy as complete response (no residual cancer with tumor bed fibrosis; TRG1), strong response (residual cancer occupying less than 50% of a fibrotic tumor bed; TRG2), or weak or no response (residual cancer occupying 50% or more, or no regression; TRG3). BCG response is excluded from this element (CAP Bladder Resection 2023).

AJCC 8th edition pTNM for urinary bladder

Category Definition Source
pTa Noninvasive papillary carcinoma CAP Bladder Resection 2023
pTis Urothelial carcinoma in situ ("flat tumor") CAP Bladder Resection 2023
pT1 Invades lamina propria (subepithelial connective tissue) CAP Bladder Resection 2023
pT2a Invades superficial muscularis propria (inner half) CAP Bladder Resection 2023
pT2b Invades deep muscularis propria (outer half) CAP Bladder Resection 2023
pT3a Invades perivesical soft tissue microscopically CAP Bladder Resection 2023
pT3b Invades perivesical soft tissue macroscopically (extravesical mass) CAP Bladder Resection 2023
pT4a Extravesical tumor invades directly into prostatic stroma, uterus or vagina (pT4 also lists seminal vesicles) CAP Bladder Resection 2023
pT4b Extravesical tumor invades pelvic wall or abdominal wall CAP Bladder Resection 2023
pN1 Single regional node in the true pelvis (perivesical, obturator, internal and external iliac or sacral) CAP Bladder Resection 2023
pN2 Multiple regional nodes in the true pelvis CAP Bladder Resection 2023
pN3 Common iliac node metastasis CAP Bladder Resection 2023
pM1a Distant metastasis limited to lymph nodes beyond the common iliacs CAP Bladder Resection 2023
pM1b Non-lymph-node distant metastasis CAP Bladder Resection 2023
  • Descriptors. The suffix (m) indicates multiple synchronous primary tumors, and "is" may be added to indicate associated carcinoma in situ. The prefix y marks classification during or after neoadjuvant therapy and records the tumor present at that examination. The prefix r marks recurrence after a disease-free interval (CAP Bladder Resection 2023).
  • pT2 and pT3 subcategories. pT2a and pT2b are assigned only on cystectomy, and pT3b is best assessed grossly as macroscopic perivesical involvement (CAP Bladder Resection 2023). Reliance on the prosector's gross assessment can misclassify pT3 tumors (Paner et al. 2017).
  • Fat and diverticula. Fat in the lamina propria and muscularis propria, and the absence of muscularis propria in diverticula, are described with their staging consequences in Non-neoplastic Lesions of the Bladder and Urothelial Tract.
  • Seminal vesicle invasion and sex differences. Bladder cancer invading the seminal vesicle had outcomes comparable to pT4b tumors, and several studies found poorer outcomes for pT4a tumors in women than in men (Paner et al. 2017).

Prostatic stromal invasion: bladder pT4a versus urethral pT2

  • Transmural route. A bladder carcinoma that invades through the bladder wall into the base of the prostate, or into extravesical fat and back into the prostate, is direct transmural invasion and is staged pT4a by bladder staging (CAP Bladder Resection 2023).
  • Transurethral mucosal route. Carcinoma that spreads along the prostatic urethral mucosa and prostatic ducts and then invades prostatic stroma is staged pT2 by urethral (prostatic urethra) staging. The concurrent bladder cancer receives its own bladder stage (CAP Bladder Resection 2023).
  • Large tumors. A large bladder carcinoma that invades full thickness and secondarily involves prostatic stroma is staged pT4 by bladder staging. Otherwise, involvement of both sites receives separate bladder and prostatic urethral stages (CAP Bladder Resection 2023).
  • Urethral checklist. Tumor involving urethral mucosa, prostatic subepithelial connective tissue, or prostatic ducts and acini with or without stromal invasion is reported with the urethral protocol (CAP Bladder Resection 2023).

Upper tract urothelial carcinoma

  • Histology. The full range of bladder subtypes occurs in the renal pelvis and ureter. The pure-histology rule for squamous, glandular and Müllerian carcinoma applies as in the bladder (CAP Ureter Renal Pelvis 2025). Upper tract carcinomas often present at a higher stage than bladder carcinomas (CAP Ureter Renal Pelvis 2025).
  • Lynch syndrome. Upper tract urothelial carcinoma develops in up to 28% of patients with known Lynch syndrome (CAP Ureter Renal Pelvis 2025). It is the third most common malignancy in Lynch syndrome. Mismatch repair protein loss occurred in 9% of upper tract carcinomas and 1% of bladder carcinomas, most often isolated MSH6 loss (8 of 10). A personal history of colorectal cancer was the only predictor, and 1% to 3% of all upper tract carcinomas may be Lynch-associated. Universal reflex mismatch repair immunohistochemistry followed by microsatellite testing has been proposed (Ju et al. 2018). EAU guidelines include assessment of Lynch syndrome risk (Rouprêt et al. 2023). Testing methods are covered in Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing.
  • Aristolochic acid and Balkan endemic nephropathy. Endemic (Balkan) nephropathy affects rural villages in Bosnia, Bulgaria, Croatia, Romania and Serbia, progresses to renal failure and is strongly associated with upper tract urothelial carcinoma. Aristolactam DNA adducts in renal cortex and tumors, and TP53 mutations dominated by A:T to T:A transversions (78% of A:T mutations), implicate dietary aristolochic acid (Grollman et al. 2007).
  • Analgesics. Renal pelvic tumors are more frequent in analgesic abusers with analgesic nephropathy and papillary necrosis (CAP Ureter Renal Pelvis 2025).
  • Anatomy that affects staging. Lamina propria is absent beneath the urothelium of the renal papillae and thin along the minor calyces. Muscularis mucosae is essentially absent in the renal pelvis and ureter, so any muscle invasion is pT2. In situ extension into collecting ducts and tubules does not change stage. Invasion of renal parenchyma is pT3, and invasion through the kidney into perinephric fat is pT4 (CAP Ureter Renal Pelvis 2025).
  • Inverted growth. Upper tract papillary carcinoma can push into subepithelial tissue as noninvasive inverted growth (pTa) that must be separated from true invasion (CAP Ureter Renal Pelvis 2025).
  • Grossing. The outer surface is inked and the ureter opened longitudinally. Sections show the relation of tumor to renal parenchyma, peripelvic fat, the nearest soft tissue margin and ureter. The bladder cuff is the key urothelial margin and is sampled perpendicularly after fixation (CAP Ureter Renal Pelvis 2025).
  • Version 2.4.0.0. Lymphatic and vascular invasion became a core element, and well-differentiated neuroendocrine tumor was added to histologic types (CAP Ureter Renal Pelvis 2025).
  • Management context. Kidney-sparing management is offered for low-risk disease with two functioning kidneys. For high-risk disease, adjuvant platinum chemotherapy after nephroureterectomy, or adjuvant nivolumab for patients unfit for or declining chemotherapy, are options (Rouprêt et al. 2023).
Category (AJCC 8th edition) Renal pelvis and ureter Source
pTa Papillary noninvasive carcinoma CAP Ureter Renal Pelvis 2025
pTis Carcinoma in situ CAP Ureter Renal Pelvis 2025
pT1 Invades subepithelial connective tissue CAP Ureter Renal Pelvis 2025
pT2 Invades the muscularis CAP Ureter Renal Pelvis 2025
pT3 Renal pelvis: beyond muscularis into peripelvic fat or renal parenchyma. Ureter: beyond muscularis into periureteric fat CAP Ureter Renal Pelvis 2025
pT4 Invades adjacent organs, or through the kidney into perinephric fat CAP Ureter Renal Pelvis 2025
pN1 Single lymph node, metastasis 2 cm or less CAP Ureter Renal Pelvis 2025
pN2 Single node with metastasis larger than 2 cm, or multiple nodes CAP Ureter Renal Pelvis 2025
  • Regional nodes. Renal pelvis: renal hilar, paracaval, aortic and retroperitoneal. Ureter: renal hilar, iliac (common, internal, external), paracaval, periureteral and pelvic. Nodes beyond these are distant metastasis (M1) (CAP Ureter Renal Pelvis 2025).

Urethral carcinoma

  • Incidence. In SEER data from 1973 to 2002, primary urethral carcinoma occurred at 4.3 per million men and 1.5 per million women per year, peaked at ages 75 to 84 years and was more common in African Americans. Histologic types were urothelial (transitional cell) carcinoma (55%), squamous cell carcinoma (21.5%) and adenocarcinoma (16.4%) (Swartz et al. 2006). From 2004 to 2016, urothelial carcinoma remained the most frequent type (Wenzel et al. 2021).
  • Histology by sex and site (CAP). In women, squamous cell carcinoma is described as most common (about 75%), mainly in the distal third. Urothelial carcinoma and adenocarcinoma each account for about 10% to 15%, and clear cell adenocarcinoma forms a significant proportion of adenocarcinomas. In men, most tumors involve the bulbomembranous urethra, followed by the penile and prostatic urethra, with squamous cell carcinoma in 80%. Urothelial carcinomas are typically proximal. Adenocarcinomas may arise from Skene glands (female) or Littre glands (male) (CAP Urethra 2024).
  • Urethral diverticulum and clear cell adenocarcinoma. Of 19 urethral clear cell adenocarcinomas, 18 occurred in women, and 12 arose within a urethral diverticulum. They showed tubulocystic, papillary and diffuse patterns with hobnail and clear cells, at least moderate pleomorphism and easily found mitoses. PSA and PSAP were negative. Four of 13 patients died of disease (Oliva and Young 1996). Clear cell adenocarcinoma is PAX8 positive (Tong et al. 2008).
  • WHO 5th edition accessory gland tumors. Carcinomas of Littre, Skene and Cowper glands are listed as urethral accessory gland tumors (CAP Urethra 2024).
  • Prostatic urethra rule. In the prostatic urethra, pT1 applies only to superficial invasion from the urethral lining. Invasion from prostatic ducts into prostatic stroma is at least pT2 (CAP Urethra 2024).
  • Sampling. One section per centimeter of tumor, including the deepest penetration, documents the relationship to corpus spongiosum, corpus cavernosum, prostate, periurethral muscle, vagina and bladder. Distal and proximal urethral margins are usually submitted en face (CAP Urethra 2024).
Category (AJCC 8th edition) Male penile urethra and female urethra Prostatic urethra Source
pTa Noninvasive papillary carcinoma Noninvasive papillary carcinoma CAP Urethra 2024
pTis Carcinoma in situ Carcinoma in situ of the prostatic urethra or periurethral or prostatic ducts without stromal invasion CAP Urethra 2024
pT1 Invades subepithelial connective tissue Invades urethral subepithelial connective tissue immediately beneath the urothelium CAP Urethra 2024
pT2 Invades corpus spongiosum or periurethral muscle Invades prostatic stroma around ducts, by direct extension from the surface or from prostatic ducts CAP Urethra 2024
pT3 Invades corpus cavernosum or anterior vagina Invades periprostatic fat CAP Urethra 2024
pT4 Invades other adjacent organs (for example, bladder wall) Invades other adjacent organs (for example, extraprostatic bladder wall or rectal wall) CAP Urethra 2024
pN1 Single regional node in the inguinal region or true pelvis (perivesical, obturator, internal and external iliac) or presacral node Single regional node in the same stations CAP Urethra 2024
pN2 Multiple regional nodes in the same stations Multiple regional nodes in the same stations CAP Urethra 2024

Squamous cell carcinoma of the bladder

  • Definition. Squamous cell carcinoma is diagnosed only when the tumor is purely squamous. Any recognizable papillary, invasive or in situ urothelial component makes it urothelial carcinoma with squamous differentiation (CAP Bladder Resection 2023). The WHO 5th edition squamous neoplasms are squamous cell carcinoma, verrucous carcinoma and squamous papilloma, and CAP also lists squamous cell carcinoma in situ (CAP Bladder Resection 2023).
  • Grading. Pure squamous cell carcinoma is graded by degree of differentiation as well, moderately or poorly differentiated (G1 to G3) (Paner et al. 2024; CAP Bladder Resection 2023).
  • Schistosoma haematobium. About two thirds of schistosome infections in Africa are caused by S. haematobium. Infection is carcinogenic and leads to squamous cell carcinoma and urothelial carcinoma of the bladder (Santos et al. 2021).
  • Keratinizing squamous metaplasia. In 34 patients, 4 had synchronous carcinoma. Six of 11 patients with metaplasia involving more than 50% of the mucosa and 2 of 16 with less extensive metaplasia later developed carcinoma. Keratinizing squamous metaplasia is a significant risk factor for bladder carcinoma, contracture and ureteral obstruction (Khan et al. 2002).
  • Verrucous carcinoma. Verrucous carcinoma is an exophytic, hyperkeratotic, well-differentiated squamous tumor with a pushing (bulbous) invasive front. Outside areas of endemic schistosomiasis it is sporadic, and it favors sites around diverticula and chronic inflammation. Metastasis is not characteristic, whereas about 25% of patients with conventional squamous cell carcinoma have metastasis at cystectomy. Immunohistochemistry does not help, and fragmented transurethral material can prevent a definite diagnosis (Leunbach et al. 2022).
  • Verrucous squamous hyperplasia. In 23 cases, 11 were associated with carcinoma at diagnosis, and all 13 tested were negative for high-risk HPV by in situ hybridization. Whether it is a precursor or a high-risk association is unresolved, and close follow-up is advised (Russell et al. 2022).
  • Precursor terms. ISUP 2024 squamous precursor terminology is described in Urothelial Neoplasia: Papillomas, Flat Lesions, Noninvasive Papillary Carcinoma, Carcinoma In Situ and Invasive Urothelial Carcinoma.

Primary adenocarcinoma of the bladder and its mimics

  • Definition and types. Primary adenocarcinoma makes up as much as 2% of bladder cancers and occurs predominantly in men. Patterns are enteric, mucinous, signet-ring cell and mixed (Santa et al. 2025). CAP lists adenocarcinoma NOS, enteric, mucinous, mixed and signet-ring cell types, and adenocarcinoma in situ (CAP Bladder Resection 2023). As with squamous cell carcinoma, the diagnosis requires pure glandular histology (CAP Bladder Resection 2023).
  • Outcome. In 72 adenocarcinomas, 24 were urachal and 48 nonurachal. Stage was the most significant predictor of outcome, and histologic type was not (Grignon et al. 1991).
  • Precursors and genetics. Possible precursors are villous adenoma, cystitis glandularis and intestinal metaplasia. KRAS, TP53 and PIK3CA mutations are shared with colorectal adenocarcinoma (Santa et al. 2025).
  • Secondary colorectal adenocarcinoma. SATB2 stained 49% of primary bladder adenocarcinomas and 77% of colorectal adenocarcinomas involving the bladder, with results similar to CDX2. Neither marker reliably separates primary from colorectal origin (Giannico et al. 2017). Among markers studied for urachal versus colorectal adenocarcinoma, only β-catenin and CK7 may help (Paner et al. 2016). The colorectal side is covered in Colorectal Adenocarcinoma: Histologic Subtypes, Grade, Tumor Budding and the Malignant Polyp.
  • Müllerian-type carcinomas. Clear cell adenocarcinoma and endometrioid carcinoma are tumors of Müllerian type (CAP Bladder Resection 2023). Clear cell adenocarcinoma of the bladder and urethra is PAX8 positive and AMACR (P504S) positive (Tong et al. 2008; Sun et al. 2008).
Feature Primary bladder adenocarcinoma Urachal adenocarcinoma Secondary colorectal adenocarcinoma Source
Location Anywhere in the bladder Dome and anterior wall, midline mass Metastasis or direct extension from the colon Santa et al. 2025; Kostara et al. 2025; Giannico et al. 2017
Patient profile Predominantly men Younger patients Known or concurrent colorectal primary Santa et al. 2025; Giannico et al. 2017
Immunohistochemistry SATB2 49%; CDX2 similar β-catenin and CK7 may help SATB2 77% Giannico et al. 2017; Paner et al. 2016
Diagnosis Pure glandular histology without a urothelial component Gross, histologic, clinical and imaging criteria with exclusion of metastasis Requires a colorectal primary; immunohistochemistry does not reliably separate it CAP Bladder Resection 2023; Reis et al. 2025; Giannico et al. 2017

Urachal carcinoma and urachal mucinous cystic tumors

  • Clinical features. Urachal carcinoma arises in the urachal remnant at the bladder dome and anterior wall. A solid or cystic midline mass with microcalcifications on CT or MRI is characteristic, and CA19-9, CA-125 and CEA may be elevated (Kostara et al. 2025). Of 130 urachal masses at the Mayo Clinic, 66 were malignant. Hematuria and age over 55 years were the strongest predictors of malignancy, and 5-year cancer-specific survival of urachal carcinoma was 49%. Grade and margin status were the only independent predictors of death, and complete extended partial cystectomy with umbilectomy was considered necessary (Ashley et al. 2006).
  • Diagnosis (ISUP 2023 Dublin consensus). Diagnosis combines gross, histologic, clinical and imaging findings with exclusion of metastasis. Nonglandular urachal carcinomas follow the nosology of bladder carcinomas, and immunohistochemistry on TUR specimens is optional (Reis et al. 2025).
WHO 5th edition criteria, noncystic urachal adenocarcinoma WHO 5th edition criteria, nonglandular urachal carcinoma (1 to 3 plus any one of 4 to 6) Source
1. Tumor in the dome or elsewhere in the bladder midline 1. Tumor in the dome or anterior wall and/or midline supravesical to the umbilicus Reis et al. 2025
2. Sharp demarcation between tumor and surface urothelium 2. Tumor epicenter away from the bladder surface Reis et al. 2025
3. Epicenter in muscularis propria or perivesical soft tissue, with intact or ulcerated overlying urothelium (surface colonization allowed) 3. No primary tumor of similar morphology elsewhere, except urothelial carcinoma of the genitourinary tract Reis et al. 2025
4. No extensive cystitis cystica et glandularis, particularly with dysplasia 4. Close relationship with urachal remnant structures Reis et al. 2025
5. No urothelial carcinoma in situ elsewhere in the bladder 5. Without an identifiable remnant, the tumor does not involve the intact bladder surface Reis et al. 2025
6. No primary adenocarcinoma in another organ 6. Without a remnant and with surface involvement: a cavitary or cystic tumor with intraluminal papillae (urothelial carcinoma) or a reverse invasive front Reis et al. 2025
  • Urachal remnants. Remnants are found in only 15% to 62.5% of urachal carcinomas, so the current criteria do not require one (Reis et al. 2025).
  • Reporting. Urachal carcinoma is excluded from the CAP bladder protocols (CAP Bladder Resection 2023). The Dublin consensus specified gross elements, sampling and histologic elements for TUR and resection reports. It called for a new staging approach and supported study of a modified bladder TNM system (Reis et al. 2025).
  • Invasive adenocarcinoma types. Noncystic invasive adenocarcinomas are enteric, mucinous, signet-ring cell, NOS or mixed, and 50% are mucinous. KRAS mutations occur in mucinous adenocarcinoma (Paner et al. 2016).
  • Mucinous cystic tumors. Urachal mucinous cystic tumors are classified like ovarian mucinous tumors: mucinous cystadenoma, mucinous cystic tumor of low malignant potential (65% of cystic tumors), the same with intraepithelial carcinoma, and microscopically or frankly invasive mucinous cystadenocarcinoma. Noninvasive cystic tumors have better progression-free survival than noncystic adenocarcinoma (Paner et al. 2016). In 55 glandular urachal neoplasms, none of 13 followed mucinous cystic tumors recurred, while 9 of 16 invasive adenocarcinomas recurred or caused death (Amin et al. 2014b). The Dublin consensus rejected a 5% or 10% cut-off for intraepithelial carcinoma in mucinous cystic tumor of low malignant potential (Reis et al. 2025).
  • Villous adenoma of the urachus. Benign urachal epithelial tumors include villous adenoma (Paner et al. 2016).
Stage Sheldon system Mayo system Source
I No invasion beyond the urachal mucosa Confined to the urachus and/or bladder Tan et al. 2026
II Invasion confined to the urachus Extends beyond the muscular layer of the urachus and/or bladder Tan et al. 2026
III Local extension into the bladder (IIIA), abdominal wall (IIIB), peritoneum (IIIC) or viscera other than the bladder (IIID) Regional lymph node metastasis Tan et al. 2026
IV Metastasis to lymph nodes (IVA) or distant sites (IVB) Nonregional lymph node or distant metastasis Tan et al. 2026
  • Comparison of systems. The Mayo system is simpler than the Sheldon system, and both predicted cancer-specific mortality equally well (Ashley et al. 2006). The bladder TNM system is not designed for urachal carcinoma and can overstage early tumors whose epicenter lies outside the bladder (Reis et al. 2025).

Neuroendocrine carcinomas of the bladder

  • WHO 5th edition terminology. Neuroendocrine neoplasms of the urinary tract are small cell neuroendocrine carcinoma, large cell neuroendocrine carcinoma, mixed neuroendocrine neoplasm, well-differentiated neuroendocrine tumor and paraganglioma (CAP Bladder Resection 2023). They are classified in a dedicated section using the 2017 IARC framework (Raspollini et al. 2022).
  • Small cell carcinoma, clinical features. In 64 patients, mean age was 66 years, men outnumbered women 3.3 to 1, 65% smoked and 88% had hematuria. All but 1 had muscle-invasive disease, 66% of cystectomies had nodal metastases and 5-year disease-specific survival was 16% (Cheng et al. 2004).
  • Mixed tumors. Small cell carcinoma was mixed with other histologic types in 68% of 64 patients, most often urothelial carcinoma, and pure and mixed tumors had similar survival (Cheng et al. 2004). In 81 cases, 54 were mixed, including urothelial carcinoma in situ in 26 (Wang et al. 2018).
  • Immunohistochemistry. Small cell carcinomas expressed synaptophysin (41 of 56), chromogranin (26 of 55) and CD56 (39 of 41), and lacked CK20 (0 of 17), GATA3 (1 of 30) and uroplakin II (1 of 22). RB1 protein was lost in most tumors (Wang et al. 2018). Nectin-4 was absent in all 15 small cell carcinomas tested (Hoffman-Censits et al. 2021).
  • Large cell and mixed neuroendocrine carcinoma. Small cell, large cell and mixed neuroendocrine carcinomas share histology, immunophenotype, Ki-67 rate and outcome. Larger nuclei in large cell and mixed tumors cause misdiagnosis as urothelial carcinoma, which can prevent early chemotherapy (Gupta et al. 2015).
  • Reporting any amount. Every subtype and divergent component is reported without a threshold (Paner et al. 2024), and CAP records the percentage of small cell and large cell neuroendocrine carcinoma (CAP Bladder Resection 2023).
  • Treatment implication. Most long-term survivors received platinum-based neoadjuvant chemotherapy followed by radical cystectomy, and neoadjuvant chemotherapy downstaged 45% of tumors (Jung et al. 2017).

Villous adenoma

Villous adenoma of the urinary tract resembles colonic villous adenoma, with finger-like processes lined by pseudostratified columnar cells with nuclear stratification and hyperchromasia. It occurs mainly in the urachus, dome and trigone of elderly patients. CK20 was positive in all cases and CK7 in 56%. Eight of 23 tumors had coexistent adenocarcinoma, and no isolated villous adenoma recurred or became invasive during a mean follow-up of 9.9 years (Cheng et al. 1999a).

Mesenchymal tumors of the bladder

  • Leiomyoma and leiomyosarcoma. Leiomyomas measured 0.5 to 4.5 cm (mean 1.6 cm), and half of the patients with high-grade leiomyosarcoma died of disease (Martin et al. 2002). Sarcomas are reported with the CAP soft tissue protocol (CAP Bladder Resection 2023). The spindle cell comparison, including leiomyosarcoma, is in Non-neoplastic Lesions of the Bladder and Urothelial Tract.
  • Hemangioma. In 19 bladder hemangiomas, mean age was 58 years, men outnumbered women 3.7 to 1 and macroscopic hematuria was typical. Tumors were small (median 0.7 cm), solitary and mainly on the posterior and lateral walls. Fifteen were cavernous, 2 capillary and 2 arteriovenous, and none recurred after biopsy with or without fulguration during a mean follow-up of 6.9 years (Cheng et al. 1999b).
  • Paraganglioma. Bladder paraganglioma accounts for about 0.05% to under 0.1% of bladder tumors (Zare et al. 2024; Menon et al. 2014). It is a catecholamine-secreting tumor, and post-micturition palpitations, headache, sweating and paroxysmal hypertension are characteristic presenting symptoms (Zare et al. 2024). In 14 tumors, growth was zellballen (72%), diffuse (21%) or ribbon-like (7%), with muscularis propria invasion in 72%. Cautery artifact caused misdiagnosis as urothelial carcinoma, and tumor cells were chromogranin and synaptophysin positive with S100-positive sustentacular cells (Menon et al. 2014). Paragangliomas are usually GATA3 positive (Miettinen et al. 2014).
  • SDH deficiency in paraganglioma. SDHB immunostaining was lost in 6 of 11 bladder paragangliomas. Five of the 6 had germline SDHB mutations, and 1 had a somatic SDHB deletion (Giubellino et al. 2015). In another series, SDHB loss occurred in 27%, patients with SDH-deficient tumors were younger (mean 39 versus 58 years), and both patients with SDHB-deficient, SDHA-intact tumors developed metastases. Loss of both SDHB and SDHA indicates an SDHA mutation (Mason et al. 2013).
  • PEComa. In 11 bladder PEComas, 9 patients were women (mean age 44.2 years). Tumors were epithelioid, cathepsin K positive in 10 of 11, HMB-45 positive in 8 of 11 and keratin negative in all. TFE3 rearrangement was found in 5 of 8 tested and was associated with epithelioid nested architecture. Two were malignant (Neumann et al. 2021).

Embryonal rhabdomyosarcoma of the bladder and prostate

  • Clinical features. Rhabdomyosarcoma is the most common tumor of the lower genitourinary tract in children, and most genitourinary cases are embryonal. Bladder and prostate tumors present with urinary or fecal retention, dysuria, infection and hematuria (Agrons et al. 1997).
  • Botryoid morphology. The botryoid form is a submucosal tumor that produces a grape-like polypoid mass within a hollow organ. It is characteristic of but not specific for bladder rhabdomyosarcoma, because yolk sac tumor and tumoral cystitis can look similar (Agrons et al. 1997). All botryoid-type embryonal rhabdomyosarcomas showed an exophytic, bulbous architecture with a subepithelial cambium layer. DICER1 alterations occurred only in the botryoid type, and botryoid tumors had better disease-specific survival than conventional embryonal tumors (8% versus 30% dead of disease) (Sharma et al. 2024).
  • Immunohistochemistry. All rhabdomyosarcomas expressed myogenin and MyoD1. Embryonal tumors showed more variable myogenin staining than alveolar tumors. Myogenin was negative in inflammatory myofibroblastic tumor, leiomyoma and leiomyosarcoma (Cessna et al. 2001). ALK staining was absent in bladder rhabdomyosarcomas (Freeman et al. 2004).
  • Outcome. In 88 children with localized bladder and prostate rhabdomyosarcoma, 70% arose in the bladder and 80% had favorable (embryonal or botryoid) histology. Six-year survival was 82%, and 40% of all patients survived event-free with normal bladder function (Arndt et al. 2004).

Prostate Anatomy, Benign Prostatic Hyperplasia, Prostatitis and Benign Mimics of Prostatic Carcinoma

Benign mimics of prostatic carcinoma. Atrophy and its variants are the lesions most often misdiagnosed as cancer, adenosis is the most problematic benign small-gland proliferation, and seminal vesicle epithelium is the normal structure that most often causes diagnostic problems (Egevad et al. 2021). Most benign mimics fall into the small-gland category of the Gleason diagram, while granulomatous prostatitis, xanthogranulomatous prostatitis and malakoplakia can simulate high-grade carcinoma (Srigley 2004).

Related page: Prostatic Adenocarcinoma: Needle Biopsy Diagnosis, Immunohistochemistry, Precursor and Intraductal Lesions, and Gleason Grading (diagnostic criteria of carcinoma, basal cell and AMACR immunohistochemistry, HGPIN and atypical small acinar proliferation) Related page: Prostate Cancer Staging, Treatment Effect and Molecular Testing; Neuroendocrine, Rare, Stromal and Hematolymphoid Tumors of the Prostate (adenoid cystic (basal cell) carcinoma, stromal tumors, therapy effect) Related page: Non-neoplastic Lesions of the Bladder and Urothelial Tract (nephrogenic adenoma, malakoplakia and BCG cystitis of the bladder) Related page: Diagnostic Enzymes and Serum Tumor Markers (PSA, free PSA and PSA density) Related page: Normal and Benign Findings in Urine Cytology (BCG and treatment effect in urine) Related page: Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria (Mycobacterium bovis BCG)

Zonal anatomy of the prostate

Region Location and histology Disease association Source
Peripheral zone Posterior prostate abutting the rectum; reached by digital rectal examination and transrectal biopsy Origin of 80%–85% of carcinomas; 68% of 88 mapped carcinomas Buyyounouski et al. 2017; McNeal et al. 1988
Transition zone Anteromedial prostate around the urethra above the verumontanum; prostatic glands mingle with sphincteric stroma Origin of BPH nodules; 10%–15% of carcinomas (24% in the mapping series), often diagnosed on transurethral resection McNeal 1978; Buyyounouski et al. 2017; McNeal et al. 1988
Central zone Base of the prostate around the ejaculatory ducts, adjacent to the seminal vesicles; tall columnar cells, Roman arches, cribriform glands, prominent basal cells Source of 5%–10% of carcinomas; mimic of HGPIN on biopsy Buyyounouski et al. 2017; Srodon and Epstein 2002
Anterior fibromuscular stroma Anterior nonglandular stroma; at the apex the anterior peripheral zone can contact it broadly Anterior tumors and anterior extraprostatic extension Fine et al. 2007
Prostatic "capsule" Condensed fibromuscular band of prostatic stroma, best seen posteriorly and posterolaterally; not recognizable at the apex, anteriorly or at the bladder neck Landmark for extraprostatic extension Buyyounouski et al. 2017
  • Transition zone carcinoma. Two thirds of 21 transition zone carcinomas were composed of columnar clear cells lining glands of widely variable size and contour, and they often appeared to arise within BPH nodules. The transition zone boundary appeared to act as a barrier to the spread of carcinomas from other zones (McNeal et al. 1988).
  • Anterior extraprostatic space. The anterior extraprostatic space contains adipose tissue, blood vessels and skeletal muscle at the apex and medium to large smooth muscle bundles at the base. The volume and position of the transition zone differ between glands with and without BPH (Fine et al. 2007).
  • Central zone histology on biopsy. Central zone histology was present in 10% of nonconsult biopsy cases, 80% of them in cores labelled base. In consult cases its features were eosinophilic cytoplasm (97%), location at the end of a core (97%), Roman arches (59%), a prominent basal cell layer (32%), cribriform formation (26%) and adjacent thick bladder neck muscle (24%). Of 26 consult cases with an outside diagnosis, 81% had been called PIN or atypical. Tall columnar cells with eosinophilic cytoplasm, a prominent basal cell layer and absent cytologic atypia identify central zone glands (Srodon and Epstein 2002).

Benign prostatic hyperplasia and transurethral resection specimens

  • Origin. In 63 autopsy prostates, BPH nodules arose selectively in the transition zone near the cylindrical urethral sphincter above the verumontanum, usually on its outer lateral aspect. Nodules originate by eccentric budding of ducts toward a focus, which suggests a local stromal inductive effect. BPH evolves through early diffuse glandular growth, small nodule proliferation and later nodule enlargement (McNeal 1978).
  • Stromal nodules. In 475 BPH specimens, stromal nodules were fibroblastic (65.2%), fibromuscular (21.6%), immature mesenchymal (8.8%) or smooth muscular (4.4%). They lay mainly in the periurethral transition zone and occurred only with hyperplastic glandular nodules (Bierhoff et al. 1996).
  • Nodule types. In 161 autopsy prostates, nodular hyperplasia began as an early stromal nodule beside the urethra. Stromal and epithelial proliferation then produced a glandular or a mixed nodule, and a leiomyomatous nodule was interpreted as smooth muscle maturation of a stromal nodule (Pradhan and Chandra 1975).
  • Associated lesions. Atypical adenomatous hyperplasia was present in 33.6% of 110 radical prostatectomies and was nearly always associated with hyperplastic nodules. Verumontanum mucosal gland hyperplasia was present in 29.1% and was significantly associated with atypical adenomatous hyperplasia (Muezzinoglu et al. 2001).
  • Clear cell cribriform hyperplasia. This rare pattern of BPH forms a transition zone nodule of medium and large cribriform acini lined by cells with pale to clear cytoplasm, bland nuclei without prominent nucleoli and an intact basal cell layer. It is not a risk factor for carcinoma (Destouni et al. 2022). It is in the differential diagnosis of Gleason pattern 4 carcinoma (Hameed and Humphrey 2010).
  • Infarct. Infarcts were found in 0.07% and 0.0009% of nonconsult biopsies in two institutions and usually involved large glands of 84–150 cc. Some patients had acute urinary retention, hematuria or sudden PSA rises of 199–287 ng/mL. Adjacent immature squamous metaplasia with visible nucleoli, squamous atypia and up to 10 mitoses was present in 14 of 15 cases; one case was misdiagnosed as urothelial carcinoma. Cysts with cellular debris, corpora amylacea and rings of collagen around squamous islands favor infarct (Milord et al. 2000).
  • TURP sampling (CAP Prostate TURP and Enucleation 4.2.0.0). Specimens of 12 g or less are submitted entirely. For larger specimens the first 12 g are submitted, with 1 cassette for every additional 5 g. Firm or yellow to orange-yellow chips are submitted preferentially. When unsuspected carcinoma involves 5% or less of the examined tissue, the remaining tissue may be submitted, especially in younger patients (CAP 2023c).
  • TURP clinical stage. Incidental carcinoma involving 5% or less of the resected tissue is cT1a, and involvement of more than 5% is cT1b. The percentage is estimated by visual inspection and reported in categories from less than 1% to more than 90% (CAP 2023c).
TURP reporting element (CAP 4.2.0.0) Content Source
Procedure TURP, or enucleation (simple or subtotal prostatectomy) CAP 2023c
Grade Gleason score as primary plus highest pattern, with Grade Group CAP 2023c
Tumor quantitation Estimated percentage of tissue involved; optional number of positive chips; dominant nodule size in enucleations CAP 2023c
Local extent if present Periprostatic fat invasion; seminal vesicle invasion CAP 2023c
Additional findings AIP, HGPIN, atypical adenomatous hyperplasia (adenosis), nodular hyperplasia, inflammation CAP 2023c

Prostatic atrophy, postatrophic hyperplasia and proliferative inflammatory atrophy

Diffuse atrophy follows radiotherapy or endocrine therapy. Focal atrophy is more frequent in the peripheral zone and increases with age; inflammation and chronic local ischemia are proposed causes. Focal atrophy is partial, complete or combined, and complete atrophy is subtyped as simple, sclerotic or hyperplastic (postatrophic hyperplasia) (Billis 2010).

Pattern Histology Basal cells and immunohistochemistry Diagnostic significance Source
Simple atrophy Subtype of complete focal atrophy; acini with loss of cytoplasmic volume Basal layer present; luminal cells of complete atrophy show aberrant 34βE12 expression (intermediate phenotype) Complete atrophy subtype; luminal cells with intermediate phenotype Billis 2010; Billis et al. 2014; Humphrey 2018
Partial atrophy Incomplete focal atrophy; may merge with complete atrophy in the same gland Immunoprofile similar to normal acini; basal cell layer often discontinuous; no chronic inflammation in partial atrophy foci Most frequent mimic of adenocarcinoma on needle biopsy Billis 2010; Billis et al. 2010; Billis et al. 2014; Egevad et al. 2021
Postatrophic hyperplasia (hyperplastic atrophy) Lobular cluster of small atrophic acini around a central dilated acinus; cuboidal cells with mild nucleomegaly; focal mildly enlarged nucleoli in 39% Basal layer invariably present but often inconspicuous; 34βE12 intact in 7 of 10 and fragmented in 3 Found in 18% of radical prostatectomies, almost exclusively in the peripheral zone Cheville and Bostwick 1995
Proliferative inflammatory atrophy Simple atrophy or postatrophic hyperplasia with chronic inflammation ERG negative in all variants of atrophy HGPIN merged with this lesion in 42.5% of 629 HGPIN lesions; carcinoma did not merge with it Putzi and De Marzo 2000; Billis et al. 2014
  • Partial and complete atrophy as a continuum. Partial and complete atrophy coexisted in 63% of 75 biopsies, and 27% showed merging of the two in the same gland. Chronic inflammation was present only in complete atrophy (Billis et al. 2010).
  • Postatrophic hyperplasia versus carcinoma. Its lobular architecture, intact or fragmented basal cell layer, inconspicuous or mildly enlarged nucleoli and adjacent atrophy with stromal fibrosis or smooth muscle atrophy separate it from carcinoma. Intraluminal crystalloids were absent in all cases (Cheville and Bostwick 1995).
  • Proliferative inflammatory atrophy and carcinogenesis. The link between proliferative inflammatory atrophy and HGPIN or carcinoma remains controversial (Billis 2010). The topographic transitions are consistent with progression of its proliferative epithelium to PIN, but they do not prove a continuum (Putzi and De Marzo 2000).
  • Atrophic pattern carcinoma. Atrophic pattern adenocarcinoma resembles benign atrophy and is graded in Prostatic Adenocarcinoma: Needle Biopsy Diagnosis, Immunohistochemistry, Precursor and Intraductal Lesions, and Gleason Grading.

Adenosis (atypical adenomatous hyperplasia)

  • Definition and location. Adenosis is a benign small-gland proliferation, mostly of the transition zone and closely associated with nodular hyperplasia. Its prevalence is 1.6%–7.3% in transurethral resections without cancer and 0.8% in needle biopsies (Armah and Parwani 2008).
  • Architecture. The lesion is partially circumscribed with a pushing border, though small acini at the edge may look infiltrative. Glands are closely packed but separate, without fusion, and vary in size and shape. Luminal borders are often irregular and serrated. Lumens are empty or contain corpora amylacea and sometimes eosinophilic crystalloids (Armah and Parwani 2008).
  • Cytology. Cells are cuboidal to low columnar with clear or lightly eosinophilic cytoplasm. Nuclei are round to oval, slightly enlarged, with fine chromatin and inconspicuous or small nucleoli (Armah and Parwani 2008).
  • Immunohistochemistry. Basal cells are patchy with p63 and 34βE12. AMACR can be strongly positive, as in the reported case of florid adenosis (Armah and Parwani 2008).
  • Relation to carcinoma. Adenosis may be architecturally more atypical than some carcinomas, and its glands often have a discontinuous or absent basal cell layer (Egevad et al. 2021). Proof of a precursor relationship to transition zone carcinoma is lacking; chromosomal anomalies were found by FISH in 9% of adenosis cases and 55% of carcinomas (Armah and Parwani 2008). Adenosis was the second most common benign mimic in 434 consultation biopsies after atrophy (Epstein 1995).
  • Sclerosing adenosis. Sclerosing adenosis is a small-acinar proliferation in dense spindle cell stroma, found in about 2% of transurethral resections. Its basal cell layer is positive for high-molecular-weight keratin, S100, smooth muscle actin and PSA, and AMACR is negative. Atypical sclerosing adenosis with cytologic atypia behaved benignly over a mean 33 months (Cheng and Bostwick 2010).

Basal cell hyperplasia and its distinction from adenoid cystic (basal cell) carcinoma

  • Basal cell hyperplasia. Basal cell hyperplasia is a nodular transition zone process in which basal cells form two or more layers within acini. Nests may be solid, cystically dilated or cribriform. Cells have scant cytoplasm and hyperchromatic nuclei; they are p63 and high-molecular-weight keratin positive and AMACR negative. The lesion carries no increased cancer risk (Destouni et al. 2022). Small dark glands, variable nuclear atypia and a pseudoinfiltrative pattern make it a mimic of carcinoma (Egevad et al. 2021).
  • Nucleoli and bcl-2. Basal cell hyperplasia may show prominent nucleoli and look infiltrative. Bcl-2 expression and the Ki-67 index were significantly higher in basaloid carcinoma than in basal cell hyperplasia with or without nucleoli; p53 did not discriminate (Yang et al. 1998).
  • Adenoid cystic (basal cell) carcinoma. In 29 carcinomas, the Ki-67 index ranged from 2% to 80%, with Ki-67 of 20% or more in 56.5%, and desmoplasia was present in 71% (Ali and Epstein 2007). An adenoid cystic-like pattern and anastomosing, irregular nests and tubules favor carcinoma over basal cell hyperplasia (Destouni et al. 2022). The entity, including its WHO name change, is covered in Prostate Cancer Staging, Treatment Effect and Molecular Testing; Neuroendocrine, Rare, Stromal and Hematolymphoid Tumors of the Prostate.
Feature Basal cell hyperplasia Adenoid cystic (basal cell) carcinoma Source
Growth Nodular, within acini, transition zone Infiltrative nests, adenoid cystic pattern, desmoplasia; bladder neck muscle invasion in 10 of 21 TURPs Destouni et al. 2022; Ali and Epstein 2007
Basal cell markers p63 and high-molecular-weight keratin positive p63 and 34βE12 positive in multiple layers in 60% Destouni et al. 2022; Ali and Epstein 2007
bcl-2 Low Diffuse in 92% Yang et al. 1998; Ali and Epstein 2007
Ki-67 Low Mean 23% Yang et al. 1998; Ali and Epstein 2007
MYB::NFIB Absent in benign basal proliferations 29%–47%, mainly adenoid cystic pattern Kench et al. 2022; Flauto et al. 2026
Behavior Benign Mostly indolent; 4 of 29 metastasized Ali and Epstein 2007

Other benign mimics of prostatic carcinoma

PSA and prostatic acid phosphatase help exclude nonprostatic mimics such as mesonephric remnant hyperplasia (Paner et al. 2008; Chen et al. 2011). Negative basal cell staining in a small focus is not diagnostic of carcinoma by itself, because some benign glands and many mimics stain unevenly (Epstein 2004).

Mimic Setting and histology Immunohistochemistry Clue to benign nature Source
Seminal vesicle and ejaculatory duct epithelium Present in 7.2% of 500 sextant biopsies; resembled HGPIN, atypical glands or carcinoma in 1.4%; small acini with pronounced nuclear atypia MUC6 diffusely positive in all 10 seminal vesicles and negative in all 40 prostatic carcinomas; PAX8 expressed from rete testis to ejaculatory duct and absent from prostatic epithelium Lipofuscin, perinuclear vacuoles and nuclear pseudoinclusions; mimicry occurs when these are inconspicuous Arista-Nasr et al. 2016; Egevad et al. 2021; Leroy et al. 2003; Tong et al. 2011
Lipofuscin in prostatic epithelium Pigment in benign epithelium in 57% of 150 specimens; also in HGPIN and carcinoma Fontana-Masson, PAS-diastase and Congo red positive; yellow autofluorescence Pigment alone does not establish seminal vesicle origin Brennick et al. 1994
Central zone glands Base of the prostate; Roman arches and cribriform glands Prominent basal cell layer Tall columnar cells with eosinophilic cytoplasm, no atypia Srodon and Epstein 2002
Cowper glands Lobules of mucin-distended acini (mucicarmine and PAS-D positive) with ducts, resembling mucinous minor salivary glands within skeletal muscle; sampled at TURP and rarely on needle biopsy Prostatic acid phosphatase negative; PSA positive in most of 7 cases in one series and negative in all 10 in another; smooth muscle actin outlines peripheral myoepithelial cells; acini 34βE12 negative in 9 of 10 cases Mucinous cytoplasm and lobular salivary-like architecture Cina et al. 1997; Saboorian et al. 1997
Verumontanum mucosal gland hyperplasia Back-to-back microacini confined to the verumontanum and adjacent posterior urethra; 14% of 341 prostatectomies and cystoprostatectomies; 29.1% of 110 prostatectomies Basal cells beneath bland cuboidal to columnar luminal cells (H&E) Corpora amylacea in 57 of 88 foci; no crystalloids or intraluminal mucin; associated with adenosis Gagucas et al. 1995; Muezzinoglu et al. 2001
Mesonephric remnant hyperplasia 0.6% of TURPs; bladder neck, base, anterior fibromuscular stroma and around seminal vesicles; lobular or infiltrative small acini, cysts, micropapillary tufts PSA and prostatic acid phosphatase negative; PAX8 diffusely positive; 34βE12 diffuse or focal; p63 largely negative; AMACR focal in 4 of 7 Lobular arrangement, PSA negativity and PAX8 positivity Bostwick et al. 2003; Chen et al. 2011
Sclerosing adenosis About 2% of TURPs; small acini in dense spindle cell stroma Basal cells positive for high-molecular-weight keratin, S100, smooth muscle actin and PSA; AMACR negative Intact basal layer with myoepithelial phenotype Cheng and Bostwick 2010
Clear cell cribriform hyperplasia Transition zone BPH nodule of cribriform acini Intact basal layer Pale to clear cytoplasm, bland nuclei Destouni et al. 2022
Nephrogenic adenoma Prostatic urethra Immunoprofile, including focal weak PSA and PSAP, covered in Non-neoplastic Lesions of the Bladder and Urothelial Tract Urothelial-tract lesion covered in Non-neoplastic Lesions of the Bladder and Urothelial Tract Paner et al. 2008
Paraganglia 4.5% of 1230 radical prostatectomies, mostly extraprostatic Chromogranin, synaptophysin and neuron-specific enolase positive; PSA negative Extraprostatic paraganglia can be mistaken for extraprostatic extension Maniar et al. 2011; Ostrowski and Wheeler 1994
Anorectal mucosa Fragments in transrectal cores Not applicable Lesions in 30 of 96,656 consult biopsies, including adenomas, a rectal neuroendocrine tumor and lymphoma Ye et al. 2010
Infarct with squamous metaplasia Large glands; acute retention or sudden PSA rise Not applicable Cystic debris, corpora amylacea, collagen rings around squamous islands Milord et al. 2000

Prostatic xanthoma and foamy gland carcinoma

  • Xanthoma. Prostatic xanthoma is a localized collection of cholesterol-laden histiocytes, usually idiopathic and sometimes associated with hyperlipidemia (Sebo et al. 1994). In 27 cases most lesions measured 0.5 mm or less, and 10 formed cords and single cells infiltrating stroma. Cells had small uniform nuclei, inconspicuous nucleoli and abundant vacuolated cytoplasm without mitoses. CD68 was diffusely positive in 94.7% and CAM5.2 in none; PSA, prostatic acid phosphatase and AMACR were positive in 6.7%, 11.8% and 8.3% (Chuang and Epstein 2007).
  • Foamy gland carcinoma. Foamy gland carcinoma has abundant xanthomatous cytoplasm, crowded or infiltrative glands and frequent dense pink intraluminal secretions. Nuclear enlargement and prominent nucleoli were absent or rare in 61% and 71% of 38 cases, and high-molecular-weight keratin was negative in 19 of 20. It was classified as intermediate-grade carcinoma, and 96% of associated ordinary carcinomas had a Gleason sum greater than 4 (Nelson and Epstein 1996). It can be pattern 3 or high-grade pattern 4 or 5 (Humphrey 2018).
  • Treated carcinoma. Xanthoma also mimics carcinoma treated with hormone therapy (Chuang and Epstein 2007).
Feature Xanthoma Foamy gland carcinoma Source
Architecture Solid nodule, or cords and single cells Crowded or infiltrative glands with lumens Chuang and Epstein 2007; Nelson and Epstein 1996
Luminal content None Dense pink secretions in 20 of 38 Nelson and Epstein 1996
Keratin CAM5.2 negative Epithelial; high-molecular-weight keratin negative Chuang and Epstein 2007; Nelson and Epstein 1996
CD68 Diffusely positive (94.7%) Not a histiocytic lesion Chuang and Epstein 2007

Prostatitis

Type of granulomatous prostatitis Histology Setting Source
Nonspecific Densely cellular granulomatous reaction filling entire lobules; may contain many eosinophils Most common type (31 of 62; 10 of 22) Epstein and Hutchins 1984; Shukla et al. 2017
Post-TURP (postsurgical) Necrotizing granulomas resembling rheumatoid nodules, sometimes rimmed by eosinophils Recent prostatic surgery Epstein and Hutchins 1984
Infectious, tuberculous Caseous granulomas Tuberculosis Epstein and Hutchins 1984
BCG-related Granulomas, acid-fast bacilli in 3 patients After intravesical BCG; at least 41% of treated patients; mean 11.5 months after therapy Oates et al. 1988
Allergic Eosinophil-rich granulomas Generalized allergic state; none in the Johns Hopkins series, 2 of 22 in another Epstein and Hutchins 1984; Shukla et al. 2017
Xanthogranulomatous Rare subtype of granulomatous prostatitis Exceptionally rare; mimics carcinoma clinically and on MRI Ji et al. 2026
Malakoplakia Von Kossa positive in 92% and PAS positive in 96% 49 patients; median PSA 7.5 ng/mL; 26% diabetic or insulin resistant; PI-RADS 4–5 lesions in some Acosta et al. 2022
IgG4-related Fibroinflammatory lesion 66 reported cases; elevated serum IgG4 in most; multiorgan disease in 57.8% Pamfil et al. 2026
  • Clinical overlap with carcinoma. In 22 cases of granulomatous prostatitis, serum PSA ranged from 0.88 to 19.22 ng/mL and 14 had hard, fixed nodules on rectal examination (Shukla et al. 2017). Granulomatous prostatitis is in the differential of Gleason pattern 4 or 5 carcinoma (Hameed and Humphrey 2010).
  • Malakoplakia. Von Hansemann histiocytes and Michaelis–Gutmann bodies are covered in Non-neoplastic Lesions of the Bladder and Urothelial Tract. Prostatic malakoplakia was diffuse or multifocal in 82%, and two cases were referred as possible stromal tumors (Acosta et al. 2022).

Seminal vesicle amyloid and other seminal vesicle lesions

  • Senile seminal vesicle amyloid. This is one of the most common forms of localized amyloidosis and is associated with aging. Mass spectrometry showed that the fibrils derive from the N-terminal portion of semenogelin I, the major secretory product of the seminal vesicle (Linke et al. 2005).
  • Typing and systemic disease. Among 150 Congo red-positive prostate specimens, localized ASem1 amyloid was the most common type (43%) and ATTR amyloid formed 37%. Seminal vesicle or ejaculatory duct involvement was pathognomonic for ASem1 amyloid (39 of 39). Systemic AL amyloidosis occurred in both prostate cases with AL amyloid, so proteomic typing is recommended (Gilani et al. 2023).
  • Cystadenoma. Seminal vesicle cystadenoma is composed of variably sized cysts lined by bland epithelium in fibromuscular stroma. Seven incidental tumors measured 0.5–1.8 cm at prostatectomy or cystoprostatectomy, and all expressed nuclear PAX8 (Desar et al. 2026).
  • Cysts. Seminal vesicle cysts were found in 60% of 45 men with autosomal dominant polycystic kidney disease (Danaci et al. 1998). Zinner syndrome combines a seminal vesicle cyst, ipsilateral ejaculatory duct obstruction and ipsilateral renal agenesis, a Wolffian duct anomaly (Kumar et al. 2022).
  • Primary carcinoma and mucinous tumors. Primary seminal vesicle carcinomas are exceedingly rare. Two low-grade mucinous tumors resembling appendiceal low-grade mucinous neoplasms carried KRAS hotspot variants (Collins et al. 2024).

Prostatic Adenocarcinoma: Needle Biopsy Diagnosis, Immunohistochemistry, Precursor and Intraductal Lesions, and Gleason Grading

Definition and current rules. Prostatic acinar adenocarcinoma is an invasive carcinoma of prostatic secretory cells that lacks a basal cell layer. Its classification follows the WHO Classification of Tumours, Urinary and Male Genital Tumours, 5th edition (2022), which made no major alterations to the prostate chapter but reorganized it and redefined "variant", "subtype" and "histologic pattern" (Surintrspanont and Zhou 2022). Grade follows the ISUP 2014 Grade Groups, the ISUP 2019 consensus and the GUPS 2019 white paper (van Leenders et al. 2020; Epstein et al. 2021). The grading of intraductal carcinoma changed in 2026 with the joint GUPS–ISUP expert consultation (Shah et al. 2026), and the 2024 ISUP precursor consensus changed the reporting of PIN (Iczkowski et al. 2025). Needle biopsies are reported with the CAP Prostate Needle Biopsy protocols, case-level and specimen-level versions 1.1.0.0 (CAP 2023a; CAP 2023b).

Related page: Prostate Anatomy, Benign Prostatic Hyperplasia, Prostatitis and Benign Mimics of Prostatic Carcinoma (zonal anatomy, atrophy, adenosis, basal cell hyperplasia and the full benign mimic table) Related page: Prostate Cancer Staging, Treatment Effect and Molecular Testing; Neuroendocrine, Rare, Stromal and Hematolymphoid Tumors of the Prostate (treatment effect and grading after therapy, prostatectomy staging, neuroendocrine and rare carcinomas, germline testing) Related page: Urothelial Neoplasia: Papillomas, Flat Lesions, Noninvasive Papillary Carcinoma, Carcinoma In Situ and Invasive Urothelial Carcinoma (high-grade urothelial carcinoma and its subtypes) Related page: Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder (urothelial carcinoma of the prostatic urethra and ducts, staging) Related page: Diagnostic Enzymes and Serum Tumor Markers (serum PSA, free PSA, PSA density and kinetics) Related page: Non-Urothelial and Secondary Malignancies in Urine Cytology (prostatic adenocarcinoma in urine) Related page: Metastatic Carcinoma in Lymph Nodes (Cytology) (metastatic prostatic carcinoma on FNA; NKX3.1 and PSA on cell block) Related page: Bone FNA (metastatic prostatic carcinoma in bone) Related page: Immunohistochemistry on Cytology Specimens (immunostains on cell blocks)

Epidemiology and risk factors of prostatic carcinoma

  • Frequency. Prostate cancer accounts for nearly one third of cancer diagnoses in US men, and only 1% are diagnosed before age 50 years. US incidence rose by 2.9% per year from 2014 through 2022, and by 4.6% and 5.6% per year for regional-stage and distant-stage disease (Siegel et al. 2026).
  • Race. Prostate cancer death rates in Black men are about two to four times those in other men (Siegel et al. 2026). African American men have the highest incidence worldwide and develop disease earlier (Rawla 2019).
  • Risk factors. The established risk factors are advanced age, ethnicity, genetic factors and family history. The average age at diagnosis is 66 years, and about 20% of patients report a family history (Rawla 2019). Germline genes are covered in Prostate Cancer Staging, Treatment Effect and Molecular Testing; Neuroendocrine, Rare, Stromal and Hematolymphoid Tumors of the Prostate.
  • Screening context. In 2018 the USPSTF recommended informed decision-making about PSA screening for asymptomatic men aged 55 to 69 years (Siegel et al. 2026). PSA assays and kinetics are covered in Diagnostic Enzymes and Serum Tumor Markers.

WHO 5th edition classification of prostatic epithelial tumors

WHO 5th edition (2022) category or type Content Previous rule (WHO 4th edition, 2016) Source
Terminology "Subtype" is a subset of a type with distinct morphology and prognostic or diagnostic implications; "histologic pattern" is an unusual morphology without prognostic meaning beyond its Gleason score; "variant" refers only to genetic alterations "Variant" was used for morphologic variants of acinar carcinoma Surintrspanont and Zhou 2022; Kench et al. 2022
Glandular neoplasms Prostatic cystadenoma; HGPIN; intraductal carcinoma; acinar adenocarcinoma; ductal adenocarcinoma; treatment-related neuroendocrine prostatic carcinoma Treatment-related neuroendocrine prostatic carcinoma not a separate type Surintrspanont and Zhou 2022
Acinar adenocarcinoma subtypes Signet-ring-like cell (≥25% signet-ring-like cells), sarcomatoid, pleomorphic giant cell, PIN-like carcinoma PIN-like carcinoma grouped with ductal adenocarcinoma patterns Surintrspanont and Zhou 2022; Kench et al. 2022
Acinar adenocarcinoma histologic patterns Atrophic (including p63-positive), pseudohyperplastic, microcystic, foamy gland, mucinous (≥25% glands with extracellular mucin) Listed as variants Surintrspanont and Zhou 2022
(Baso)squamous neoplasms Adenosquamous carcinoma; squamous cell carcinoma; adenoid cystic (basal cell) carcinoma Basal cell carcinoma Surintrspanont and Zhou 2022; Kench et al. 2022
Mesenchymal tumors unique to the prostate Prostatic stromal tumor of uncertain malignant potential; prostatic stromal sarcoma Prostate-specific stromal tumors in the WHO classification since 2004 Surintrspanont and Zhou 2022; Lian et al. 2026
Tumors moved to other chapters Neuroendocrine, mesenchymal, hematolymphoid and metastatic tumors are consolidated across genitourinary sites; urothelial carcinoma of the prostate and prostatic urethra is in the urinary tract chapter Described within the prostate chapter Surintrspanont and Zhou 2022; Kench et al. 2022
Grade terminology "WHO grade" is suggested for the Grade Group (also called ISUP grade) Grade Groups introduced in the 2016 edition Surintrspanont and Zhou 2022

Needle biopsy handling and reporting

  • Number and submission of cores. A biopsy case generally contains 12 to 14 cores from systematic transrectal or transperineal mapping, with or without MRI-targeted cores. Single cores in site-specific labelled containers are ideal, and two cores per container are acceptable; more than two cores per container increase fragmentation (CAP 2023b).
  • Level of grading. A Gleason score is assigned to each separately identified biopsy site, including each MRI-targeted lesion. Multiple cores in one container are graded individually when the urologist has marked their locations with different coloured inks (CAP 2023b). If multiple cores in one container are not separately designated, a Gleason score is assigned to that specimen (CAP 2023b).
  • Case-level summary. The case-level summary records procedure (systematic, targeted or both), positive sites, the highest Gleason score and its site, an overall grade for systematic biopsies when sites differ (global or composite technique), a grade for each targeted lesion and an optional combined systematic and targeted grade (CAP 2023a).
  • Tumor quantitation. The number of positive cores out of the total and the percentage and/or linear millimeters of each core involved are reported. Reporting the core with the greatest percentage of tumor is an option, because some active surveillance protocols exclude men with any core involved by more than 50% (CAP 2023b).
  • Discontinuous foci. In a 20-mm core with 1-mm foci at each end, involvement can be recorded as 10% (foci added, intervening tissue subtracted) or 100% (measured end to end). Both measurements may be reported; the end-to-end measurement correlates better with radical prostatectomy findings in most studies (CAP 2023b).
  • Tumor microfocus. A carcinoma of a few glands too small to grade confidently is left ungraded. Cores with carcinoma present only as perineural invasion are also not graded (CAP 2023b). Minute (<1 mm) foci of pattern 4 or 5 are graded with caution (van Leenders et al. 2020).
  • Local extent on biopsy. Carcinoma in fat on a biopsy indicates at least pT3a. Carcinoma in seminal vesicle-type tissue sampled unintentionally may be intraprostatic seminal vesicle or ejaculatory duct and does not establish pT3b; a biopsy directed at the extraprostatic seminal vesicle that contains carcinoma indicates at least pT3b (CAP 2023b).
  • Benign targeted cores. When targeted cores from a PI-RADS 4–5 lesion are benign, the benign findings that may explain the imaging (for example, inflammation or granulomas) are reported (van Leenders et al. 2020).
Specimen-level element (CAP 1.1.0.0) Content Source
Location Site-specific label, TRUS lesion or MRI-guided target CAP 2023b
Histologic type WHO 5th edition types and acinar subtypes CAP 2023b
Grade Gleason score and Grade Group; percentage of pattern 4 for Gleason score 7; optional percentages of patterns 4 and 5 for scores 8 and above CAP 2023b
Intraductal carcinoma Present or absent; incorporated into grade (yes, no, cannot be determined) CAP 2023b
Cribriform glands For Gleason score 7 or 8 CAP 2023b
Quantitation Positive and total cores; percentage and/or length; measurement technique for discontinuous foci CAP 2023b
Local extent Periprostatic fat invasion; seminal vesicle or ejaculatory duct invasion CAP 2023b
Optional Lymphatic or vascular invasion; perineural invasion; AIP; HGPIN; ASAP; inflammation; treatment effect CAP 2023b

Diagnostic criteria of acinar adenocarcinoma on needle biopsy

The diagnosis rests on a constellation of architectural, nuclear, cytoplasmic and luminal features, and infiltrative growth, prominent nucleoli and absent basal cells are the most useful criteria (Magi-Galluzzi 2018). Small foci are assessed by comparing the atypical glands with adjacent benign glands (Epstein 2004).

Feature in 300 limited carcinomas on consultation biopsy Frequency Source
Small glands between larger benign glands 80% Epstein 1995
Nuclear enlargement 77% Epstein 1995
Prominent nucleoli 76% (absent in 24%, rare in another 25%) Epstein 1995
Pink acellular intraluminal secretions 53% Epstein 1995
Amphophilic cytoplasm 39% Epstein 1995
Blue-tinged mucinous secretions 34% Epstein 1995
Crystalloids 25% Epstein 1995
Adjacent PIN 13% Epstein 1995
Mitotic figures 11% Epstein 1995
Perineural invasion 3% Epstein 1995
  • Number of features. Even in limited carcinomas, 85% of specimens showed three or more of these features in addition to architectural atypia. The malignant foci contained a median of 20 glands (range 2 to 300) (Epstein 1995).
  • Grade correlations. Gleason score correlated positively with prominent nucleoli and amphophilic cytoplasm and inversely with crystalloids (Epstein 1995).
  • Features diagnostic in themselves. Glomerulations, mucinous fibroplasia (collagenous micronodules) and perineural invasion are diagnostic of carcinoma on their own (Epstein 2004). They are pathognomonic but uncommon in small foci (Magi-Galluzzi 2018).
  • Glomerulations. Glomerulations are dilated glands containing an intraluminal cribriform structure with a single point of attachment. On biopsy they occur only in carcinoma, were accompanied by pattern 4 or 5 carcinoma in 84% of 45 cases and are graded as pattern 4 (Lotan and Epstein 2009).
  • Major and minor criteria. Major criteria are an infiltrative glandular growth pattern, absent basal cells, and nuclear atypia (nucleomegaly and nucleolomegaly). Minor criteria are wispy blue intraluminal mucin, pink amorphous secretions, mitotic figures, intraluminal crystalloids, adjacent HGPIN, amphophilic cytoplasm and nuclear hyperchromasia. Perineural invasion is found in 11%–37% of biopsies with carcinoma but only 0%–3% of minimal carcinomas, and collagenous micronodules in 1%–5% (Humphrey 2007).

Immunohistochemistry of prostatic adenocarcinoma

Marker Expression and performance Pitfalls Source
p63 (nuclear), high-molecular-weight cytokeratin 34βE12 and CK5/6 (cytoplasmic) Label basal cells of benign glands; absent in adenocarcinoma Benign glands do not all label uniformly, and mimics label even less often; negative staining of a small focus is not diagnostic by itself Epstein 2004; Paner et al. 2008
AMACR (P504S) 97% sensitivity and 100% specificity in 94 biopsies with moderate or strong staining as positive; about 80% of limited carcinomas; 99% of foci <1 mm in another series 60%–70% of foamy gland, pseudohyperplastic and atrophic carcinomas; positive in almost all HGPIN, some adenosis and some benign glands Rubin et al. 2002; Epstein 2004; Andrews and Humphrey 2014
Triple cocktail (p63, 34βE12 or CK5/6, AMACR) Dual chromogen stain on one slide; AMACR positive with negative basal markers supports carcinoma in the right morphologic context Not ordered prospectively on all biopsies Paner et al. 2008
ERG Positive in 45% of carcinoma foci <1 mm; informative in a minority of AMACR-weak foci Occasionally positive in HGPIN and benign glands; negative in atrophy, basal cell hyperplasia and squamous metaplasia Andrews and Humphrey 2014; He et al. 2011
NKX3.1 Sensitivity 98.6% and specificity 99.7% for metastatic prostatic adenocarcinoma; 94.7% of high-grade primaries One invasive lobular breast carcinoma positive among 349 nonprostatic tumors Gurel et al. 2010; Chuang et al. 2007
PSA 94.2% of metastatic and 97.4% of high-grade primary carcinomas Often focal or weak in poorly differentiated carcinoma Gurel et al. 2010; Chuang et al. 2007
Prostatic acid phosphatase (PSAP) 98.6% of metastatic carcinomas Low or focal expression in some poorly differentiated tumors Gurel et al. 2010
PSMA and prostein (P501S) 92.1% and 100% of high-grade primaries; more cells stain than with PSA PSMA is frequently lost with neuroendocrine transformation Chuang et al. 2007; Flauto et al. 2026
  • High-grade prostatic versus urothelial carcinoma. PSA is the first screening marker. P501S, PSMA, NKX3.1 and proPSA help when PSA is negative or equivocal. High-molecular-weight keratin (91.4%) and p63 (82.9%) labelled high-grade urothelial carcinoma more often than thrombomodulin (68.6%) or S100P (71.4%), and prostate cancers showed at most scattered weak urothelial-marker staining (Chuang et al. 2007). Uroplakin and GATA3 also support urothelial origin (Destouni et al. 2022).
  • Origin of metastases. NKX3.1, PSMA and ERG support prostatic origin, GATA3 and CDX2 help exclude urothelial and gastrointestinal primaries, and a panel is preferred because single antigens may be lost in dedifferentiated tumors (Flauto et al. 2026).

High-grade prostatic intraepithelial neoplasia

  • Definition. HGPIN is a proliferation of atypical secretory cells within ducts and acini of normal size, without expansion. Nuclei are enlarged and hyperchromatic with prominent nucleoli; necrosis is absent and the basal cell layer is preserved, although it can be fragmented (Destouni et al. 2022).
  • Architectural patterns. Tufting, micropapillary and flat patterns remain; none carries clinical significance, and naming them in reports is discouraged (Surintrspanont and Zhou 2022). Vacuolated, foamy and mucinous patterns have also been described (Surintrspanont and Zhou 2022).
  • Cribriform pattern (changed rule). The WHO 5th edition removed cribriform HGPIN as a pattern and places such lesions in atypical intraductal proliferation (AIP); the 2016 edition listed four patterns including cribriform (Surintrspanont and Zhou 2022; Kench et al. 2022).
  • Incidence and risk. HGPIN is found in 5%–8% of needle biopsies. The median literature risk of cancer after a biopsy diagnosis of HGPIN was 24.1%, close to the risk after a benign biopsy, and routine repeat biopsy within the first year is not needed (Epstein and Herawi 2006). Repeat-biopsy cancer risk is about 20% for unifocal and 30%–40% for multifocal HGPIN (Surintrspanont and Zhou 2022).
  • Distinction from IDC-P. Gland expansion, involvement of more than six glands, an irregular contour and a biphasic cell population favor IDC-P. ERG expression and PTEN loss favor IDC-P, whereas HGPIN is usually ERG negative with intact PTEN (Destouni et al. 2022; Shah et al. 2026).
PIN reporting rule ISUP 2024 precursor consensus Previous rule Source
Low-grade PIN Not reported Not reported because of poor reproducibility and low cancer risk (2006 review; WHO 2022; CAP 2023) Iczkowski et al. 2025; Epstein and Herawi 2006; Surintrspanont and Zhou 2022; CAP 2023b
HGPIN next to carcinoma or ASAP Need not be reported, in biopsy or prostatectomy CAP: optional in biopsies with carcinoma Iczkowski et al. 2025; CAP 2023b
Multifocal isolated HGPIN Continues to be reported; stronger evidence as a predictor of later cancer CAP: isolated PIN reported, especially if more than one site is involved Iczkowski et al. 2025; CAP 2023b
Unifocal HGPIN Clinical significance uncertain Reported as isolated PIN Iczkowski et al. 2025; CAP 2023b
Cribriform HGPIN Redesignated AIP WHO 2016 pattern of HGPIN Iczkowski et al. 2025; Surintrspanont and Zhou 2022

Intraductal carcinoma of the prostate (IDC-P)

  • Definition (WHO 5th edition). IDC-P is a neoplastic epithelial proliferation involving pre-existing, generally expanded duct-acinar structures, with architectural and cytologic atypia beyond what is acceptable for HGPIN (Kench et al. 2022). The WHO recognized IDC-P as a distinct entity in 2016 (Shah et al. 2026).
  • Biology. Most IDC-P represents retrograde intraductal spread of high-grade invasive carcinoma. A minority found without invasive carcinoma or with only Grade Group 1 carcinoma in prostatectomies may be a precursor ("precursor-type IDC-P"); in biopsies, IDC-P is much more likely to be the invasive type (Shah et al. 2026). IDC-P shares the TMPRSS2::ERG status of the adjacent invasive carcinoma (Destouni et al. 2022).
  • Frequency. Isolated IDC-P is found in 0.06%–0.26% of needle biopsies, and invasive carcinoma is nearly always present in the prostatectomy (Kench et al. 2022). Its prevalence rises from 2.1% in low-risk cohorts to 23.1%, 36.7% and 56% in moderate-risk, high-risk and metastatic or recurrent disease (Shah et al. 2026).
  • Original Guo and Epstein study. In 27 biopsies with only IDC-P, all 6 prostatectomies contained Gleason score 8 or 9 invasive carcinoma, 5 with nonfocal extraprostatic extension, and 3 of 16 men without prostatectomy developed bone metastases (Guo and Epstein 2006).
  • Prognosis. IDC-P associated with invasive carcinoma is an independent adverse factor for biochemical recurrence, progression-free survival, distant metastasis and disease-specific survival (Kench et al. 2022).
  • Basal cells. Retention of basal cells is required, but flattened peripheral tumor cells can mimic basal cells, and the basal layer of IDC-P is often discontinuous and may be absent in the plane of section (Shah et al. 2026). Corpora amylacea and branched architecture support IDC-P when basal cells are not readily identified (Destouni et al. 2022).
  • Urothelial carcinoma in prostatic ducts. Coexisting urothelial carcinoma in situ or papillary carcinoma in the urethra, nuclear grooves (low-grade tumors only), PSA and PSAP negativity, and p63, uroplakin and GATA3 positivity separate intraductal spread of urothelial carcinoma from IDC-P (Destouni et al. 2022). Bizarre atypia alone qualifies as IDC-P only after radiation atypia and pagetoid spread of high-grade urothelial carcinoma are excluded (Shah et al. 2026).
  • Germline testing. The NCCN and similar guidelines recommend genetic testing when IDC-P is present, so its presence is reported even when it is incorporated into the grade (Shah et al. 2026).
Diagnostic criteria of IDC-P Original Guo and Epstein criteria (2006) Updated criteria (WHO 5th edition; GUPS 2019; GUPS–ISUP 2026) Source
Solid or dense cribriform growth Diagnostic Diagnostic; dense cribriform means more cells than luminal spaces (>50% epithelium) Guo and Epstein 2006; Epstein et al. 2021; Shah et al. 2026
Loose cribriform or micropapillary growth Requires nuclei 6× normal or larger, or comedonecrosis WHO 5th edition: enlarged nuclei, with the 6× size criterion removed; modified Guo–Epstein (GUPS 2019; GUPS–ISUP 2026): marked (bizarre or pleomorphic) atypia or nonfocal comedonecrosis Guo and Epstein 2006; Kench et al. 2022; Epstein et al. 2021; Shah et al. 2026
Dense cribriform or solid growth with lesser atypia Not addressed Need not show marked atypia to qualify as IDC-P (ISUP 2024) Iczkowski et al. 2025
Marked atypia without expansile or dense growth Not addressed Sufficient in rare cases (GUPS–ISUP 2026, 90% agreement); fell just short of consensus at ISUP 2024 (65%) Shah et al. 2026; Iczkowski et al. 2025
Basal cell immunohistochemistry Basal cells confirmed in all 27 cases Desirable criterion; recommended to separate AIP or IDC-P from invasive cribriform pattern 4 when no obvious invasive carcinoma is present and to confirm pure IDC-P Guo and Epstein 2006; Kench et al. 2022; Shah et al. 2026
Single gland Not addressed One unequivocal gland suffices; number of loose cribriform glands is not a criterion Shah et al. 2026

Grading rules for IDC-P: ISUP 2019, GUPS 2019 and the joint GUPS–ISUP 2026 recommendation

The joint 2026 recommendation replaces the conflicting 2019 rules of the two societies. The WHO 5th edition (2022) endorsed neither 2019 position and asked pathologists to state which rule they used (Kench et al. 2022), and CAP 1.1.0.0 records whether IDC-P was incorporated into the grade (CAP 2023b).

Scenario ISUP 2019 GUPS 2019 Joint GUPS–ISUP 2026 (current) Source
Pure IDC-P (no invasive carcinoma) Not graded (91% agreement) Not graded Not graded (100%); confirm with basal cell immunohistochemistry van Leenders et al. 2020; Epstein et al. 2021; Shah et al. 2026
IDC-P with invasive carcinoma Incorporated into the Gleason score (76%); cribriform as pattern 4, solid or comedonecrosis as pattern 5 Excluded from the Gleason score and Grade Group; reported separately Incorporated regardless of Grade Group of the invasive component (73%–77%); a 30% minority favored exclusion when the invasive component is only pattern 3 van Leenders et al. 2020; Epstein et al. 2021; Shah et al. 2026
IDC-P with Grade Group 1 invasive carcinoma Incorporated Excluded Incorporated (70%); the case becomes Grade Group 2–4 and needs a comment, expert review and multidisciplinary discussion Shah et al. 2026
IDC-P spatially distinct from invasive carcinoma (for example, contralateral core) Not addressed separately Excluded Not incorporated; mentioned in a comment (87%) Shah et al. 2026
IDC-P with only marked atypia Not addressed separately Excluded, as for all IDC-P Not included in the final grade until more evidence is available Shah et al. 2026
Basal cell immunohistochemistry Not needed for grading because IDC-P is graded as invasive carcinoma Performed only if the result would change the highest Gleason score or Grade Group Used to confirm pure IDC-P, IDC-P with only pattern 3, and AIP versus invasive cribriform carcinoma Surintrspanont and Zhou 2022; Epstein et al. 2021; Shah et al. 2026
Comment on IDC-P Presence and significance commented on (83%) Reported in biopsy and prostatectomy Always reported, even when incorporated van Leenders et al. 2020; Epstein et al. 2021; Shah et al. 2026
Biopsy versus prostatectomy Same rule Same rule Same rule (different rules rejected, 3% agreement) Shah et al. 2026
  • Effect of incorporation. Including IDC-P changed the Grade Group in 1.6% of biopsies and 0.6% of prostatectomies in one study, while another series of 123 biopsies found a 1–2 group increase in 23% (Kench et al. 2022). Incorporation makes the resulting Grade Groups heterogeneous: pattern 3 invasive carcinoma with more than 50% cribriform IDC-P is now reported as Grade Group 3, the same group as Grade Group 3 invasive carcinoma with IDC-P (Shah et al. 2026).
  • Management. Active surveillance is not appropriate for Grade Group 1 carcinoma with IDC-P (93%), and management of isolated IDC-P on biopsy factors in MRI findings (90%) (Shah et al. 2026).

Atypical intraductal proliferation (AIP)

  • WHO 5th edition definition. AIP is an intraductal proliferation with features exceeding those of HGPIN but not meeting strict criteria for IDC-P. Loose cribriform proliferations without severe atypia or necrosis, formerly called cribriform HGPIN, belong here (Kench et al. 2022; Shah et al. 2026). The GUPS 2019 white paper preferred the same term (Epstein et al. 2021). AIP shows PTEN loss and ERG overexpression similar to IDC-P and is a potential marker of unsampled high-grade carcinoma (Kench et al. 2022).
  • CAP description. AIP is a loose cribriform intraductal growth lacking the nuclear atypia or intraluminal necrosis required for IDC-P; it may represent unsampled IDC-P and is associated with adverse features at prostatectomy (CAP 2023b).
  • Risk. AIP carries about a 50% risk of carcinoma or IDC-P on repeat biopsy (Surintrspanont and Zhou 2022).
  • Joint GUPS–ISUP 2026 terminology. AIP is diagnosed only when IDC-P is favored but its criteria are not fully met (90%), and it is reported as "AIP, suspicious for IDC-P" (77%). Any AIP with cribriform architecture is reported in this way. AIP is not incorporated into the Gleason score, even when invasive carcinoma is present (Shah et al. 2026).
  • ISUP 2024. AIP alone or with Grade Group 1 carcinoma warrants an explanatory comment; agreement was not reached on reporting AIP in the presence of invasive carcinoma (Iczkowski et al. 2025).
  • Immunohistochemistry. ERG positivity with PTEN loss favors AIP or IDC-P over HGPIN, but an ERG-negative, PTEN-intact profile does not exclude IDC-P and does not separate AIP from IDC-P (Shah et al. 2026).
Feature HGPIN AIP, suspicious for IDC-P IDC-P Source
Duct size Normal size without expansion No size criterion in the definitions Expanded Destouni et al. 2022; Kench et al. 2022
Architecture Tufting, micropapillary, flat Loose cribriform or lumen-spanning growth short of IDC-P Solid, dense cribriform, or loose cribriform with marked atypia or comedonecrosis Destouni et al. 2022; Shah et al. 2026
Nuclear atypia Enlarged nuclei, prominent nucleoli Beyond HGPIN, short of IDC-P Marked atypia may be present Destouni et al. 2022; CAP 2023b
Necrosis Absent Absent Comedonecrosis may be present Destouni et al. 2022; Shah et al. 2026
Basal cells Preserved, may be fragmented Retained At least partially retained, often discontinuous Destouni et al. 2022; Shah et al. 2026
ERG and PTEN Usually ERG negative, PTEN intact ERG positive with PTEN loss in some ERG positive with PTEN loss in about 50% Shah et al. 2026
Biopsy implication Repeat biopsy not routinely needed; multifocal reported About 50% risk of carcinoma on repeat biopsy Usually associated with high-grade invasive carcinoma Epstein and Herawi 2006; Surintrspanont and Zhou 2022; Shah et al. 2026
Grading Not graded Not graded Graded with invasive carcinoma (2026); pure IDC-P not graded Shah et al. 2026

Atypical small acinar proliferation (ASAP)

  • Definition and frequency. Atypical glands suspicious for carcinoma are small foci that cannot be diagnosed as carcinoma with certainty, often because the focus is under-sampled. They form an average of 5% of needle biopsy diagnoses (Epstein and Herawi 2006). CAP lists the finding as atypical small acinar proliferation or small focus of atypical glands (CAP 2023b).
  • Cancer risk. The average risk of carcinoma after an atypical diagnosis is about 40% (Epstein and Herawi 2006), and 40%–50% in a later series (He et al. 2011).
  • Rebiopsy. Repeat biopsy within 3 to 6 months is recommended, with increased sampling of the atypical site and adjacent ipsilateral and contralateral sites (Epstein and Herawi 2006). Atypical diagnoses are the most likely to change on expert review, so consultation before rebiopsy is encouraged (Epstein and Herawi 2006).
  • Ancillary tests. Basal cell markers and AMACR reduce atypical diagnoses but give false-positive and false-negative results (Epstein and Herawi 2006). ERG staining of atypical foci did not predict carcinoma on later biopsy (He et al. 2011).

Gleason grading and Grade Groups

The Gleason system applies to all prostatic adenocarcinomas except those showing treatment effect (CAP 2023b). The ISUP 2014 conference defined the contemporary patterns and adopted the five Grade Groups with 90% agreement; the WHO accepted them for its 2016 edition (Epstein et al. 2016a).

Gleason pattern Morphology (ISUP 2014) Source
3 Individual discrete well-formed glands; branched glands are allowed Epstein et al. 2016a; CAP 2023b
4 Poorly formed, fused, cribriform and glomeruloid glands; must be seen at 10× lens magnification; occasional poorly formed or fused glands between well-formed glands are insufficient Epstein et al. 2016a
5 Sheets, cords, single cells, small solid cylinders, solid medium to large nests with rosette-like spaces; unequivocal comedonecrosis, even if focal Epstein et al. 2016a
Borderline 3 versus 4, or crush artifact Lower grade favored Epstein et al. 2016a
Mucinous carcinoma Graded by the underlying growth pattern (formerly all graded pattern 4) Epstein et al. 2016a
Hypernephromatoid cancer Term not used Epstein et al. 2016a
Grade Group Gleason score Definition (CAP) Source
1 ≤6 Only individual discrete well-formed glands CAP 2023b
2 3+4=7 Predominantly well-formed glands with a lesser component of poorly formed, fused or cribriform glands CAP 2023b
3 4+3=7 Predominantly poorly formed, fused or cribriform glands with a lesser component of well-formed glands CAP 2023b
4 4+4=8, 3+5=8, 5+3=8 Only poorly formed, fused or cribriform glands; or well-formed glands with a lesser component lacking glands, or the reverse CAP 2023b
5 9–10 Lack of gland formation or necrosis, with or without poorly formed, fused or cribriform glands CAP 2023b
  • Validation. Grade Groups were validated in more than 20,000 prostatectomies, 16,000 biopsies and 5,000 biopsies followed by radiation (Epstein et al. 2016a). Hazard ratios for recurrence relative to Gleason score 6 were 1.9, 5.1, 8.0 and 11.7 for scores 3+4, 4+3, 8 and 9–10 (Epstein et al. 2016b).
  • Reporting. The Grade Group is reported with the Gleason score (CAP 2023b). AJCC 8th edition staging uses both (Buyyounouski et al. 2017).

Gleason grading rules for needle biopsy and radical prostatectomy

Rule Needle biopsy Radical prostatectomy Source
Score Most common plus highest pattern Primary plus secondary pattern CAP 2023b; CAP 2023d
Higher-grade component <5% Included as the secondary pattern (>95% pattern 3 with <5% pattern 4 is 3+4=7) Pattern 5 <5% with patterns 3 and 4 is reported as a minor tertiary pattern 5 and does not change the Grade Group CAP 2023b; Epstein et al. 2017; CAP 2023d
Lower-grade component <5% Ignored (>95% pattern 4 with <5% pattern 3 is 4+4=8) Ignored CAP 2023b
Three patterns 75% pattern 3, 20%–25% pattern 4 and <5% pattern 5 is 3+5=8 Pattern 5 of 5% or more becomes the secondary pattern CAP 2023b; CAP 2023d; van Leenders et al. 2020
Multiple sites or nodules Separate score for each site and each MRI-targeted lesion Separate score for each dominant nodule and for a smaller nodule of higher stage or grade; scores are not averaged CAP 2023b; Epstein et al. 2017; CAP 2023d
  • Two-pattern prostatectomy tumors with a minimal higher pattern (ISUP 2019 versus GUPS 2019). For >95% pattern 3 with <5% pattern 4, ISUP reports 3+3=6 with minor pattern 4 and GUPS reports 3+4=7. For >95% pattern 3 with <5% pattern 5, ISUP reports 3+3=6 with minor pattern 5 and GUPS reports 3+5=8. For >95% pattern 4 with <5% pattern 5, ISUP reports 4+4=8 with minor pattern 5 and GUPS reports 4+5=9. The WHO 5th edition did not adopt the ISUP approach, and a comment is required if it is used (Surintrspanont and Zhou 2022). CAP accepts either approach with a comment (CAP 2023d).
  • Percentage of pattern 4. ISUP 2019 reached consensus to report percent pattern 4 in all Grade Group 2 and 3 biopsies; prostatectomies were excluded from this consensus (van Leenders et al. 2020). GUPS 2019 reports it in biopsies with Grade Groups 2 and 3 and in lower-grade jars when another jar has Gleason score 8, as <5% or <10% and then 10% increments (Epstein et al. 2021). CAP recommends reporting it for all Gleason score 7 biopsies and notes that men with 3+4=7 and ≤10% pattern 4 may be eligible for active surveillance (CAP 2023b).
  • Cribriform carcinoma. ISUP defines the cribriform pattern as a confluent sheet of contiguous malignant epithelial cells with multiple glandular lumina easily visible at low power (10× objective), without intervening stroma or mucin (Kench et al. 2022). Transluminal bridging and a peripheral clear space occupying <50% of the gland circumference are reliable features (Kench et al. 2022). ISUP 2019 agreed to comment on cribriform pattern 4 in Gleason score 7 (97%) and 8 (84%) carcinoma at biopsy and prostatectomy, and 93% agreed that cribriform pattern 4 has a worse prognosis than poorly formed or fused pattern 4 (van Leenders et al. 2020). GUPS 2019 reports its presence or absence in biopsies and prostatectomies with pattern 4 (Epstein et al. 2021). CAP records cribriform glands for Gleason score 7 or 8 only (CAP 2023b). Large cribriform glands (>0.25 mm) predicted recurrence, metastasis and disease-specific death in one study (Kench et al. 2022).
  • Glomeruloid glands. Glomeruloid glands are graded pattern 4 regardless of morphology (Epstein et al. 2016a).
MRI-targeted and systematic biopsies ISUP 2019 GUPS 2019 Source
Several cores from one MRI-targeted lesion One global score per lesion (78%); individual targeted cores not graded separately (81% against) One overall grade for the lesion, as if the involved cores were one long core van Leenders et al. 2020; Epstein et al. 2021
Global score for systematic biopsies No consensus (54%) Single global score allowed van Leenders et al. 2020; Epstein et al. 2021
Different scores in systematic and targeted cores No consensus on a global score (41%) A single global score factoring both systematic and targeted cores van Leenders et al. 2020; Epstein et al. 2021

Acinar adenocarcinoma subtypes and histologic patterns

Because subtype and pattern thresholds need the whole tumor, biopsies may be reported descriptively, for example "adenocarcinoma with signet ring-like cell features" or "with mucinous features" (CAP 2023b).

Subtype or pattern (WHO 5th edition) Morphology Grading or behavior Source
Atrophic pattern (including p63-positive) Cytoplasmic volume loss resembling benign atrophy; sporadic or after radiation or hormonal therapy Pattern 3 Humphrey 2018; Surintrspanont and Zhou 2022
Pseudohyperplastic pattern Glands simulating hyperplasia, with papillary infoldings, luminal undulations and branching Pattern 3 Humphrey 2018
Microcystic pattern Cystically dilated glands Pattern 3 Humphrey 2018
Foamy gland pattern Abundant xanthomatous cytoplasm, pyknotic or bland nuclei, pink secretions Pattern 3, 4 or 5 Humphrey 2018; Nelson and Epstein 1996
Mucinous pattern ≥25% of glands with extracellular mucin; secondary colorectal or urothelial mucinous tumors excluded Graded by underlying pattern; ERG expression similar to acinar carcinoma; 10-year survival about 78% Surintrspanont and Zhou 2022; Epstein et al. 2016a; Flauto et al. 2026
PIN-like carcinoma (subtype) Crowded, large discrete glands with flat or tufted epithelium and absent basal cells; columnar or cuboidal cells Gleason score 3+3=6; prognosis like low-grade acinar carcinoma; RAF/RAS pathway mutations in 60% Surintrspanont and Zhou 2022; Kench et al. 2022
Signet-ring-like cell (subtype) ≥25% cells with intracytoplasmic vacuoles displacing the nucleus; NKX3.1, PSA and PSAP support prostatic origin over gastrointestinal or bladder primaries Aggressive; about 10% metastatic at diagnosis Surintrspanont and Zhou 2022; Flauto et al. 2026
Pleomorphic giant cell (subtype) Bizarre, markedly enlarged pleomorphic cells; admixed high-grade conventional carcinoma; reduced prostate markers Poor prognosis; frequent prior therapy; 51 reported cases El-Zaatari et al. 2021
Sarcomatoid (subtype) Biphasic epithelial and mesenchymal malignancy; often follows treated adenocarcinoma Metastatic in 7 of 8 patients; TP53 most frequently altered; about one third metastatic at diagnosis Tekin et al. 2026; Flauto et al. 2026

Prostatic ductal adenocarcinoma

  • Morphology. Ductal adenocarcinoma shows papillary and/or complex cribriform glands lined by tall pseudostratified columnar cells with elongated nuclei. Lumens of its cribriform glands tend to be slit-like (Surintrspanont and Zhou 2022).
  • WHO 5th edition rule. The term ductal adenocarcinoma is reserved for prostatectomies with more than 50% ductal morphology, with the percentage of the ductal component reported. Biopsies with pure or mixed ductal morphology are reported as "adenocarcinoma with ductal features" (Surintrspanont and Zhou 2022; Kench et al. 2022). Ductal adenocarcinoma remains a separate type from acinar carcinoma in the 5th edition (Kench et al. 2022).
  • Frequency. Ductal adenocarcinoma forms 2.6% of prostatic carcinomas, and the pure form 0.2%–0.4% (Surintrspanont and Zhou 2022).
  • Grade. Ductal adenocarcinoma is graded pattern 4, and pattern 5 when comedonecrosis is present (Destouni et al. 2022).
  • Behavior. It has higher biochemical recurrence, worse metastasis-free and overall survival and a lower response to androgen deprivation than high-grade acinar carcinoma. It metastasizes to lung and liver and to brain, skin, penis and testis (Kench et al. 2022).
  • Periurethral tumors. About 10% of periurethral ductal carcinomas found on transurethral biopsy or resection lack an acinar component and may be removed by the resection alone; repeat resection and transrectal biopsy are performed before radical treatment (Surintrspanont and Zhou 2022).
  • Molecular features. Ductal carcinoma shares ERG rearrangements with coexisting acinar carcinoma in most studies. Mutations of CTNNB1 and APC are more frequent, and DNA repair gene alterations, including homologous recombination and mismatch repair genes, were found in 49% of 51 patients (Kench et al. 2022).

Gleason score and Grade Group calculator for prostatic adenocarcinoma

Prostate Cancer Staging, Treatment Effect and Molecular Testing; Neuroendocrine, Rare, Stromal and Hematolymphoid Tumors of the Prostate

Classification, reporting protocol and staging edition. Carcinomas other than adenocarcinoma form less than 1% of prostatic tumors and occur pure or admixed with adenocarcinoma (CAP 2023d). Classification follows the WHO Classification of Tumours, Urinary and Male Genital Tumours, 5th edition (2022), with the 4th edition (2016) rule stated where it changed (Surintrspanont and Zhou 2022; Kench et al. 2022). Prostatectomies are reported with the CAP Prostate Radical Prostatectomy protocol 4.3.0.0 (CAP 2023d) and staged with the AJCC 8th edition, which remains current for the prostate (Buyyounouski et al. 2017).

Related page: Prostatic Adenocarcinoma: Needle Biopsy Diagnosis, Immunohistochemistry, Precursor and Intraductal Lesions, and Gleason Grading (diagnostic criteria, immunohistochemistry, IDC-P and all Gleason grading rules) Related page: Prostate Anatomy, Benign Prostatic Hyperplasia, Prostatitis and Benign Mimics of Prostatic Carcinoma (zonal anatomy, basal cell hyperplasia, xanthoma and other mimics) Related page: Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder (AJCC staging of urothelial carcinoma of the prostatic urethra and bladder, embryonal rhabdomyosarcoma) Related page: Non-neoplastic Lesions of the Bladder and Urothelial Tract (inflammatory myofibroblastic tumor and postoperative spindle cell nodule) Related page: Diagnostic Enzymes and Serum Tumor Markers (serum PSA and PSA kinetics after treatment) Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (Lynch syndrome and mismatch repair testing methods) Related page: Metastatic Carcinoma in Lymph Nodes (Cytology) (metastatic prostatic carcinoma in lymph nodes) Related page: Bone FNA (metastatic prostatic carcinoma in bone)

Neuroendocrine tumors of the prostate

A 2013 working committee classified prostatic neuroendocrine differentiation into usual adenocarcinoma with neuroendocrine differentiation, adenocarcinoma with Paneth cell neuroendocrine differentiation, carcinoid tumor, small cell carcinoma, large cell neuroendocrine carcinoma and mixed neuroendocrine carcinoma with acinar adenocarcinoma (Epstein et al. 2014).

Tumor Definition and morphology Immunohistochemistry Clinical significance and grading Source
Adenocarcinoma with neuroendocrine differentiation Almost all prostatic adenocarcinomas contain scattered neuroendocrine cells Neuroendocrine markers positive in scattered cells No proven prognostic or therapeutic value; routine synaptophysin and chromogranin staining is not recommended Surintrspanont and Zhou 2022; Kench et al. 2022
Adenocarcinoma with Paneth cell-like neuroendocrine differentiation Bright eosinophilic cytoplasmic granules in benign glands, HGPIN or carcinoma; involved cancer cells form cords, nests and single cells with bland nuclei Neuroendocrine markers positive Only the conventional component is graded; pure or predominant Paneth cell-like carcinoma is not graded and generally has a favorable prognosis Surintrspanont and Zhou 2022
Well-differentiated neuroendocrine tumor (formerly carcinoid tumor) Cords and trabeculae of monotonous cells with salt-and-pepper chromatin Prostate markers negative; neuroendocrine markers positive Not associated with high-grade carcinoma or prior therapy Surintrspanont and Zhou 2022
Small cell neuroendocrine carcinoma Oat cell (64%) or intermediate cell morphology; necrosis 40%, rosettes 29%, Indian filing 21%, giant bizarre cells 19% Neuroendocrine marker positive in 88%; PSA 19%, P501S 28%, PSMA 25%, TTF-1 52%; 60% negative for all three prostate markers Pure in 57%; prior adenocarcinoma in 42%; median serum PSA 4.0 ng/mL; admixed adenocarcinoma Gleason score ≥8 in 85% Wang and Epstein 2008
Large cell neuroendocrine carcinoma Large polygonal cells with high-grade nuclei, prominent nucleoli, ample eosinophilic cytoplasm, nests and trabeculae with palisading, necrosis Neuroendocrine markers positive Exceedingly rare Surintrspanont and Zhou 2022
Treatment-related neuroendocrine prostatic carcinoma (WHO 5th edition type) Complete neuroendocrine differentiation, or partial differentiation with adenocarcinoma, after androgen deprivation therapy; primary or metastatic p53 in most; TTF-1 in about half; PSA, PAP, P501S and NKX3.1 usually lost; Ki-67 typically >80%; 10%–15% of small cell carcinomas lack neuroendocrine markers 10.5%–17% of metastatic castration-resistant cancers after androgen receptor signalling inhibitors; median survival 7 months after diagnosis; neuroendocrine component not graded Kench et al. 2022; Surintrspanont and Zhou 2022
  • Change in the WHO 5th edition. Treatment-related neuroendocrine prostatic carcinoma is a distinct tumor type of the prostate chapter, defined by its link to androgen deprivation therapy and lineage plasticity. The WHO 4th edition (2016) had no separate treatment-related type (Surintrspanont and Zhou 2022; Kench et al. 2022).
  • Pathogenesis of the treatment-related form. Concordant ERG rearrangements in the neuroendocrine carcinoma and the earlier hormone-naive adenocarcinoma indicate transdifferentiation. Loss of TP53, RB1 and PTEN provides the genomic setting for the epigenetic switch (Surintrspanont and Zhou 2022). It typically emerges after 18–36 months of androgen deprivation (Collins and Cheng 2026).
  • De novo neuroendocrine carcinoma. Neuroendocrine carcinoma without a history of prostatic adenocarcinoma or its treatment forms less than 1% of prostate cancers (Surintrspanont and Zhou 2022). Pure small cell carcinoma has a worse prognosis than mixed tumors (Surintrspanont and Zhou 2022).
  • Mixed tumors. Mixed adenocarcinoma and neuroendocrine carcinoma account for 43%–50% of prostatic small cell carcinomas, and the adenocarcinoma component is Gleason score 8 or higher in 85% (Surintrspanont and Zhou 2022; Wang and Epstein 2008). The transition is usually abrupt in one review (Surintrspanont and Zhou 2022), whereas gradual merging was more common than a sharp demarcation in the largest series (Wang and Epstein 2008).
  • Targetable surface antigen. DLL3 is expressed in most neuroendocrine prostate cancers and is largely absent from benign prostate and conventional adenocarcinoma (Flauto et al. 2026).

Rare carcinomas of the prostate

Tumor Morphology Immunohistochemistry and genetics Behavior Source
Adenoid cystic (basal cell) carcinoma Adenoid cystic pattern with hyaline globules, small solid basaloid nests with peripheral palisading, or both; desmoplasia; bladder neck invasion frequent on TURP p63 and high-molecular-weight keratin positive in basal layers; PSA and PSAP negative; bcl-2 diffuse in 92%; Ki-67 mean 23%; MYB::NFIB in 29%–47%, mainly adenoid cystic pattern Mostly indolent with local infiltration; metastases in 4 of 29; large solid nests with necrosis, high Ki-67 and weak basal marker staining in aggressive cases Kench et al. 2022; Ali and Epstein 2007; Destouni et al. 2022
Adenosquamous carcinoma Glandular and squamous components; often after androgen deprivation or radiotherapy Squamous component PSA and PSAP negative, may express high-molecular-weight keratin; TP53, RB1 and PTEN alterations About 31% metastatic at diagnosis; 10-year survival about 20% Flauto et al. 2026
Squamous cell carcinoma Squamous carcinoma, pure (8 of 33) or admixed with adenocarcinoma PSA and PSAP only very focal in 12% of squamous components; 34βE12 diffusely positive in >95%; CK7 and CK20 do not separate squamous from glandular components 21 of 33 had prior adenocarcinoma, often treated with hormones or radiation; mean survival 24 months Parwani et al. 2004; Surintrspanont and Zhou 2022
Urothelial carcinoma of the prostate Carcinoma in situ in prostatic urethra or ducts, or invasive carcinoma arising there or penetrating from the bladder CK5/6 and CK5 separate prostatic basal cells from in situ carcinoma; markers against IDC-P in Prostatic Adenocarcinoma: Needle Biopsy Diagnosis, Immunohistochemistry, Precursor and Intraductal Lesions, and Gleason Grading Prostatic stromal or periprostatic invasion carries more nodal metastasis and worse survival than carcinoma in situ or urethral lamina propria invasion Fichtenbaum et al. 2012; Shen et al. 2006
  • WHO name change. Adenoid cystic (basal cell) carcinoma is the WHO 5th edition (2022) name; the WHO 4th edition (2016) name was basal cell carcinoma. The change reflects the morphologic and MYB::NFIB overlap with salivary adenoid cystic carcinoma, and metastasis from a salivary or other primary must be excluded (Kench et al. 2022). The former name remains acceptable (Surintrspanont and Zhou 2022).
  • Urothelial carcinoma involving the prostate. In 214 cystoprostatectomies, prostatic involvement was found in 32%. Of 39 invasive tumors, 26% penetrated directly from the bladder and the rest arose from the prostatic urethra or ducts (Shen et al. 2006). The WHO 5th edition moved urothelial carcinoma of the prostate and prostatic urethra to the urinary tract chapter (Surintrspanont and Zhou 2022). Its staging (urethral pT2 versus bladder pT4a) is covered in Bladder Cancer Staging and Biomarkers, Upper Tract and Urethral Carcinoma, and Nonurothelial Tumors of the Bladder.

Treatment effect in prostatic carcinoma

Gleason grading is not applied to carcinoma with treatment effect after androgen deprivation or radiation; carcinoma without treatment effect, including new carcinoma, can still be graded (CAP 2023d). When residual tumor shows no or minimal effect, it can be graded with the treated component excluded and a comment on the limits of grading (Collins and Cheng 2026).

Therapy Benign tissue Carcinoma Immunohistochemistry Grading Source
Radiation (external beam, brachytherapy) Fewer glands, expanded fibrotic stroma, conspicuous atypical basal cells with vacuolated cytoplasm and smudged nuclei, metaplasia, hyalinized vessels; changes persist more than 5 years Distorted glands or isolated cells with vacuolated cytoplasm and enlarged nuclei with macronucleoli; infiltrative growth and perineural invasion identify residual carcinoma Basal markers negative and AMACR positive in residual carcinoma; Ki-67 helps; radiation-atypical benign cells lack mitoses Not graded when treatment effect is prominent; response stratified as minimal, intermediate or severe Collins and Cheng 2026
Androgen deprivation Atrophy, basal cell hyperplasia, cytoplasmic vacuolization, stromal prominence, squamous metaplasia; visible after about 3 months Sparse small glands with compressed or absent lumens, isolated cells and cords, pyknotic nuclei, absent nucleoli, foamy histiocyte-like cytoplasm PSA, NKX3.1 and AMACR reduced; androgen receptor patchy Not graded when treatment effect is present; graded if no effect is seen Collins and Cheng 2026
Focal ablation (HIFU, cryotherapy, photodynamic therapy, laser) Sharply demarcated coagulative necrosis, fibrosis, hemosiderin, inflammation in the treated zone Residual carcinoma, often outside the treated zone, keeps typical morphology; 63% of men had persistent tumor on post-HIFU biopsy in one series Basal markers and AMACR remain interpretable Graded as usual Collins and Cheng 2026
Chemotherapy (docetaxel, mitoxantrone) Not well characterized Collapsed glands without lumens (46%), single cells with pyknotic nuclei (28%), vacuolated cytoplasm (26%) No specific change No chemotherapy-specific rule; carcinoma showing treatment effect is not graded (CAP 2023d); chemotherapy effect is often subtle on biopsy Collins and Cheng 2026; CAP 2023d
  • Histologic mimics after therapy. Androgen deprivation effects resemble atrophic and foamy gland patterns of carcinoma (Collins and Cheng 2026). Xanthoma is covered in Prostate Anatomy, Benign Prostatic Hyperplasia, Prostatitis and Benign Mimics of Prostatic Carcinoma. Pancytokeratin highlights subtle treated carcinoma cells (Paner et al. 2008).
  • Outcome after radiation. Residual carcinoma without treatment effect on post-radiation biopsy was followed by local failure in more than 55% at 5 years, compared with less than 20% when marked treatment effect was present (Collins and Cheng 2026).
  • Reporting. CAP records treatment effect as no known presurgical therapy, not identified, radiation effect, hormonal effect or other effect (CAP 2023d).

Radical prostatectomy handling and reporting

  • Fixation and inking. The prostate is measured separately from the seminal vesicles and fixed in buffered formalin for 18 to 24 hours. The entire surface is inked with at least two colors to show laterality (CAP 2023d).
  • Sampling. The prostate may be submitted entirely or partially. With a visible tumor, the tumor with its periprostatic tissue and margins is submitted together with the entire apical and bladder neck margins and the junction of each seminal vesicle with the prostate. Without a visible tumor, one effective scheme submits the posterior half of each slice plus a mid-anterior block from each side (CAP 2023d).
  • Apical and bladder neck margins. These margins are submitted entirely as radial (cone) or parallel (parasagittal) sections; parallel sections are more uniform (CAP 2023d).
  • Whole mounts. ISUP 2009 reached no consensus on whole mounts versus standard blocks and left the choice to the pathologist; partial or complete embedding is acceptable if the partial method is stated, and apex and base are examined by the cone method with sagittal sectioning (Samaratunga et al. 2011).
  • Grading and quantitation. Tumor volume is reported as a percentage of tissue, dominant nodule dimensions or positive blocks (CAP 2023d). ISUP 2009 reached consensus that some quantitative measure of tumor volume be reported without prescribing a method (van der Kwast et al. 2011).
Feature Definition and rule (CAP 4.3.0.0) Prognostic or staging significance Source
Extraprostatic extension (EPE) Tumor admixed with fat, or in loose connective tissue or neurovascular bundle perineural spaces at the level of fat or beyond; at the apex, anterior prostate and bladder neck, where fat is scant, tumor beyond the normal glandular prostate pT3a; uncommon in Gleason score 6 carcinoma CAP 2023d
Tumor in apical skeletal muscle or anterior fibromuscular stroma Not EPE Remains pT2 if otherwise confined CAP 2023d
Focal versus nonfocal EPE Focal: a few glands outside the prostate or tumor occupying less than 1 high-power field in 1 or 2 sections; nonfocal: more extensive 5-year progression-free survival 73% (focal) and 42% (nonfocal) CAP 2023d
Bladder neck invasion Carcinoma in the thick intersecting smooth muscle bundles of the bladder neck without benign prostatic glands, including separately submitted bladder neck Microscopic invasion is pT3a CAP 2023d; Buyyounouski et al. 2017
Seminal vesicle invasion Carcinoma in the muscular wall of the extraprostatic seminal vesicle; intraprostatic seminal vesicle and ejaculatory duct involvement excluded pT3b; worse than EPE CAP 2023d
Lymphatic or vascular invasion Tumor cells in an endothelium-lined space, usually without a muscular wall; up to 21.5% of prostatectomies Independent predictor of biochemical recurrence and progression; does not change pT CAP 2023d
Perineural invasion Common Not an independent predictor; optional CAP 2023d
Margin Positive when tumor touches ink; tumor close to ink is negative. Reported elements: location, linear length (3 mm is a prognostic cutoff), focality, relation to EPE and Gleason pattern at the margin Any pattern 4 or 5 at the margin doubled the risk of PSA recurrence; a margin in an area of EPE is more adverse than an intraprostatic incision CAP 2023d
Intraprostatic incision ("pT2+") Positive margin within the prostate Not interpreted as EPE; margin status is not used for pT CAP 2023d
Lymph nodes Number examined and number positive; optional size of the largest deposit pN0 or pN1 CAP 2023d
  • Margin locations. Positive margins are most common at the apex, posteriorly and posterolaterally (CAP 2023d).

  • Apical margin without fat. Tumor at the apical margin without fat in the section is pT2 with a positive margin, although some experts assign pT3 (Buyyounouski et al. 2017).

AJCC 8th edition pathologic staging of prostatic carcinoma

Category AJCC 8th edition definition Previous rule (AJCC 7th edition) Source
pT1 No pathologic T1 category Unchanged CAP 2023d; Buyyounouski et al. 2017
pT2 Organ-confined, without subcategories pT2a: unilateral, less than one half of one lobe; pT2b: unilateral, more than one half of one lobe; pT2c: bilateral Buyyounouski et al. 2017; CAP 2023d
pT3a Unilateral or bilateral extraprostatic extension, or microscopic invasion of the bladder neck Unchanged; pT3 substaging is the same as in the 7th edition CAP 2023d; Buyyounouski et al. 2017
pT3b Invasion of seminal vesicle(s) Unchanged; pT3 substaging is the same as in the 7th edition CAP 2023d; Buyyounouski et al. 2017
pT4 Tumor fixed or invading adjacent structures other than seminal vesicles: external sphincter, rectum, bladder, levator muscles, pelvic wall Unchanged CAP 2023d; Buyyounouski et al. 2017
pN0 No positive regional nodes Unchanged CAP 2023d; Buyyounouski et al. 2017
pN1 Metastasis in regional nodes (pelvic nodes of the true pelvis below the common iliac bifurcation) Unchanged CAP 2023d; Buyyounouski et al. 2017
M1a Distant lymph nodes outside the true pelvis Unchanged CAP 2023d; Buyyounouski et al. 2017

The AJCC 8th edition summary lists pT2 as the only change among these categories (Buyyounouski et al. 2017).

  • Reason for the pT2 change. pT2 substaging lacked prognostic value, laterality required an arbitrary midline, and tumor volume is more prognostic (Buyyounouski et al. 2017). ISUP 2009 had already made pT2 substaging optional, with 65.5% of attendees favoring its discontinuation (van der Kwast et al. 2011).
  • Grade and PSA in stage groups. AJCC 8th edition stage groups use T, N, M, serum PSA and Grade Group; stage III includes some organ-confined tumors with high PSA or high grade (Buyyounouski et al. 2017).
  • No prostatectomy. Without prostatectomy no pathologic stage is assigned, unless a biopsy confirms a regional nodal (pN1) or distant (pM1) metastasis. Prostatectomy without lymph nodes is pNX (Buyyounouski et al. 2017).
  • Suffixes and prefixes. "m" records multiple primary tumors, "y" staging after neoadjuvant therapy and "r" recurrent tumor (CAP 2023d).
CAP Radical Prostatectomy 4.3.0.0 core element Content Source
Histologic type WHO 5th edition types and acinar subtypes CAP 2023d
Grade Gleason score, Grade Group, minor tertiary pattern 5, percentage of pattern 4 (recommended), intraductal carcinoma and whether incorporated, cribriform glands CAP 2023d
Treatment effect Radiation, hormonal or other CAP 2023d
Tumor quantitation Percentage of prostate involved and/or dominant nodule size CAP 2023d
Extent EPE (focal or nonfocal, location), bladder neck invasion, seminal vesicle invasion CAP 2023d
Invasion Lymphatic and/or vascular invasion; optional perineural invasion CAP 2023d
Margins Status, location, optional length, focality, relation to EPE and Gleason pattern at margin CAP 2023d
Lymph nodes and pTNM Nodes examined and positive; AJCC 8th edition pT and pN with y, r and m modifiers CAP 2023d

Molecular pathology and germline testing in prostate cancer

  • Initiating events. MYC overexpression, GSTP1 promoter hypermethylation, telomere shortening and ETS gene fusions are the main initiating events. ETS fusions occur in up to 50% of prostate cancers. In fusion-negative tumors, SPOP, FOXA1, IDH1 and FLI1 mutations occur and are mutually exclusive (Surintrspanont and Zhou 2022).
  • TMPRSS2::ERG. The 5′ untranslated region of the androgen-regulated gene TMPRSS2 fuses to ERG or ETV1, and 23 of 29 cancers carried ERG or ETV1 rearrangements by FISH (Tomlins et al. 2005). ERG immunostaining correlates closely with the rearrangement (He et al. 2011).
  • SPOP. SPOP is the most frequently mutated gene, altered in 6%–15% of tumors; SPOP-mutant cancers lack ETS rearrangements and form a distinct molecular subtype (Barbieri et al. 2012).
  • Progression events. Gain of 8q24 (MYC), loss of PTEN and inactivation of TP53 mark progression (Surintrspanont and Zhou 2022). Losses of NKX3.1 (8p21) and PTEN (10q23) and AR gains are common alterations (Barbieri et al. 2012). PTEN loss is more frequent in cribriform carcinoma (Kench et al. 2022).
  • Actionable alterations in metastatic disease. Homologous recombination repair deficiency, MSI-high or mismatch repair deficiency (1%–5%) and CDK12 deficiency (1%–5%) are the main targets. DNA damage response gene alterations occur in 19% of localized and up to 31% of metastatic cancers (Surintrspanont and Zhou 2022).
  • Histology as a trigger. Ductal, intraductal and cribriform carcinomas are enriched for BRCA2, ATM and PALB2 alterations, and ductal differentiation is enriched for mismatch repair deficiency (Flauto et al. 2026).
Gene or alteration Germline or somatic Frequency and association Clinical use Source
BRCA2 Germline and somatic 5.3% of 692 men with metastatic disease (most common); biallelic somatic loss associated with IDC-P and cribriform glands PARP inhibitor eligibility; priority treatment gene; active surveillance discussion; screening from age 40 in carriers Pritchard et al. 2016; Kench et al. 2022; Giri et al. 2020
BRCA1 Germline and somatic 0.9% of metastatic cases Priority treatment gene; PARP inhibitor cohort A Pritchard et al. 2016; Giri et al. 2020; de Bono et al. 2020
ATM Germline and somatic 1.6% of metastatic cases PARP inhibitor cohort A; clinical trial eligibility Pritchard et al. 2016; de Bono et al. 2020; Giri et al. 2020
CHEK2 Germline 1.9% of metastatic cases with data Included in germline panels Pritchard et al. 2016; Surintrspanont and Zhou 2022
PALB2, RAD51D Germline 0.4% each of metastatic cases Included in germline panels Pritchard et al. 2016
HOXB13 G84E Germline 1.4% of 5083 cases versus 0.1% of controls; 3.1% in early-onset familial cancer Considered in germline panels and screening Ewing et al. 2012; Giri et al. 2020
MLH1, MSH2, MSH6, PMS2 Germline (Lynch syndrome) and somatic MSI-high or mismatch repair deficiency in 1%–5% Pembrolizumab for MSI-high or dMMR solid tumors; priority treatment genes Surintrspanont and Zhou 2022; Marcus et al. 2019; Giri et al. 2020
CDK12 Somatic 1%–5% Variable sensitivity to immune checkpoint inhibitors Surintrspanont and Zhou 2022
TMPRSS2::ERG Somatic Most common ETS fusion; ERG immunostain as surrogate Diagnostic adjunct of limited value; does not stratify atypical biopsies Tomlins et al. 2005; He et al. 2011
SPOP Somatic 6%–15%; exclusive of ETS fusions Molecular subtype Barbieri et al. 2012
PTEN loss Somatic Progression; cribriform carcinoma Not ready for routine active surveillance use (GUPS 2019) Surintrspanont and Zhou 2022; Epstein et al. 2021
RB1 and TP53 loss Somatic Treatment-related and de novo neuroendocrine carcinoma Platinum chemotherapy; DLL3-directed agents investigational Surintrspanont and Zhou 2022; Flauto et al. 2026
  • Germline prevalence. Deleterious germline DNA repair mutations were found in 11.8% of men with metastatic prostate cancer, independent of age or family history, compared with 4.6% of men with localized cancer (Pritchard et al. 2016).
  • Germline testing indications (NCCN, as summarized in the WHO review). The NCCN recommends germline testing for high- or very-high-risk localized, regional or metastatic cancer and for a suggestive family history, with panels including the mismatch repair genes and BRCA1, BRCA2, ATM, PALB2 and CHEK2, and consideration of HOXB13 (Surintrspanont and Zhou 2022).
  • Philadelphia 2019 consensus. Large germline panels and somatic testing are recommended for metastatic cancer, and metastatic disease or a family history suggesting hereditary cancer is an indication for germline testing (Giri et al. 2020).
  • PARP inhibition. In the phase 3 PROfound trial of men with metastatic castration-resistant cancer progressing on enzalutamide or abiraterone, olaparib prolonged imaging-based progression-free survival in men with BRCA1, BRCA2 or ATM alterations (median 7.4 versus 3.6 months; hazard ratio 0.34) (de Bono et al. 2020).
  • Immune checkpoint inhibition. The FDA approved pembrolizumab on 23 May 2017 for unresectable or metastatic MSI-high or mismatch repair-deficient solid tumors that progressed after prior treatment, the first approval based on a biomarker without regard to primary site (Marcus et al. 2019).
  • Tissue-based genomic classifiers (ASCO 2020 guideline). Oncotype Dx Prostate, Prolaris, Decipher, Decipher PORTOS and ProMark were the commercially available tests with multi-cohort validation. They may improve risk stratification when added to clinical factors and are endorsed only when the result is likely to change a management decision, such as active surveillance or adjuvant versus salvage radiotherapy after prostatectomy; they are not recommended for routine use. The sample with the highest volume of the highest Gleason pattern is tested (Eggener et al. 2020).

Stromal and other mesenchymal tumors of the prostate

  • Prostatic stromal tumor of uncertain malignant potential (STUMP). In 50 specialized stromal tumors, patients were 27 to 83 years old and presented with obstruction, an abnormal rectal examination, hematuria or raised PSA. STUMP showed four patterns: atypical stromal cells among benign glands, hypercellular stroma resembling glandular-stromal hyperplasia, myxoid stroma and a phyllodes pattern. Five recurred or grew locally, and 7 were associated with sarcoma concurrently or later; histologic pattern did not predict behavior (Herawi and Epstein 2006a).
  • Prostatic stromal sarcoma. Low-grade stromal sarcomas invaded locally around the seminal vesicle without recurrence on follow-up; high-grade sarcomas metastasized, and one patient died of disease (Herawi and Epstein 2006a). Stromal sarcoma shows storiform, epithelioid, fibrosarcomatous, phyllodes or patternless growth (Lian et al. 2026), and the stromal cells express CD34 and progesterone receptor (Gaudin et al. 1998).
  • WHO classification. Prostate-specific stromal tumors (STUMP and stromal sarcoma) have been classified separately since the 2004 WHO edition and remain in the prostate chapter of the 5th edition because they arise from specialized prostatic stroma (Lian et al. 2026; Surintrspanont and Zhou 2022).
Tumor Morphology Immunohistochemistry Behavior Source
STUMP Atypical stromal cells among benign glands, hypercellular stroma, myxoid stroma or phyllodes pattern In 9 stromal proliferations and sarcomas: CD34 positive (8 of 8) and progesterone receptor positive (6 of 7); estrogen receptor 1 of 7; desmin 4 of 8 and smooth muscle actin 3 of 9; S100 negative Local recurrence; association with sarcoma Herawi and Epstein 2006a; Gaudin et al. 1998
Prostatic stromal sarcoma Hypercellular atypical spindle cells, mitoses, necrosis; phyllodes or other patterns CD34 and progesterone receptor positive, as in STUMP (same series); smooth muscle actin, desmin and HHF-35 negative in every stromal sarcoma Low grade locally invasive; high grade metastasizes Herawi and Epstein 2006a; Gaudin et al. 1998
Gastrointestinal stromal tumor Fascicular spindle cells, focal epithelioid features; often rectal or perirectal with the epicenter outside the prostate CD117 diffuse in 8 of 8; CD34 in 7 of 8; S100, desmin and smooth muscle actin negative Treated with imatinib Herawi et al. 2006b
Leiomyosarcoma Malignant smooth muscle tumor; prostate less common than bladder Smooth muscle actin, desmin, h-caldesmon and vimentin positive Aggressive; prior radiotherapy implicated Settaf-Cherif et al. 2025

Lymphoma and leukemia involving the prostate

  • Frequency. Lymphoma involved prostate specimens or pelvic nodes in 29 of 4831 cases (0.6%): 18 were incidental without a prior history and 11 occurred with known lymphoma (Chu et al. 2005).
  • Incidental lymphoma. Of the 18 incidental cases, 13 were small lymphocytic lymphoma/chronic lymphocytic leukemia, 3 marginal zone lymphoma and 1 mantle cell lymphoma. Ten involved pelvic nodes only and 8 were primary prostatic lymphomas. Involvement was often subtle and resembled chronic prostatitis or reactive lymphoid hyperplasia, so immunohistochemistry or molecular studies were needed (Chu et al. 2005).
  • Secondary involvement. Known lymphomas involving the prostate were small lymphocytic lymphoma/chronic lymphocytic leukemia (4), follicular lymphoma (4), mantle cell lymphoma (2) and diffuse large B-cell lymphoma (1), usually easy to diagnose (Chu et al. 2005).
  • Reporting. Lymphomas are reported with the CAP lymphoma protocols (CAP 2023d).

References

  1. Abdou NI, NaPombejara C, Sagawa A, et al. Malakoplakia: evidence for monocyte lysosomal abnormality correctable by cholinergic agonist in vitro and in vivo. N Engl J Med. 1977;297(26):1413-9. doi:10.1056/NEJM197712292972601. PMID 200843
  2. Abulaban A, Yanchenko N, Briski LM, et al. Stromal and Epithelial Architectural Alterations Mimicking Invasion (Pseudoinvasion) in Noninvasive Papillary Urothelial Carcinoma. Arch Pathol Lab Med. 2024;148(9):1007-1013. doi:10.5858/arpa.2023-0185-OA. PMID 38133938
  3. Acosta AM, Sangoi AR, Maclean F, et al. Prostatic malakoplakia: clinicopathological assessment of a multi-institutional series of 49 patients. Histopathology. 2022;81(4):520-528. doi:10.1111/his.14729. PMID 35876721
  4. Agrons GA, Wagner BJ, Lonergan GJ, et al. From the archives of the AFIP. Genitourinary rhabdomyosarcoma in children: radiologic-pathologic correlation. Radiographics. 1997;17(4):919-37. doi:10.1148/radiographics.17.4.9225391. PMID 9225391
  5. Akiyama Y, Homma Y, Maeda D. Pathology and terminology of interstitial cystitis/bladder pain syndrome: A review. Histol Histopathol. 2019;34(1):25-32. doi:10.14670/HH-18-028. PMID 30015351
  6. Al-Ahmadie HA, Iyer G, Lee BH, et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet. 2016;48(4):356-8. doi:10.1038/ng.3503. PMID 26901067
  7. Ali TZ, Epstein JI. Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol. 2007;31(5):697-705. doi:10.1097/01.pas.0000213395.42075.86. PMID 17460452
  8. Amin MB, Comperat E, Epstein JI, et al. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Adv Anat Pathol. 2021;28(4):179-195. doi:10.1097/PAP.0000000000000308. PMID 34128483
  9. Amin MB, Ro JY, el-Sharkawy T, et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol. 1994;18(12):1224-32. doi:10.1097/00000478-199412000-00005. PMID 7977945
  10. Amin MB, Smith SC, Eble JN, et al. Glandular neoplasms of the urachus: a report of 55 cases emphasizing mucinous cystic tumors with proposed classification. Am J Surg Pathol. 2014;38(8):1033-45. doi:10.1097/PAS.0000000000000250. PMID 25025366 (cited as Amin et al. 2014b)
  11. Amin MB, Trpkov K, Lopez-Beltran A, et al. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e20-34. doi:10.1097/PAS.0000000000000240. PMID 25029121
  12. Andrews C, Humphrey PA. Utility of ERG versus AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue. Am J Surg Pathol. 2014;38(7):1007-12. doi:10.1097/PAS.0000000000000205. PMID 24705308
  13. Anjum MI, Ahmed M, Shrotri N, et al. Benign polyps with prostatic-type epithelium of the urethra and the urinary bladder. Int Urol Nephrol. 1997;29(3):313-7. doi:10.1007/BF02550928. PMID 9285303
  14. Arista-Nasr J, Trolle-Silva A, Aguilar-Ayala E, et al. Seminal epithelium in prostate biopsy can mimic malignant and premalignant prostatic lesions. Actas Urol Esp. 2016;40(1):17-22. doi:10.1016/j.acuro.2015.08.004. PMID 26515119
  15. Armah HB, Parwani AV. Atypical adenomatous hyperplasia (adenosis) of the prostate: a case report with review of the literature. Diagn Pathol. 2008;3:34. doi:10.1186/1746-1596-3-34. PMID 18700013
  16. Arndt C, Rodeberg D, Breitfeld PP, et al. Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from intergroup rhabdomyosarcoma study iv. J Urol. 2004;171(6 Pt 1):2396-403. doi:10.1097/01.ju.0000127752.41749.a4. PMID 15126860
  17. Ashley RA, Inman BA, Sebo TJ, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107(4):712-20. doi:10.1002/cncr.22060. PMID 16826585
  18. Baker PM, Young RH. Radiation-induced pseudocarcinomatous proliferations of the urinary bladder: a report of 4 cases. Hum Pathol. 2000;31(6):678-83. doi:10.1053/hupa.2000.7894. PMID 10872660
  19. Bapir R, Aghaways I, Yasseen HA, et al. Bladder malakoplakia mimicking a bladder tumor: A case report and brief review of the literature. Med Int (Lond). 2026;6(1):8. doi:10.3892/mi.2025.292. PMID 41473680
  20. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685-9. doi:10.1038/ng.2279. PMID 22610119
  21. Baydar D, Amin MB, Epstein JI. Osteoclast-rich undifferentiated carcinomas of the urinary tract. Mod Pathol. 2006;19(2):161-71. doi:10.1038/modpathol.3800521. PMID 16322750
  22. Beeter MC, Fazili T, Yeh YA. Nephrogenic Adenoma of the Prostatic Urethra Mimicking Prostatic and Bladder Carcinomas. Cureus. 2023;15(3):e35998. doi:10.7759/cureus.35998. PMID 37041930
  23. Bierhoff E, Vogel J, Benz M, et al. Stromal nodules in benign prostatic hyperplasia. Eur Urol. 1996;29(3):345-54. doi:10.1159/000473774. PMID 8740022
  24. Billis A, Meirelles L, Freitas LL. Mergence of partial and complete atrophy in prostate needle biopsies: a morphologic and immunohistochemical study. Virchows Arch. 2010;456(6):689-94. doi:10.1007/s00428-010-0904-x. PMID 20361207 (cited as Billis et al. 2010)
  25. Billis A, Piaza AC, Meirelles L, et al. Focal prostatic atrophy: morphologic classification and immunohistochemistry. Anal Quant Cytopathol Histpathol. 2014;36(2):71-81. PMID 24902359
  26. Billis A. Prostatic atrophy. Clinicopathological significance. Int Braz J Urol. 2010;36(4):401-9. doi:10.1590/s1677-55382010000400003. PMID 20815946
  27. Bishara A, Saeed H, Akkielah L, et al. Malakoplakia in Immunocompromised Hosts: A Case Series and Literature Review. Diseases. 2026;14(8):284. doi:10.3390/diseases14080284. PMID 42645092
  28. Blomqvist P, Joulhay Ian L, Holmin E, et al. Malignancy yield and clinical predictors in radiologically detected adult urachal anomalies: A retrospective cohort study. BJUI Compass. 2026;7(10):e70284. doi:10.1002/bco2.70284. PMID 42840620
  29. Borhan WM, Cimino-Mathews AM, Montgomery EA, et al. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder. Am J Surg Pathol. 2017;41(11):1570-1575. doi:10.1097/PAS.0000000000000922. PMID 28786878
  30. Bostwick DG, Qian J, Ma J, et al. Mesonephric remnants of the prostate: incidence and histologic spectrum. Mod Pathol. 2003;16(7):630-5. doi:10.1097/01.MP.0000074733.10777.78. PMID 12861057
  31. Brave MH, Maguire WF, Weinstock C, et al. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2024;30(21):4815-4821. doi:10.1158/1078-0432.CCR-24-1393. PMID 39230571
  32. Brennick JB, O'Connell JX, Dickersin GR, et al. Lipofuscin pigmentation (so-called "melanosis") of the prostate. Am J Surg Pathol. 1994;18(5):446-54. doi:10.1097/00000478-199405000-00003. PMID 7513501
  33. Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(3):245-253. doi:10.3322/caac.21391. PMID 28222223
  34. Cesaro S, Dalianis T, Hanssen Rinaldo C, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018;73(1):12-21. doi:10.1093/jac/dkx324. PMID 29190347
  35. Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol. 2001;25(9):1150-7. doi:10.1097/00000478-200109000-00005. PMID 11688574
  36. Chen YB, Fine SW, Epstein JI. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy. Am J Surg Pathol. 2011;35(7):1054-61. doi:10.1097/PAS.0b013e318218df97. PMID 21606823
  37. Cheng L, Bostwick DG. Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma. Histopathology. 2010;56(5):627-31. doi:10.1111/j.1365-2559.2010.03525.x. PMID 20459573
  38. Cheng L, Montironi R, Bostwick DG. Villous adenoma of the urinary tract: a report of 23 cases, including 8 with coexistent adenocarcinoma. Am J Surg Pathol. 1999;23(7):764-71. doi:10.1097/00000478-199907000-00003. PMID 10403298
  39. Cheng L, Nascimento AG, Neumann RM, et al. Hemangioma of the urinary bladder. Cancer. 1999;86(3):498-504. doi:10.1002/(sici)1097-0142(19990801)86:3<498::aid-cncr19>3.0.co;2-6. PMID 10430259 (cited as Cheng et al. 1999b)
  40. Cheng L, Pan CX, Yang XJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004;101(5):957-62. doi:10.1002/cncr.20456. PMID 15329903
  41. Cheng L, Zhang S, Wang M, et al. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Hum Pathol. 2023;133:56-75. doi:10.1016/j.humpath.2022.06.005. PMID 35700749
  42. Cheville JC, Bostwick DG. Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma. Am J Surg Pathol. 1995;19(9):1068-76. doi:10.1097/00000478-199509000-00011. PMID 7544958
  43. Chiba M, Toki A, Sugiyama A, et al. Urethral caruncle in a 9-year-old girl: a case report and review of the literature. J Med Case Rep. 2015;9:71. doi:10.1186/s13256-015-0518-7. PMID 25884921
  44. Chu PG, Huang Q, Weiss LM. Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases. Am J Surg Pathol. 2005;29(5):693-9. doi:10.1097/01.pas.0000153122.65138.b1. PMID 15832096
  45. Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31(8):1246-55. doi:10.1097/PAS.0b013e31802f5d33. PMID 17667550
  46. Chuang AY, Epstein JI. Xanthoma of the prostate: a mimicker of high-grade prostate adenocarcinoma. Am J Surg Pathol. 2007;31(8):1225-30. doi:10.1097/PAS.0b013e31802be3c2. PMID 17667547
  47. Cina SJ, Silberman MA, Kahane H, et al. Diagnosis of Cowper's glands on prostate needle biopsy. Am J Surg Pathol. 1997;21(5):550-5. doi:10.1097/00000478-199705000-00007. PMID 9158679
  48. College of American Pathologists. Cancer protocol templates (versions, posting dates and summaries of changes). https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). No DOI or PMID. Cited as CAP Protocol Templates 2026.
  49. College of American Pathologists. Protocol for the examination of biopsy and transurethral resection of bladder tumor (TURBT) specimens from patients with carcinoma of the urinary bladder, version 4.3.0.0. Posted June 2025. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). No DOI or PMID. Cited as CAP Bladder Biopsy 2025.
  50. College of American Pathologists. Protocol for the examination of cystectomy specimens from patients with carcinoma of the urinary bladder, version 4.2.0.0. Posted September 2023. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). No DOI or PMID. Cited as CAP Bladder Resection 2023.
  51. College of American Pathologists. Protocol for the examination of prostate needle biopsies from patients with carcinoma of the prostate gland: case level reporting, version 1.1.0.0. Posted September 2023. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). No DOI or PMID. Cited as CAP 2023a.
  52. College of American Pathologists. Protocol for the examination of radical prostatectomy specimens from patients with carcinoma of the prostate gland, version 4.3.0.0. Posted September 2023. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). No DOI or PMID. Cited as CAP 2023d.
  53. College of American Pathologists. Protocol for the examination of resection specimens from patients with carcinoma of the ureter or renal pelvis, version 2.4.0.0. Posted March 2025. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). No DOI or PMID. Cited as CAP Ureter Renal Pelvis 2025.
  54. College of American Pathologists. Protocol for the examination of TURP and enucleation specimens from patients with carcinoma of the prostate gland, version 4.2.0.0. Posted September 2023. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). No DOI or PMID. Cited as CAP 2023c.
  55. Collins K, Cheng L. Treatment-related changes in the prostate: past, present and future therapies. Histopathology. 2026;88(1):40-52. doi:10.1111/his.15507. PMID 41384710
  56. Collins K, Galea LA, Foroughi F, et al. Genomic analysis of primary epithelial neoplasms of the seminal vesicle identifies a subset of mucinous cystic tumours driven by KRAS mutations. Histopathology. 2024;84(7):1192-1198. doi:10.1111/his.15167. PMID 38409850
  57. Collins K, Gupta S, Cheng L. Updates in bladder and prostate pathology: Diagnostic consensus and clinical relevance. Hum Pathol. 2026;169:106018. doi:10.1016/j.humpath.2025.106018. PMID 41412445
  58. Corica FA, Husmann DA, Churchill BM, et al. Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. Urology. 1997;50(3):427-31. doi:10.1016/S0090-4295(97)00294-X. PMID 9301710
  59. Cox R, Epstein JI. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am J Surg Pathol. 2011;35(9):1337-42. doi:10.1097/PAS.0b013e318222a653. PMID 21836490
  60. Craig JR, Hart WR. Benign polyps with prostatic-type epithelium of the urethra. Am J Clin Pathol. 1975;63(3):343-7. doi:10.1093/ajcp/63.3.343. PMID 1115041
  61. Danaci M, Akpolat T, Baştemir M, et al. The prevalence of seminal vesicle cysts in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1998;13(11):2825-8. doi:10.1093/ndt/13.11.2825. PMID 9829485
  62. Das JP, Vargas HA, Lee A, et al. The urachus revisited: multimodal imaging of benign & malignant urachal pathology. Br J Radiol. 2020;93(1110):20190118. doi:10.1259/bjr.20190118. PMID 32045264
  63. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091-2102. doi:10.1056/NEJMoa1911440. PMID 32343890
  64. de Reijke TM, Kurth KH, Sylvester RJ, et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). J Urol. 2005;173(2):405-9. doi:10.1097/01.ju.0000150425.09317.67. PMID 15643181
  65. Desar S, Muthusamy S, Kenigsberg AP, et al. Incidental cystadenomas of the seminal vesicle: an institutional series. Int J Surg Pathol. 2026;34(2):342-349. doi:10.1177/10668969251370310. PMID 40905744
  66. Destouni M, Lazaris AC, Tzelepi V. Cribriform patterned lesions in the prostate gland with emphasis on differential diagnosis and clinical significance. Cancers (Basel). 2022;14(13):3041. doi:10.3390/cancers14133041. PMID 35804812
  67. Downes MR, Hartmann A, Shen S, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System Performance. Am J Surg Pathol. 2024;48(1):e1-e10. doi:10.1097/PAS.0000000000002059. PMID 37246824
  68. Downes MR, Lopez-Beltran A, Contieri R, et al. International Society of Urological Pathology Consensus Meeting 2024: Working Group 2 Preneoplastic and Precursor Lesions of the Urinary Bladder. Am J Surg Pathol. 2025;49(12):e46-e57. doi:10.1097/PAS.0000000000002440. PMID 40590266
  69. Egevad L, Delahunt B, Furusato B, et al. Benign mimics of prostate cancer. Pathology. 2021;53(1):26-35. doi:10.1016/j.pathol.2020.08.006. PMID 33070957
  70. Eggener SE, Rumble RB, Armstrong AJ, et al. Molecular biomarkers in localized prostate cancer: ASCO guideline. J Clin Oncol. 2020;38(13):1474-1494. doi:10.1200/JCO.19.02768. PMID 31829902
  71. El-Ghoneimi A, Harper L, Pierucci UM, et al. Management of patients with posterior urethral valves "from the fetus to adolescence": French national diagnostic and care protocol (NDCP). Orphanet J Rare Dis. 2025;20(1):225. doi:10.1186/s13023-025-03712-5. PMID 40355883
  72. El-Zaatari ZM, Thomas JS, Divatia MK, et al. Pleomorphic giant cell carcinoma of prostate: rare tumor with unique clinicopathological, immunohistochemical, and molecular features. Ann Diagn Pathol. 2021;52:151719. doi:10.1016/j.anndiagpath.2021.151719. PMID 33640702
  73. Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38(6):756-67. doi:10.1097/PAS.0000000000000208. PMID 24705311
  74. Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med. 2021;145(4):461-493. doi:10.5858/arpa.2020-0015-RA. PMID 32589068
  75. Epstein JI, Amin MB, Reuter VE, et al. Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2017;41(4):e1-e7. doi:10.1097/PAS.0000000000000820. PMID 28177964
  76. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244-52. doi:10.1097/PAS.0000000000000530. PMID 26492179 (cited as Epstein et al. 2016a)
  77. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006;175(3 Pt 1):820-34. doi:10.1016/S0022-5347(05)00337-X. PMID 16469560
  78. Epstein JI, Hutchins GM. Granulomatous prostatitis: distinction among allergic, nonspecific, and post-transurethral resection lesions. Hum Pathol. 1984;15(9):818-25. doi:10.1016/s0046-8177(84)80142-2. PMID 6432674
  79. Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69(3):428-35. doi:10.1016/j.eururo.2015.06.046. PMID 26166626 (cited as Epstein et al. 2016b)
  80. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol. 2004;17(3):307-15. doi:10.1038/modpathol.3800050. PMID 14739905
  81. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol. 1995;26(2):223-9. doi:10.1016/0046-8177(95)90041-1. PMID 7860053
  82. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141-9. doi:10.1056/NEJMoa1110000. PMID 22236224
  83. Fan K, Schaefer RF, Venable M. Urethral verumontanal polyp: evidence of prostatic origin. Urology. 1984;24(5):499-501. doi:10.1016/0090-4295(84)90334-0. PMID 6495464
  84. Fatima N, Canter DJ, Carthon BC, et al. Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases. Can J Urol. 2015;22(3):7783-7. No DOI. PMID 26068625
  85. Fichtenbaum EJ, Marsh WL, Zynger DL. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate. Am J Clin Pathol. 2012;138(2):190-7. doi:10.1309/AJCP5ZC4GQVNWTYR. PMID 22904129
  86. Fine SW, Al-Ahmadie HA, Gopalan A, et al. Anatomy of the anterior prostate and extraprostatic space: a contemporary surgical pathology analysis. Adv Anat Pathol. 2007;14(6):401-7. doi:10.1097/PAP.0b013e3181597a9c. PMID 18049129
  87. Flauto F, Neola G, Cimadamore A, et al. Non-conventional histologies of prostate cancer: from morphology to biology-driven precision oncology. Oncologist. 2026;31(11):oyag391. doi:10.1093/oncolo/oyag391. PMID 42832307
  88. Freeman A, Geddes N, Munson P, et al. Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumours of the bladder: a preliminary clinicopathological study of nine cases and review of the literature. Mod Pathol. 2004;17(7):765-71. doi:10.1038/modpathol.3800078. PMID 15105807
  89. Fukui I, Yokokawa M, Sekine H, et al. Carcinoma in situ of the urinary bladder. Effect of associated neoplastic lesions on clinical course and treatment. Cancer. 1987;59(1):164-73. doi:10.1002/1097-0142(19870101)59:1<164::aid-cncr2820590132>3.0.co;2-z. PMID 3791145
  90. Gagucas RJ, Brown RW, Wheeler TM. Verumontanum mucosal gland hyperplasia. Am J Surg Pathol. 1995;19(1):30-6. doi:10.1097/00000478-199501000-00004. PMID 7802135
  91. Gaudin PB, Rosai J, Epstein JI. Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol. 1998;22(2):148-62. doi:10.1097/00000478-199802000-00002. PMID 9500215
  92. Giannico GA, Gown AM, Epstein JI, et al. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract. Hum Pathol. 2017;67:152-159. doi:10.1016/j.humpath.2017.07.002. PMID 28711650
  93. Gilani SI, Dasari S, Tekin B, et al. Identification of amyloidosis of the urinary tract and prostate: opportunities for early diagnosis & intervention in systemic disease. Hum Pathol. 2023;142:62-67. doi:10.1016/j.humpath.2023.11.001. PMID 37979953
  94. Giri VN, Knudsen KE, Kelly WK, et al. Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020;38(24):2798-2811. doi:10.1200/JCO.20.00046. PMID 32516092
  95. Giubellino A, Lara K, Martucci V, et al. Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations. Am J Surg Pathol. 2015;39(11):1488-92. doi:10.1097/PAS.0000000000000534. PMID 26457353
  96. Golijanin D, Yossepowitch O, Beck SD, et al. Carcinoma in a bladder diverticulum: presentation and treatment outcome. J Urol. 2003;170(5):1761-4. doi:10.1097/01.ju.0000091800.15071.52. PMID 14532771
  97. Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer. 1991;67(8):2165-72. doi:10.1002/1097-0142(19910415)67:8<2165::aid-cncr2820670827>3.0.co;2-m. PMID 1706216
  98. Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A. 2007;104(29):12129-34. doi:10.1073/pnas.0701248104. PMID 17620607
  99. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol. 2006;19(12):1528-35. doi:10.1038/modpathol.3800702. PMID 16980940
  100. Gupta A, Wang HL, Policarpio-Nicolas ML, et al. Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma. Am J Surg Pathol. 2004;28(9):1224-9. doi:10.1097/01.pas.0000131544.18266.a4. PMID 15316323
  101. Gupta S, Thompson RH, Boorjian SA, et al. High grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine carcinoma. Pathology. 2015;47(6):533-42. doi:10.1097/PAT.0000000000000301. PMID 26308137
  102. Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010;34(8):1097-105. doi:10.1097/PAS.0b013e3181e6cbf3. PMID 20588175
  103. Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis/chronic pelvic pain syndrome. Annu Rev Med. 2006;57:195-206. doi:10.1146/annurev.med.57.011205.135654. PMID 16409145
  104. Hameed O, Humphrey PA. Pseudoneoplastic mimics of prostate and bladder carcinomas. Arch Pathol Lab Med. 2010;134(3):427-43. doi:10.5858/134.3.427. PMID 20196670
  105. Harik LR, Merino C, Coindre JM, et al. Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases. Am J Surg Pathol. 2006;30(7):787-94. doi:10.1097/01.pas.0000208903.46354.6f. PMID 16819319
  106. He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am J Surg Pathol. 2011;35(4):608-14. doi:10.1097/PAS.0b013e31820bcd2d. PMID 21383613
  107. Herawi M, Epstein JI. Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases. Am J Surg Pathol. 2006;30(6):694-704. doi:10.1097/00000478-200606000-00004. PMID 16723846 (cited as Herawi and Epstein 2006a)
  108. Herawi M, Montgomery EA, Epstein JI. Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: a clinicopathologic study of 8 cases. Am J Surg Pathol. 2006;30(11):1389-95. doi:10.1097/01.pas.0000209847.59670.c8. PMID 17063078 (cited as Herawi et al. 2006b)
  109. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31(5):673-80. doi:10.1097/01.pas.0000213438.01278.5f. PMID 17460449
  110. Hoffman-Censits JH, Lombardo KA, Parimi V, et al. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. Appl Immunohistochem Mol Morphol. 2021;29(8):619-625. doi:10.1097/PAI.0000000000000938. PMID 33901032
  111. Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70(1):106-119. doi:10.1016/j.eururo.2016.02.028. PMID 26996659
  112. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol. 2007;60(1):35-42. doi:10.1136/jcp.2005.036442. PMID 17213347 (cited as Humphrey 2007)
  113. Humphrey PA. Variants of acinar adenocarcinoma of the prostate mimicking benign conditions. Mod Pathol. 2018;31(S1):S64-70. doi:10.1038/modpathol.2017.137. PMID 29297496
  114. Iczkowski KA, De Marzo AM, Agarwal N, et al. International Society of Urological Pathology consensus on cancer precursor lesions. Working Group 1: the prostate. Am J Surg Pathol. 2025;49(12):e33-e45. doi:10.1097/PAS.0000000000002430. PMID 40545966
  115. Jennings RW. Prune belly syndrome. Semin Pediatr Surg. 2000;9(3):115-20. doi:10.1053/spsu.2000.7556. PMID 10949420
  116. Ji M, Chen Y, Feng H, et al. Xanthogranulomatous prostatitis mimicking prostate carcinoma: a case report and comprehensive literature review. Front Med (Lausanne). 2026;13:1883799. doi:10.3389/fmed.2026.1883799. PMID 42712458
  117. Johnson MH, Strope SA. Encrusted cystitis. Urology. 2012;79(3):e31-2. doi:10.1016/j.urology.2011.12.013. PMID 22386439
  118. Ju JY, Mills AM, Mahadevan MS, et al. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas. Am J Surg Pathol. 2018;42(11):1549-1555. doi:10.1097/PAS.0000000000001141. PMID 30148743
  119. Jung K, Ghatalia P, Litwin S, et al. Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clin Genitourin Cancer. 2017;15(3):e337-e343. doi:10.1016/j.clgc.2016.09.005. PMID 27991416
  120. Kench JG, Amin MB, Berney DM, et al. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology. 2022;81(4):447-458. doi:10.1111/his.14711. PMID 35758185
  121. Khan MS, Thornhill JA, Gaffney E, et al. Keratinising squamous metaplasia of the bladder: natural history and rationalization of management based on review of 54 years experience. Eur Urol. 2002;42(5):469-74. doi:10.1016/s0302-2838(02)00358-5. PMID 12429156
  122. Khan N, Abu Ghanem Y, Ng W, et al. Cystitis Glandularis: A 10-Year Institutional Experience and Review of the Literature. Cureus. 2025;17(12):e98588. doi:10.7759/cureus.98588. PMID 41357718
  123. Koga S, Shindo K, Matsuya F, et al. Acute hemorrhagic cystitis caused by adenovirus following renal transplantation: review of the literature. J Urol. 1993;149(4):838-9. doi:10.1016/s0022-5347(17)36227-4. PMID 8455254
  124. Kostara K, Palmisano L, Shenasan P, et al. Urachal adenocarcinoma: a case report and literature review. J Surg Case Rep. 2025;2025(12):rjaf973. doi:10.1093/jscr/rjaf973. PMID 41415483
  125. Krieger JN. Prostatitis revisited: new definitions, new approaches. Infect Dis Clin North Am. 2003;17(2):395-409. doi:10.1016/s0891-5520(03)00003-5. PMID 12848476
  126. Kumar S, G KI, Khalil-Khan A, et al. Zinner syndrome. Cureus. 2022;14(11):e31308. doi:10.7759/cureus.31308. PMID 36382324
  127. Kunju LP. Nephrogenic adenoma: report of a case and review of morphologic mimics. Arch Pathol Lab Med. 2010;134(10):1455-9. doi:10.5858/2010-0226-CR.1. PMID 20923300
  128. LaFontaine PD, Middleman BR, Graham SD, et al. Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology. 1997;49(3):363-6. doi:10.1016/s0090-4295(96)00507-9. PMID 9123699
  129. Lane Z, Epstein JI. Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia. Am J Surg Pathol. 2008;32(5):758-64. doi:10.1097/PAS.0b013e31816092b5. PMID 18379418
  130. Lane Z, Epstein JI. Pseudocarcinomatous epithelial hyperplasia in the bladder unassociated with prior irradiation or chemotherapy. Am J Surg Pathol. 2008;32(1):92-7. doi:10.1097/PAS.0b013e3180eaa1dc. PMID 18162775
  131. Leong AS, Wannakrairot P, Jose J, et al. Bacillus Calmette-Guérin-treated superficial bladder cancer: correlation of morphology with immunophenotyping. J Pathol. 1990;162(1):35-41. doi:10.1002/path.1711620108. PMID 2231190
  132. Leroy X, Ballereau C, Villers A, et al. MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinoma. Am J Surg Pathol. 2003;27(4):519-21. doi:10.1097/00000478-200304000-00013. PMID 12657938
  133. Leunbach TL, Stilling C, Tabor MB, et al. Caveats in the diagnosis of suspected non-endemic verrucous carcinoma in the urinary bladder. BJU Int. 2022;129(4):457-459. doi:10.1111/bju.15715. PMID 35347834
  134. Li H, Bhardwaj S, Feng M, et al. Lipid-Rich Urothelial Carcinoma: A Contemporary Clinicopathologic Study of 40 Patients With Transcriptional Tumor Profiling. Am J Surg Pathol. 2026;50(11):1269-1280. doi:10.1097/PAS.0000000000002595. PMID 42596534
  135. Li W, Liang Y, Deavers MT, et al. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014;142(6):864-71. doi:10.1309/AJCP1J0JPJBPSUXF. PMID 25389341
  136. Lian H, Feng W, Zhang M, et al. Phyllodes-predominant prostatic stromal sarcoma concurrent with prostate adenocarcinoma: a case report and literature review. Front Oncol. 2026;16:1742518. doi:10.3389/fonc.2026.1742518. PMID 41756326
  137. Liang Y, Heitzman J, Kamat AM, et al. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014;45(7):1466-72. doi:10.1016/j.humpath.2014.02.023. PMID 24745616
  138. Linke RP, Joswig R, Murphy CL, et al. Senile seminal vesicle amyloid is derived from semenogelin I. J Lab Clin Med. 2005;145(4):187-93. doi:10.1016/j.lab.2005.02.002. PMID 15962837
  139. Lopez Beltran A, Montironi R, Cheng L. Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. Histopathology. 2014;64(6):872-9. doi:10.1111/his.12345. PMID 24321001
  140. Lopez-Beltran A, Montironi R, Raspollini MR, et al. Iatrogenic pathology of the urinary bladder. Semin Diagn Pathol. 2018;35(4):218-227. doi:10.1053/j.semdp.2018.03.001. PMID 29576423
  141. Lopez-Beltran A, Raspollini MR, Hansel D, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Working Group 3: Subcategorization of T1 Bladder Cancer. Am J Surg Pathol. 2024;48(1):e24-e31. doi:10.1097/PAS.0000000000002121. PMID 37737692
  142. Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023;389(21):1961-1971. doi:10.1056/NEJMoa2308849. PMID 37870920
  143. Lotan TL, Epstein JI. Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol. 2009;40(4):471-7. doi:10.1016/j.humpath.2008.10.002. PMID 19128819
  144. Lott S, Wang M, Zhang S, et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Mod Pathol. 2009;22(5):627-32. doi:10.1038/modpathol.2009.28. PMID 19287463
  145. Maetzold E, Takacs EB. Urethral Pathology in Women. Curr Urol Rep. 2022;23(10):225-234. doi:10.1007/s11934-022-01109-6. PMID 36114996
  146. Magi-Galluzzi C. Prostate cancer: diagnostic criteria and role of immunohistochemistry. Mod Pathol. 2018;31(S1):S12-21. doi:10.1038/modpathol.2017.139. PMID 29297490
  147. Maguire WF, Chang E, Mulkey F, et al. FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2026;32(20):4519-4524. doi:10.1158/1078-0432.CCR-26-1154. PMID 42584173
  148. Maniar KP, Unger PD, Samadi DB, et al. Incidental prostatic paraganglia in radical prostatectomy specimens: a diagnostic pitfall. Int J Surg Pathol. 2011;19(6):772-4. doi:10.1177/1066896911414567. PMID 21791487
  149. Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res. 2021;27(17):4685-4689. doi:10.1158/1078-0432.CCR-21-0327. PMID 34083238
  150. Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753-3758. doi:10.1158/1078-0432.CCR-18-4070. PMID 30787022
  151. Martin SA, Sears DL, Sebo TJ, et al. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic comparison of leiomyoma and leiomyosarcoma. Am J Surg Pathol. 2002;26(3):292-300. doi:10.1097/00000478-200203000-00002. PMID 11859200
  152. Mason EF, Sadow PM, Wagner AJ, et al. Identification of succinate dehydrogenase-deficient bladder paragangliomas. Am J Surg Pathol. 2013;37(10):1612-8. doi:10.1097/PAS.0b013e318293d83c. PMID 23797725
  153. Matz EL, Hsieh MH. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. Urology. 2017;100:16-19. doi:10.1016/j.urology.2016.07.030. PMID 27566144
  154. Maxwell JP, Wang C, Wiebe N, et al. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth. Diagn Pathol. 2015;10:3. doi:10.1186/s13000-015-0234-z. PMID 25886613
  155. Mazal PR, Schaufler R, Altenhuber-Müller R, et al. Derivation of nephrogenic adenomas from renal tubular cells in kidney-transplant recipients. N Engl J Med. 2002;347(9):653-9. doi:10.1056/NEJMoa013413. PMID 12200552
  156. McDaniel AS, Chinnaiyan AM, Siddiqui J, et al. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3. Am J Surg Pathol. 2014;38(12):1664-71. doi:10.1097/PAS.0000000000000267. PMID 24921643
  157. McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol. 2003;16(7):623-9. doi:10.1097/01.MP.0000073973.74228.1E. PMID 12861056
  158. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25(8):1074-8. doi:10.1097/00000478-200108000-00013. PMID 11474293 (cited as McKenney et al. 2001b)
  159. McKenney JK, Gomez JA, Desai S, et al. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001;25(3):356-62. doi:10.1097/00000478-200103000-00010. PMID 11224606 (cited as McKenney et al. 2001a)
  160. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12(12):897-906. doi:10.1097/00000478-198812000-00001. PMID 3202246
  161. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978;15(4):340-5. PMID 75197
  162. Menon S, Goyal P, Suryawanshi P, et al. Paraganglioma of the urinary bladder: a clinicopathologic spectrum of a series of 14 cases emphasizing diagnostic dilemmas. Indian J Pathol Microbiol. 2014;57(1):19-23. doi:10.4103/0377-4929.130873. PMID 24739826
  163. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38(1):13-22. doi:10.1097/PAS.0b013e3182a0218f. PMID 24145643
  164. Milord RA, Kahane H, Epstein JI. Infarct of the prostate gland: experience on needle biopsy specimens. Am J Surg Pathol. 2000;24(10):1378-84. doi:10.1097/00000478-200010000-00007. PMID 11023099
  165. Montgomery EA, Shuster DD, Burkart AL, et al. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol. 2006;30(12):1502-12. doi:10.1097/01.pas.0000213280.35413.1b. PMID 17122505
  166. Montironi R, Cheng L, Scarpelli M, et al. How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme? Diagn Pathol. 2011;6:31. doi:10.1186/1746-1596-6-31. PMID 21473752
  167. Muezzinoglu B, Erdamar S, Chakraborty S, et al. Verumontanum mucosal gland hyperplasia is associated with atypical adenomatous hyperplasia of the prostate. Arch Pathol Lab Med. 2001;125(3):358-60. doi:10.5858/2001-125-0358-VMGHIA. PMID 11231483
  168. Munari E, Querzoli G, Brunelli M, et al. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection. Front Immunol. 2022;13:954910. doi:10.3389/fimmu.2022.954910. PMID 35967344
  169. Naiditch JA, Radhakrishnan J, Chin AC. Current diagnosis and management of urachal remnants. J Pediatr Surg. 2013;48(10):2148-52. doi:10.1016/j.jpedsurg.2013.02.069. PMID 24094971
  170. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol. 1996;20(4):419-26. doi:10.1097/00000478-199604000-00004. PMID 8604808
  171. Netto GJ, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82(5):469-482. doi:10.1016/j.eururo.2022.07.002. PMID 35965208
  172. Neumann NM, Haffner MC, Argani P, et al. Histopathologic Characterization of Bladder Perivascular Epithelioid Cell Neoplasms (PEComa): A Series of 11 Cases With a Subset Having TFE3 Rearrangements. Am J Surg Pathol. 2021;45(2):169-177. doi:10.1097/PAS.0000000000001592. PMID 33002920
  173. Nickel JC, True LD, Krieger JN, et al. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 2001;87(9):797-805. doi:10.1046/j.1464-410x.2001.02193.x. PMID 11412216
  174. Nigwekar P, Tamboli P, Amin MB, et al. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol. 2009;33(3):417-24. doi:10.1097/PAS.0b013e318186c45e. PMID 19011563
  175. Norlén LJ, Ekelund P, Hedelin H, et al. Effects of indwelling catheters on the urethral mucosa (polypoid urethritis). Scand J Urol Nephrol. 1988;22(2):81-6. doi:10.1080/00365599.1988.11690390. PMID 3206219
  176. Oates RD, Stilmant MM, Freedlund MC, et al. Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer. J Urol. 1988;140(4):751-4. doi:10.1016/s0022-5347(17)41803-9. PMID 3418796
  177. Oliva E, Pinheiro NF, Heney NM, et al. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. Hum Pathol. 2013;44(5):860-6. doi:10.1016/j.humpath.2012.08.011. PMID 23199526
  178. Oliva E, Young RH. Clear cell adenocarcinoma of the urethra: a clinicopathologic analysis of 19 cases. Mod Pathol. 1996;9(5):513-20. No DOI. PMID 8733766
  179. Ostrowski ML, Wheeler TM. Paraganglia of the prostate. Location, frequency, and differentiation from prostatic adenocarcinoma. Am J Surg Pathol. 1994;18(4):412-20. PMID 8141432
  180. Oxley JD, Cottrell AM, Adams S, et al. Ketamine cystitis as a mimic of carcinoma in situ. Histopathology. 2009;55(6):705-8. doi:10.1111/j.1365-2559.2009.03437.x. PMID 19919587
  181. Pamfil C, Mihon MI, Surdu V, et al. IgG4-related prostatitis: expanding the spectrum of IgG4-related disease. A systematic review. Clin Exp Rheumatol. 2026;44(7):1341-1348. doi:10.55563/clinexprheumatol/i8eh4g. PMID 41562347
  182. Paner GP, Annaiah C, Gulmann C, et al. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol. 2014;45(7):1473-82. doi:10.1016/j.humpath.2014.02.024. PMID 24780825
  183. Paner GP, Kamat A, Netto GJ, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. 2024;48(1):e11-e23. doi:10.1097/PAS.0000000000002077. PMID 37382156
  184. Paner GP, Lopez-Beltran A, Sirohi D, et al. Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin. Adv Anat Pathol. 2016;23(2):71-83. doi:10.1097/PAP.0000000000000110. PMID 26849813
  185. Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch Pathol Lab Med. 2008;132(9):1388-96. doi:10.5858/2008-132-1388-BPIDIP. PMID 18788849
  186. Paner GP, Montironi R, Amin MB. Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. Adv Anat Pathol. 2017;24(3):113-127. doi:10.1097/PAP.0000000000000152. PMID 28398951
  187. Paner GP, Ro JY, Wojcik EM, et al. Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol. 2007;31(9):1420-9. doi:10.1097/PAS.0b013e3180588283. PMID 17721199
  188. Parwani AV, Kronz JD, Genega EM, et al. Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol. 2004;28(5):651-7. doi:10.1097/00000478-200405000-00014. PMID 15105655
  189. Perrino CM, Eble J, Kao CS, et al. Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients. Hum Pathol. 2019;90:27-36. doi:10.1016/j.humpath.2019.04.012. PMID 31054897
  190. Portugal-Gaspar F, Lopez-Beltran A, Paner GP, et al. Giant cell carcinoma of the urinary bladder : Clinicopathologic analysis and oncological outcomes. Virchows Arch. 2024;485(3):535-546. doi:10.1007/s00428-024-03858-w. PMID 39023556
  191. Pradhan BK, Chandra K. Morphogenesis of nodular hyperplasia--prostate. J Urol. 1975;113(2):210-3. doi:10.1016/s0022-5347(17)59446-x. PMID 46291
  192. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-53. doi:10.1056/NEJMoa1603144. PMID 27433846
  193. Przybycin CG, McKenney JK, Nguyen JK, et al. Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma: Clinicopathologic Series of 16 Cases. Am J Surg Pathol. 2020;44(10):1322-1330. doi:10.1097/PAS.0000000000001532. PMID 32931680
  194. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology. 2000;56(5):828-32. doi:10.1016/s0090-4295(00)00776-7. PMID 11068311
  195. Raspollini MR, Comperat EM, Lopez-Beltran A, et al. News in the classification of WHO 2022 bladder tumors. Pathologica. 2022;115(1):32-40. doi:10.32074/1591-951X-838. PMID 36704871
  196. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89. doi:10.14740/wjon1191. PMID 31068988
  197. Reis H, Al-Ahmadie H, Gaisa NT, et al. The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms. Am J Surg Pathol. 2025;49(11):e18-e26. doi:10.1097/PAS.0000000000002416. PMID 40471793
  198. Ro JY, Ayala AG, el-Naggar A. Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol. 1987;11(9):668-73. doi:10.1097/00000478-198709000-00002. PMID 3631381
  199. Rouprêt M, Seisen T, Birtle AJ, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol. 2023;84(1):49-64. doi:10.1016/j.eururo.2023.03.013. PMID 36967359
  200. Rubin MA, Zhou M, Dhanasekaran SM, et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287(13):1662-70. doi:10.1001/jama.287.13.1662. PMID 11926890
  201. Russell DH, Vang R, Epstein JI, et al. Verrucous Squamous Hyperplasia of the Urinary Bladder: A Series of 23 Cases. Arch Pathol Lab Med. 2022;146(12):1508-1513. doi:10.5858/arpa.2021-0320-OA. PMID 35486484
  202. Saboorian MH, Huffman H, Ashfaq R, et al. Distinguishing Cowper's glands from neoplastic and pseudoneoplastic lesions of prostate: immunohistochemical and ultrastructural studies. Am J Surg Pathol. 1997;21(9):1069-74. doi:10.1097/00000478-199709000-00011. PMID 9298883
  203. Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of Bladder Cancer. Med Sci (Basel). 2020;8(1):15. doi:10.3390/medsci8010015. PMID 32183076
  204. Samaratunga H, Delahunt B, Yaxley J, et al. Tumour-like lesions of the urinary bladder. Pathology. 2021;53(1):44-55. doi:10.1016/j.pathol.2020.08.005. PMID 33070959
  205. Samaratunga H, Montironi R, True L, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol. 2011;24(1):6-15. doi:10.1038/modpathol.2010.178. PMID 20834234
  206. Santa F, Akgul M, Tannous E, et al. Primary adenocarcinoma of the urinary tract and its precursors: Diagnostic criteria and classification. Hum Pathol. 2025;155:105734. doi:10.1016/j.humpath.2025.105734. PMID 39988060
  207. Santos LL, Santos J, Gouveia MJ, et al. Urogenital Schistosomiasis-History, Pathogenesis, and Bladder Cancer. J Clin Med. 2021;10(2):205. doi:10.3390/jcm10020205. PMID 33429985
  208. Sebo TJ, Bostwick DG, Farrow GM, et al. Prostatic xanthoma: a mimic of prostatic adenocarcinoma. Hum Pathol. 1994;25(4):386-9. doi:10.1016/0046-8177(94)90147-3. PMID 7512940
  209. Settaf-Cherif L, Czarnogórski MC, Ostrowski A, et al. Leiomyosarcoma of lower urinary tract: literature review. Cent European J Urol. 2025;78(4):494-502. doi:10.5173/ceju.2025.0157. PMID 41725966
  210. Shah RB, Varma M, Zhou M, et al. The Genitourinary Pathology Society and International Society of Urological Pathology joint expert consultation recommendations on intraductal carcinoma of the prostate. Histopathology. 2026;88(1):8-23. doi:10.1111/his.70046. PMID 41384645. Correction in: Histopathology. 2026;89(3):568. doi:10.1111/his.70227. PMID 42478522
  211. Sharma AE, Dermawan JK, Chiang S, et al. Botryoid-type Embryonal Rhabdomyosarcoma: A Comprehensive Clinicopathologic and Molecular Appraisal With Cross-comparison to its Conventional-type Counterpart. Am J Surg Pathol. 2024;48(12):1557-1567. doi:10.1097/PAS.0000000000002300. PMID 39210566
  212. Shen SS, Lerner SP, Muezzinoglu B, et al. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006;37(6):726-34. doi:10.1016/j.humpath.2006.01.027. PMID 16733214
  213. Shukla P, Gulwani HV, Kaur S. Granulomatous prostatitis: clinical and histomorphologic survey of the disease in a tertiary care hospital. Prostate Int. 2017;5(1):29-34. doi:10.1016/j.prnil.2017.01.003. PMID 28352621
  214. Siegel RL, Kratzer TB, Wagle NS, et al. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043. doi:10.3322/caac.70043. PMID 41528114
  215. Smeulders N, Woodhouse CR. Neoplasia in adult exstrophy patients. BJU Int. 2001;87(7):623-8. doi:10.1046/j.1464-410x.2001.02136.x. PMID 11350401
  216. Smith AK, Hansel DE, Jones JS. Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. Urology. 2008;71(5):915-8. doi:10.1016/j.urology.2007.11.079. PMID 18455631
  217. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Mod Pathol. 2004;17(3):328-48. doi:10.1038/modpathol.3800055. PMID 14976539
  218. Srodon M, Epstein JI. Central zone histology of the prostate: a mimicker of high-grade prostatic intraepithelial neoplasia. Hum Pathol. 2002;33(5):518-23. doi:10.1053/hupa.2002.124032. PMID 12094377
  219. Sun K, Huan Y, Unger PD. Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S. Arch Pathol Lab Med. 2008;132(9):1417-22. doi:10.5858/2008-132-1417-CCAOUB. PMID 18788852
  220. Surintrspanont J, Zhou M. Prostate pathology: what is new in the 2022 WHO Classification of Urinary and Male Genital Tumors? Pathologica. 2022;115(1):41-56. doi:10.32074/1591-951X-822. PMID 36645399 (summarizes the WHO Classification of Tumours, Urinary and Male Genital Tumours, 5th edition)
  221. Swartz MA, Porter MP, Lin DW, et al. Incidence of primary urethral carcinoma in the United States. Urology. 2006;68(6):1164-8. doi:10.1016/j.urology.2006.08.1057. PMID 17141838
  222. Tan T, Peng X, Shang D, et al. Treatment outcomes and next-generation sequencing of a rare malignancy - urachal carcinoma: case report and literature review. Front Oncol. 2026;16:1744925. doi:10.3389/fonc.2026.1744925. PMID 42094195
  223. Tekin B, Datta L, Zargham R, et al. Sarcomatoid carcinoma of the prostate: a single institution experience with emphasis on molecular genetic findings. Hum Pathol. 2026;167:105988. doi:10.1016/j.humpath.2025.105988. PMID 41285178
  224. Thomas AA, Lane BR, Thomas AZ, et al. Emphysematous cystitis: a review of 135 cases. BJU Int. 2007;100(1):17-20. doi:10.1111/j.1464-410X.2007.06930.x. PMID 17506870
  225. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-8. doi:10.1126/science.1117679. PMID 16254181
  226. Tong GX, Melamed J, Mansukhani M, et al. PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol. 2006;19(3):356-63. doi:10.1038/modpathol.3800535. PMID 16400326
  227. Tong GX, Memeo L, Colarossi C, et al. PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract. Am J Surg Pathol. 2011;35(10):1473-83. doi:10.1097/PAS.0b013e318227e2ee. PMID 21934480
  228. Tong GX, Weeden EM, Hamele-Bena D, et al. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol. 2008;32(9):1380-7. doi:10.1097/PAS.0b013e31816b1020. PMID 18670350
  229. Town MV, Kim KJ, Vu A, et al. Bladder exstrophy: navigating long-term outcomes. Transl Androl Urol. 2025;14(6):1797-1806. doi:10.21037/tau-2024-631. PMID 40687642
  230. Tsuzuki T, Epstein JI. Fibroepithelial polyp of the lower urinary tract in adults. Am J Surg Pathol. 2005;29(4):460-6. doi:10.1097/01.pas.0000155153.64360.1a. PMID 15767798
  231. US Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. April 5, 2024. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 (accessed 2026-11-17). No DOI or PMID. Cited as FDA 2024.
  232. van der Kwast TH, Amin MB, Billis A, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011;24(1):16-25. doi:10.1038/modpathol.2010.156. PMID 20818340
  233. van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44(8):e87-e99. doi:10.1097/PAS.0000000000001497. PMID 32459716
  234. Verhagen PC, Nikkels PG, de Jong TP. Eosinophilic cystitis. Arch Dis Child. 2001;84(4):344-6. doi:10.1136/adc.84.4.344. PMID 11259238
  235. Volmar KE, Fritsch MK, Perlman EJ, et al. Patterns of congenital lower urinary tract obstructive uropathy: relation to abnormal prostate and bladder development and the prune belly syndrome. Pediatr Dev Pathol. 2001;4(5):467-72. doi:10.1007/s10024001-0042-1. PMID 11779049
  236. Walker NF, Gan C, Olsburgh J, et al. Diagnosis and management of intradiverticular bladder tumours. Nat Rev Urol. 2014;11(7):383-90. doi:10.1038/nrurol.2014.131. PMID 24934450
  237. Wang G, Xiao L, Zhang M, et al. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018;79:57-65. doi:10.1016/j.humpath.2018.05.005. PMID 29763719
  238. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32(1):65-71. doi:10.1097/PAS.0b013e318058a96b. PMID 18162772
  239. Warrick JI, Al-Ahmadie H, Berman DM, et al. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility. Am J Surg Pathol. 2024;48(1):e32-e42. doi:10.1097/PAS.0000000000002053. PMID 37199442
  240. Wasco MJ, Daignault S, Bradley D, et al. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. Hum Pathol. 2010;41(2):163-71. doi:10.1016/j.humpath.2009.07.015. PMID 19800100
  241. Wenzel M, Nocera L, Collà Ruvolo C, et al. Incidence rates and contemporary trends in primary urethral cancer. Cancer Causes Control. 2021;32(6):627-634. doi:10.1007/s10552-021-01416-2. PMID 33751293
  242. Weyerer V, Weisser R, Moskalev EA, et al. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. Histopathology. 2019;75(6):865-875. doi:10.1111/his.13958. PMID 31348552
  243. Whitmore KE, Fall M, Sengiku A, et al. Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26 Suppl 1:26-34. doi:10.1111/iju.13971. PMID 31144757
  244. Williamson SR, Zhang S, Lopez-Beltran A, et al. Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol. 2011;35(4):474-83. doi:10.1097/PAS.0b013e31820f709e. PMID 21383609
  245. Wu Q, Lu P, Zhang X, et al. Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review. BMC Cancer. 2026;26(1):680. doi:10.1186/s12885-026-16097-w. PMID 42050475
  246. Xin Z, Zhao C, Huang T, et al. Intestinal metaplasia of the bladder in 89 patients: a study with emphasis on long-term outcome. BMC Urol. 2016;16(1):24. doi:10.1186/s12894-016-0142-x. PMID 27267922
  247. Yang XJ, McEntee M, Epstein JI. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67. Hum Pathol. 1998;29(12):1447-50. doi:10.1016/s0046-8177(98)90014-4. PMID 9865831
  248. Ye H, Montgomery E, Epstein JI. Incidental anorectal pathologic findings in prostatic needle core biopsies: a 13-year experience from a genitourinary pathology consult service. Hum Pathol. 2010;41(12):1674-81. doi:10.1016/j.humpath.2010.06.006. PMID 20869745
  249. Yousef GM, Naghibi B, Hamodat MM. Malakoplakia outside the urinary tract. Arch Pathol Lab Med. 2007;131(2):297-300. doi:10.5858/2007-131-297-MOTUT. PMID 17284117
  250. Zare A, Bighamian M, Moloudi F, et al. Bladder Paraganglioma Presenting as Post-Micturition Palpitations: A Case Report. Case Rep Oncol. 2024;17(1):484-489. doi:10.1159/000538073. PMID 38529343